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 i 
Abstract 
Gene therapy is a promising approach for the treatment of diseases of the central 
nervous system. However, there is an unmet need for systems to regulate the 
levels of therapeutic transgenes. In this study, we investigate recently described 
destabilisation domain technology - novel regulatory systems that may offer 
advantages over existing methodologies. The destabilisation domain (DD) 
paradigm is composed of a conditionally stabilised protein domain that can be 
genetically fused to any protein of interest. Upon translation of this fusion partner 
in cells, the unstable DD targets the fusion protein to be degraded by the 
proteasome. The fusion protein is rescued by the presence of a ligand that 
stabilises the DD, forming a rapid, reversible and tunable regulatory system. We 
utilised two different forms of DD to create regulatable vectors suitable for use in 
vitro - to test the ability of the system to regulate fluorescent reporter proteins in 
cell lines and primary cultured neurons - and in vivo. After choosing the most 
favourable DD, we developed the technology to regulate levels of therapeutic 
genes suitable for the treatment of spinal cord injury (the nuclear receptor retinoic 
acid receptor β2) and Parkinson’s disease (the novel neurotrophic factor CDNF 
(conserved dopamine neurotrophic factor)). We found we could use the 
regulatable vector systems to provide dose-dependent gene expression in vitro, 
and long-term gene expression in vivo by oral administration of the stabilising 
ligand, with minimal levels of transgenes in the absence of the ligand. We suggest 
that with further optimisation, DD regulatory technology may provide an 
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1.1 Gene therapy  
Gene therapy, as its name suggests, is the use of genetic material such as DNA 
or RNA as a pharmaceutical drug to treat disease. The basic concept of gene 
therapy is to introduce genetic material into individuals’ cells to supplement, 
replace or correct genetic defects so as to rectify conditions arising from genetic 
disease. The first approved gene therapy experiment in humans took place in 
1990, where a four-year old girl was treated for ADA-SCID (adenosine 
deaminase deficient severe combined immunodeficiency); the effects were 
temporary but successful (Blaese et al., 1995) Since then, gene therapy clinical 
trials have been conducted for a number of different diseases, for example 
various forms of severe combined immunodeficiency disease (SCID), 
leukaemia, retinal diseases and Parkinson’s disease. In the last five years, 
clinical successes that have been reported, for example in retinal diseases 
(reviewed by Ali, 2012), have revived interest in gene therapy and this area of 
research continues to be hotly pursued by scientists. 
Efficient gene transfer continues to represent one of the largest obstacles limiting 
the success of gene therapy. Many clinical trials are now using viral vectors to 
transfer DNA into cells as viruses are exceedingly well adapted for this purpose, 
as they must enter cells as part of their replicative life cycle. Viral particles are 
nanoscale-sized objects, usually sheltering their nucleic acid genome within a 
protective protein shell that mediates entry into cells. The most commonly used 
viral vectors have been created by modifying retroviruses (RV), adeno viruses 
(AdV), adeno-associated virus (AAV), lentiviruses (LV) and herpes simplex 
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virus (HSV). These vectors vary in their suitability to different therapeutic 
situations. 
1.1.1 Retroviral vectors 
The retroviral genome of gammaretroviruses such as Moloney-murine leukaemia 
virus (MoMLV) is 9-11kb long and when integrated (provirus form) consist of 
two identical 400-700bp sequences called long terminal repeats (LTRs) flanking 
three essential genes: gag, pol, env. The remainder of the genome contains four 
other genes necessary for completing the viral life cycle (Miller, 1992). When 
constructing vectors, these five genes must remain in the genome, while the gag 
pol and env can be removed and replaced with a therapeutic gene of interest 
(GOI). GOI expression will be driven by the promoters residing in the 5’LTR, or 
by CMV/LTR hybrid promoters. Removing gag pol and env from the vectors 
blocks the ability of the virus to replicate once it has invaded the host cell, 
therefore making them safer for use in humans. However, to enable production 
of infectious vector particles gag pol and env must be provided in trans by using 
a cell line expressing the three proteins (Miller, 1990). In this way, the particles 
will contain all the necessary machinery to invade cells. Once inside host cells, 
reverse transcriptase (present in the virion) converts the mRNA to DNA, before 
the proviral DNA is integrated into the host genome by integrase, also present in 
the virion.  
Initial safety issues stemmed from recombination events between the vector 
construct and the packaging constructs, resulting in the generation of replication 
competent particles. To combat this, the gag/pol and env were divided into 
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separate constructs in the packaging cells. The risk that vector mobilisation will 
be mediated by endogenous retroviruses in the target cells prompted the 
development of self-inactivating vectors. In these vectors, LTR mediated 
transcription is prevented, and completely replaced with separate promoters (Yu 
et al., 1986).  
After initial successes in treating diseases such as severe combined 
immunodeficiency (SCID) (Cavazzana-Calvo et al., 2000) (Aiuti et al., 2002) 
(Ott et al., 2006), a series of events marred these discoveries, such as the death 
of a patient (Hacein-Bey-Abina et al., 2003) and the development of leukaemia 
in others (Yu et al., 1986; Miller, 1990; 1992; Blaese et al., 1995; Buckley, 
2002; Hacein-Bey-Abina et al., 2003; Kohn et al., 2003; McCormack and 
Rabbitts, 2004; Ali, 2012) due to activation of oncogenes by the retroviral 
promoters. Since this time, retroviral based vectors have been much less 
considered, partly because of these insertional mutagenesis problems. A further 
major limitation of retroviral vectors is their inability to transduce non-dividing 
cells, reducing their use for gene therapy in the central nervous system (CNS). 
1.1.2 Lentiviral vectors 
Unlike retroviruses, lentiviruses have the ability to cross the nuclear membrane 
and can therefore transduce non-dividing cells. Like retroviruses they integrate 
into the host genome to provide stable, long-term expression, while producing 
only a minimal immune response. The first lentiviral vectors were developed 
from human immune deficiency virus-1 (HIV-1). 
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In addition to gag pol and env, HIV-1 also contains an extra set of six accessory 
genes that are essential for the viral life cycle. Through the development of three 
different generations of vectors (Zufferey et al., 1997; Dull et al., 1998; 
Cavazzana-Calvo et al., 2000; Naldini, 2001; Aiuti et al., 2002; Hacein-Bey-
Abina et al., 2003; Ott et al., 2006), these genes have been removed, in the 
interest of improving safety (Sinn et al., 2005). Third generation vectors require 
only three of the original nine viral genes, which are provided in trans and split 
between four separate plasmids which must be cotransfected into packaging 
cells to yield functional vectors. The first plasmid corresponds to the self-
inactivating therapeutic gene transfer vector, in which the GOI, promoter and 
polyadenylation signal reside. A strong promoter outside the LTRs (long 
terminal repeats) in the packaging cells drives transcription of this construct, 
while the LTRs themselves are attenuated such that they cannot trigger 
transcription of provirus after integration or form functional virus if a wild type 
HIV infection arises. The central poly purine tract/central termination sequence 
(cPPT/CTS - part of pol gene) remains, as this increases viral titres by enhancing 
reverse transcriptase and pre-integration complex nuclear transport (Follenzi et 
al., 2000; Zennou et al., 2000). An RRE (rev responsive element) is also 
included. A second plasmid provides gag and pol genes, while a third provides 
rev (to ensure efficient nuclear export of full-length of vector mRNA into 
cytosol by binding RRE) and a fourth provides the coat protein, usually the 
broad spectrum vesicular stomatitis virus G protein (VSV-G), although the 
tropism can be modified by pseudotyping the virus with different coat proteins 
(Watson et al., 2002). For example, using Rabies-G coat protein will enable to 
the vector to retrogradely transduce neurons, while VSV-G will not (Cronin et 
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al., 2005). This ability means that lentiviral vectors can be applied into muscle 
and transduce nerve terminals in the periphery, before being retrogradely 
transported to the cell bodies and provide long term expression once integrated. 
This approach is being investigated for motor neuron disease (Azzouz et al., 
2004a).  
Vectors derived from viruses that are non-pathogenic to humans, such as simian 
immunodeficiency virus (SIV), feline immunodeficiency virus (FIV) and equine 
infectious anaemia virus (EIAV) provide a means of working with vectors that 
may have improved safety profiles (Sinn et al., 2005; Valori et al., 2008). 
Indeed, EIAV vectors are being used in clinical trials to deliver a dopamine 
replacement strategy in Parkinson’s patients (Azzouz et al., 2002). Acute 
immune responses to lentiviral vectors are weak or non existent in primates 
(Kordower et al., 2000) and even animals that have been primed to have an 
adaptive immune response by pre-injection of viral capsid proteins do react 
when encountering them again (Follenzi et al., 2000), suggesting that these 
vectors are particularly non-immunogenic. 
With low immunogenicity, genome integration, large cloning capacity and the 
ability to modulate their transduction properties by pseudotyping, lentiviral 
vectors offer an attractive tool for delivering genes to the CNS. 
1.1.3 Adenovirus (AdV) vectors. 
Adenoviral vectors were one of the first vector systems used for gene delivery to 
the CNS. The wild-type AdV is a pathogen of humans, causing a range of 
ailments from the respiratory system disease to gastroenteritis and conjunctivitis. 
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However, the tropism of AdV for the respiratory system and conjunctiva is 
mainly due to the mode of transmission of the virus; indeed, the CAR (coxsackie 
adenovirus receptor) that mediates viral entry to cells is ubiquitously expressed 
and the virus can enter both diving and non-dividing cells (Law and Davidson, 
2005; Cohen et al., 2012). More than 50 serotypes of AdV have been isolated 
and classified into 6 groups. Most gene therapy vectors are derived from 
serotypes 2 and 5; both belong to group C of the family. The viral genome is 
36kb of double stranded DNA, consisting of early transcriptional units (that 
become activated upon cell infection), delayed early transcriptional units and 
one major late transcription unit, all flanked by two identical 103bp inverted 
terminal repeats (ITRs). The first generation of viruses was created by deleting 
certain early transcriptional units and replacing them with a therapeutic gene of 
interest (GOI), including a promoter and polyadenylation signal (reviewed by 
Danthinne and Imperiale, 2000). However, expression of remaining viral 
proteins resulted in a strong immune response to cells transduced by these 
vectors (Hermens and Verhaagen, 1997; Thomas et al., 2000; Watson et al., 
2002; Azzouz et al., 2004a; Cronin et al., 2005), and led to the death of one 
patient in a clinical trial when AdV vectors were applied to the liver (Batshaw et 
al., 1999; Lehrman, 1999). To try to combat these issues, in the second 
generation vectors more of the early transcriptional units were removed, but this 
did not abrogate the immune response and resulted in lower GOI expression 
(Wang and Finer, 1996). Third generation (‘gutless’) vectors are characterized 
by the near complete removal of the AdV genome, only the ITRs and DNA 
packaging signal (ψ) are retained (Kochanek et al., 1996; Parks et al., 1996). 
Production of these vectors is entirely reliant on the producing cells expressing 
Chapter 1 - Introduction 
 - 8 -
all the necessary proteins in trans. They are relatively easy to design and produce 
high titre preparations. The removal of viral genes has given these vectors a 
large maximum cloning capacity of approximately 30kb. As the immune 
response to cells that have been transduced is lowered, gene expression from 
these vectors in vivo is observed over much longer periods (Barcia et al., 2007). 
Although the capsid proteins themselves initiate an immune response (Kafri et 
al., 1998; Follenzi et al., 2000; Kordower et al., 2000; McCaffrey et al., 2008), 
reports suggest that these vectors can be used safely in the brain at low titres . In 
addition, pseudotyping capsid proteins with different AdV serotypes may 
decrease the immune response further (Nayak and Herzog, 2010). While the 
broad tropism of AdV vectors may be of use in many situations, a clinical setting 
may require more control over the cells that express the vectors. For this 
purpose, capsid engineering and cell specific promoters have been used to target 
viral expression (Coughlan et al., 2010).  
The potential risks of immunogenicity perhaps explain why these vectors have 
been mostly implemented in situations where an immune response would not 
deleterious to the therapy. For example AdV based treatments of glioma have 
entered clinical trials (reviewed by Danthinne and Imperiale, 2000; Gwendalyn 
D King, 2005; Mohyeldin and Chiocca, 2012).  
1.1.4 Adeno-associated virus (AAV) vectors 
AAV is a non-pathogenic single stranded DNA virus that can transduce both 
dividing and non-dividing cells. Over 100 AAV variants have been isolated in 
primates alone and new serotypes are being continuously discovered. They have 
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not been associated with disease in humans, yet more than 80% of adults over 20 
show an antibody response to AAV, proving they have encountered the virus 
(Erles et al., 1999).  
All of the serotypes that have been extensively characterized (at least AAV1-
AAV12) thus far share very similar structure, size and genetic organisation, only 
differing in the proteins that form the viral capsid, which determines the receptor 
selectivity of the virus (Wu et al., 2006). Of these, AAV2 is the most studied 
serotype and formed the basis of the development of AAV vectors. The 
receptors that different AAV serotype capsids bind are all widely expressed. 
Pseudotyping AAV2 vectors with different capsids extends the tropism of the 
virus to permissive organs (including neurons, photoreceptors). However, 
transduction of cell types that are resistant to AAV2 gene transfer (such as 
endothelial cells and fibroblasts) will not be improved. AAV2 viruses enter cells 
by clathrin-mediated endocytosis, escaping the early endosome and translocating 
to a perinuclear location. After shedding their capsid proteins in the nucleus, 
second strand synthesis is mediated by endogenous DNA repair mechanisms to 
form a double stranded DNA molecule required for gene expression (Ferrari et 
al., 1996). The wild type virus genome consists of two structural genes Rep and 
Cap, responsible for replication and capsidation respectively. These genes are 
flanked by two non-coding 145nt inverted terminal repeats (ITRs). An internal 
complementary stretch in the first 125nt of the ITR forms a T-shaped hairpin 
structure. Viral expression of the Rep gene in the host allows site-specific 
integration into the AAVS1 locus human chromosome 19 (Kotin et al., 1992). In 
the creation of an AAV vector, all viral genes have been removed except the ITR 
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sequences, creating a 4.7kb cloning capacity (Ferrari et al., 1997). To produce 
viral particles, Rep and Cap genes must be provided in trans, along with other 
adenovirus helper genes in the producing cells (Mezzina and Merten, 2011). 
Therefore, without the rep gene expressed in host cells, the viral genome forms 
episodic concatamers, with some random integration events (Wang and Finer, 
1996; Tenenbaum et al., 2003; Smith, 2008). A limitation of AAV vectors lies in 
the small packaging capacity. However, the formation of genomic concatamers 
by head-to-tail recombination of the ITRs has been exploited as a means to 
increase capacity. This method requires co-transduction of cells with two 
different AAV particles that have the genomic load split between them (Nakai et 
al., 2000; Duan et al., 2002). Expression will only occur after recombination and 
the efficiency is often reduced. Once transduced with AAV vectors, cells in vivo 
have been seen to express GOI for the entire lifetime of rodents.  
As AAV vectors do not express viral proteins, immune reactions to transduced 
cells are not evident although, similar to adenoviruses, the immune system can 
react to the capsid proteins (Mingozzi and A High, 2011). However, versatility 
provided by the range of tropisms of AAV serotypes can be used to improve 
efficiency and pattern of transduction in the specific regions in the CNS. For 
example, while AAV2 has a tropism for neurons in the brain (Bartlett et al., 
1998), it binds heparin sulphate proteoglycan (HSPGs – cell surface receptor for 
AAV2) present in the extracellular matrix (Paterna et al., 2004; Broekman et al., 
2006; McFarland et al., 2009), limiting its ability to diffuse away from the 
infusion site. AAV1, 5, 7 and 8 show greater diffusion through the parenchyma 
as they do not bind HSPGs. Astrocytes are preferentially transduced by AAV4 in 
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the subventricular zone (Liu et al., 2005), AAV5 transduces astrocytes and 
neurons in the striatum (Coughlan et al., 2010) (reviewed by Burger et al., 2005) 
while, in the cortex, AAV1 led to the most efficient transduction of corticospinal 
tract (CST) neurons (Hutson et al., 2011). Further to the isolated serotypes, 
studies are recombining capsid proteins, inserting DNA, and directing evolution 
to improve their characteristics even further (reviewed by Erles et al., 1999; 
Asokan et al., 2012; Bartel et al., 2012). AAV vectors are becoming one of the 
most utilised gene therapy vectors for use in the CNS (McCown, 2005) with 
phase I trials targeting diseases such as Alzheimer’s disease, Canavan’s disease 
and phase II clinical trials underway for Parkinson’s disease (Weinberg et al., 
2012). 
1.1.5 Herpes simplex virus-based  (HSV) vectors 
HSV is a naturally neurotropic human virus that can transduce both dividing and 
non-dividing cells and can establish latency. This means that the viral genome 
remains episomal in the cell nucleus for the lifetime of the host organism. Wild 
type HSV also has a lytic life cycle, which results in viral replication and cell 
death.  
There are three types of HSV vectors: attenuated, replication-deficient, and 
amplicon vectors. Attenuated vectors can replicate in rapidly dividing cells, but 
have had certain genes removed required for replication in non-dividing cells. 
However, several studies have shown these vectors do replicate after inoculation 
into the brain (Frampton et al., 2005), suggesting that these vectors are perhaps 
best suited towards oncolytic therapy of cancer (Harrow et al., 2004). 
Chapter 1 - Introduction 
 - 12 - 
Replication defective vectors lack more genes that render them unable to 
replicate in neurons. There is a phase I clinical underway using them to treat 
pain (Wolfe et al., 2009). Amplicon vectors (or helper-dependent vectors) have 
had nearly all viral elements removed to give a 150kb cloning capacity. The 
amplicon consists of the GOI cassette, a minimal HSV replication (ori) and 
cleavage/packaging (pac) genes. To produce the particles, the amplicon is either 
co-transfected with sets of partially overlapping cosmids, or a single bacterial 
artificial chromosome, as a source of the viral proteins required to package the 
DNA into particles (Kotin et al., 1992). The potential of HSV vectors to deliver 
large genetic loads long term is appealing, yet the relative complexity and lack 
of understanding of the HSV genome hampers wider utilisation of this system. 
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Figure 1-1 A chart to show the development of vectors from viruses 
Adapted from Giacca et al., 2012 
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1.2 Regulation of gene therapy vectors  
Gene therapy offers many advantages for treating neurological disorders; not 
least its ability to induce long-term, high level expression of therapeutic genes in 
the CNS. Often, studies using viral vectors use powerful constitutive promoters, 
to ensure that the therapeutic GOI is expressed a high enough levels to cause an 
effect (Ramezani et al., 2000). For example preclinical studies in Parkinson’s 
disease have noted a relationship between vector dose and enzyme function or 
behavioural improvements (Ferrari et al., 1997; Forsayeth et al., 2006).  
However, it is often the case that prolonged or high levels of proteins can lead to 
problems. For example, striatal overexpression of glial derived neurotrophic 
factor (GDNF) can lead to GDNF release and aberrant fibre sprouting at 
downstream striatal targets in an animal model of PD (Georgievska et al., 2002). 
Systemic administration of ciliary neurotrophic factor (CNTF) or brain derived 
neurotrophic factor (BDNF) led to substantial weight loss and anorexia in 
humans (Pelleymounter et al., 1995; Anon, 1996). It may also be necessary to 
tune the level of therapy. For example, aromatic L-amino acid decarboxylase 
(AADC) therapy for Parkinson’s disease has the potential to increase L-DOPA 
induced dyskinesias in patients if too high a dose is received (Cress, 2008). As 
Parkinson’s disease is progressive, the level of therapy required may change. An 
ideal viral vector would therefore direct transgene expression as long as the 
therapeutic protein is needed at the level that is required, for as long as the 
therapeutic protein improves disease symptoms.  
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Many approaches have been attempted to regulate the levels of proteins being 
produced. Here we will focus on systems that are of use in the context of vector 
mediated gene therapy, rather than controlling the levels of endogenously 
produced proteins (from genes). Many of these systems rely on a 
pharmacological ligand to bring about activation or inactivation of the system. 
To be suitable for clinical use, a pharmacological regulated system should 
ideally fulfil the following criteria. The ligand should be an “on switch”, so that 
it activates the system that has been inactivated until such time that it is required. 
This is preferable to systems that are activated until “turned off” by a ligand, as 
this will require prolonged exposure to the drug to silence the system. 
Furthermore, the induction kinetics will rely on the rate of clearance of the drug, 
which may take longer than is desirable. It is necessary that the regulation is 
tightly controlled, so that there is minimal activation when the transgene is not 
wanted. It must facilitate rapid transition between the on and off state, in a 
reversible manner, such that precise temporal regulation can be repeatedly 
achieved, to potentially coincide with therapeutic windows. There should be a 
dose-dependent increase in the levels of target gene upon induction of the 
system so levels of therapy can be tuned to individual patients. The ligand 
should be specific to the regulatory system and not cause off target effects, yet 
also be able to penetrate into tissues. In order to be safe, the system must not 
promote immunogenic responses and be compatible with prolonged therapeutic 
use. Furthermore, the system must be applicable to as wide a range of cells types 
as possible so it can be used to regulate different genes in as many tissues or 
organs as may be required. It must also be a simple as possible, to avoid using 
multiple genetic manipulations. Even when the system does not require a 
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pharmacological ligand, many of these goals are desirable. Many regulatory 
systems have been developed and some have already been tested in vivo, 
although none have as yet been implemented in the clinic, indicating the 
difficulty in meeting these criteria.  
1.2.1 TetOn/TetOFF systems 
Tetracycline (Tet) regulated systems are based on the E. coli TN10 Tet 
resistance operon, comprised of the Tet operator (TetO) DNA sequence and the 
Tet repressor protein (TetR) (Wissmann et al., 1986). When Tet (or its derivative 
Doxycycline (Dox)) binds to the TetR protein, the change in conformation 
prevents it from binding to the operator sequence, allowing gene transcription. 
When the drug is removed this is reversible and the TetR can once again bind 
and block transcription. These components were developed into a regulatory 
system by Gossen and Bujard (Gossen and Bujard, 1992) Seven repeats of the 
TetO (called TRE – Tet responsive elements) were fused upstream of a minimal 
CMV promoter (that has low intrinsic activity) upstream of a gene of interest. 
TetR was fused to the eukaryotic VP16 transactivation domain to produce the 
tTA (Tet-controlled transcriptional activator), operational under its own 
promoter and polyadenylation signals autonomous from the TRE cassette. In the 
presence of Dox, the tTA cannot bind to the TRE and the gene of interest is 
silenced. However, when Dox is removed tTA can binds to the TRE, resulting in 
the expression of the gene of interest. The functionality of this system has been 
proven in the CNS in vivo (Harding et al., 1998). However, this approach has 
limitations. It is only suitable for situations when the system will be required to 
be activated for long periods, as silencing gene expression will require chronic 
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administration of Dox. Furthermore, the kinetics of activation of the system is 
largely dependent on the clearance of Dox.  
In a bid to provide a more useful system from these initial findings, four further 
Tet regulated systems have been developed: TetON, TetKRAB, 
TetONcombined and Autoregulatory loop-based TetON-TetOFF. 
TetON was developed by randomly mutating the TetR to form rTetR. Four 
mutations led to a reversal in the binding properties of the TetR such that in the 
presence of Dox, the rTetR bound to the TRE (Gossen et al., 1995). By fusing 
the VP16 transactivator to the rTetR (to form rtTA), gene expression could be 
induced by the addition of Dox. The kinetics of activation were more rapid than 
the TetOFF system (Gossen et al., 1995; Kistner et al., 1996) and this system has 
been investigated in non-human primates (Favre et al., 2002). However, this 
system also had limitations. The VP16 domain was found to exhibit some 
affinity for the TRE in the absence of Dox, leading to low levels of gene 
expression in the off state (Goverdhana et al., 2005). Furthermore, high levels of 
Dox were needed for maximal activation, prompting concerns that these levels 
could not easily be reached in the brain. To combat these concerns, Urlinger and 
colleagues induced further mutations to rtTA. Several mutants were tested and 
rtTA2-M2 was found to have lower basal activation and improved sensitivity to 
Dox (Urlinger et al., 2000; Lamartina et al., 2002; Mingozzi and A High, 2011). 
It is this form of TetON that has now been studied in non human primates 
(Latta-Mahieu et al., 2002; Chenuaud, 2004; Stieger et al., 2006). However, 
immunological responses to cells expressing the rtTA have been reported (Favre 
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et al., 2002; Latta-Mahieu et al., 2002; Chenuaud, 2004; Liu et al., 2005; Guiner 
et al., 2007).  
TetON-KRAB was a different approach aimed at lowering the immunogenicity 
of the viral protein VP16 transactivator. KRAB (Krupple-Associated Box) 
domains (Bellefroid et al., 1991) were isolated from zinc finger proteins Kox1 
(Deuschle et al., 1995) or Kid-1 (Witzgall et al., 1994a; 1994b; Hutson et al., 
2011). These transrepressive domains (Margolin et al., 1994) are known to 
inhibit RNA polymerases up to 3kb away from the zinc finger binding site 
(Deuschle et al., 1995). Fusion to TetR formed TetR-KRAB also known as tTS 
(Deuschle et al., 1995), or tTS
Kid 
(Freundlieb et al., 1999). In this system, the 
minimal CMV promoter used for the original TetOn system was replaced with a 
constitutive active CMV promoter downstream of the TRE. Thus, in the absence 
of Dox, tTS binds to TRE and inhibits the CMV promoter. This system 
reportedly lowered basal activity(Freundlieb et al., 1999), yet the maximal 
expression levels were effected in some cases (Lamartina et al., 2003; Gardaneh 
and O'Malley, 2004; McCown, 2005). There are few reports of this system being 
explored further in vivo. 
Bujard and colleagues continued to improve the system by co-expressing rtTA 
and tTS from a bicistronic expression cassette, separated by an internal ribosome 
entry (IRES) site. In the absence of Dox, tTS binds TRE and silences gene 
expression, yet in the presence of Dox the tTS will be released, allowing rtTA 
can bind to bind TRE leading to increased maximal activation (Baron and 
Bujard, 2000; Lamartina et al., 2003; Harrow et al., 2004; Weinberg et al., 
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2012). This system has been used in several in vivo studies (including in the 
CNS (Xiong et al., 2006; Chen et al., 2008; Wolfe et al., 2009)), yet the clinical 
application is likely to be delayed due safety concerns relating to the expression 
of three foreign proteins. 
Another strategy to reduce the immunogenic response and decrease background 
activation is to limit the production of these proteins to the time at which Dox is 
supplied by placing both rtTA and transgene - separated by an IRES fragment - 
under the control of a Tet-inducible promoter, which is simply the TRE coupled 
to a minimal CMV (Strathdee et al., 1999; Gould et al., 2000; Markusic, 2005). 
Very low levels of the rtTA are produced in the absence of Dox, so there is very 
tight regulation over the transgene. However, there is enough produced such that 
when Dox is supplied, the rtTA can bind to the TRE and transactivate the 
cassette. The induction of this system is delayed, as the rtTA must first reach 
sufficient levels to fully activate the TRE. These system have been studies in 
vivo in the CNS (reviewed by Stieger et al., 2009), however, immunogenic 
responses have again been seen with these constructs (Markusic et al., 2010).  
As a ligand to regulate gene expression, Dox satisfies many of the 
aforementioned criteria. It has been used as a treatment for infectious diseases 
for many years and is thus well characterized. It is almost 100% bioavailable 
after oral administration (compared to intravenous administration) and 
penetrates tissues effectively, including the brain. Long-term administration has 
lead to renal toxicity and photosensitivity and a decrease in bone growth rate in 
youngsters (Agwuh and MacGowan, 2006). The possibility of raising antibiotic 
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resistance through excessive use of Dox may be solved by using 4-
epidoxycycline, a metabolite of Dox that does not have antibiotic activity (Eger 
et al., 2004). 
Underlying problems that hinder the use of Tet regulated systems are those 
relating to the basal leakiness exhibited by the rtTA-M2 transactivator 
(Georgievska et al., 2004a; Wakeman et al., 2011), and conflicting reports 
regarding the immunogenic responses to this chimeric bacteria/viral protein 
system (Wissmann et al., 1986; Gossen and Bujard, 1992; Gossen et al., 1995; 
Harding et al., 1998; Favre et al., 2002; Latta-Mahieu et al., 2002; Chenuaud, 
2004; Ginhoux et al., 2004; Guiner et al., 2007; Cress, 2008; Han et al., 2010). 
Recent attempts have been made to reduce the immunogenicity of the rtTA 
(Zaldumbide et al., 2010), while others have increased the sensitivity of rtTA to 
Dox, implying a lower dose would be required to achieve maximal expression 
(Favre et al., 2002; Zhou et al., 2006). While further development of this system 
is required before entering the clinic, it is the most established method for 
regulating levels of gene therapy agents.  
1.2.2 Ecdysone 
Ecdysone is a steroid hormone that triggers moulting and metamorphosis in 
insects by stimulating the ecdysone receptor (EcR). Functional EcR is a non-
covalent hetero-dimeric receptor with the insect ultraspiracle protein (USP), 
which together bind ecdysone response elements (EREs) in DNA to activate 
gene transcription (Yao et al., 1992; 1993; Goverdhana et al., 2005; reviewed by 
Riddiford et al., 2000). No and colleagues developed an inducible system (No et 
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al., 1996) by creating a novel transactivator form of the truncated EcR fused to 
transactivational domains of the glutocorticoid receptor and VP16 (VgEcR). 
This domain therefore responds to ecdysone, but has enhanced transcriptional 
activity. Human retinoic X receptor (RXR) was used as a dimerization partner in 
replacement of the USP (Thomas et al., 1993). Co-expression of VgEcR and 
RXR in cells containing an improved ERE (E/GRE) allowed induction of 
transgenes when ecdysone was applied, but tight regulation implies that the 
system is not induced by endogenous mammalian nuclear hormone receptors. A 
direct comparison of ecdysone to tetracycline regulated systems available at the 
time indicated that ecdysone had lower basal expression, greater inducibilty and 
more rapid induction kinetics (No et al., 1996). This system has been modified 
for use in lentiviral vector technology, such that all components are contained in 
a single expression cassette (Galimi et al., 2005). A hybrid Drosphila/Bombyx 
(Suhr et al., 1998) EcR was developed that does not require RXR (Hoppe et al., 
2000), simplifying the system and reducing potential risks associated with 
overexpressing a protein involved in endogenous signalling pathways. 
This system was further improved by the development of potent activating 
ligands. Plants produce phytoecdysones as a defence against feeding insects, 
leading to abnormal moulting (Kubo and Klocke, 1983) and muristerone A 
(murA) had been isolated from seeds of a plant (Ipomoea calonyction) 
(Canonica et al., 1972). Growing interest in the system required more readily 
available ligands, such as ponasterone A (PonA, from Pomoea calonyction) 
(Saez et al., 2000) among many others. As steroid hormone analogues they have 
good pharmacological properties (Bellefroid et al., 1991; Deuschle et al., 1995; 
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Bathori et al., 2008; Lapenna et al., 2009),  and appear to be non-toxic (Spencer 
et al., 1993). 
The system has been used in animal models (Margolin et al., 1994; Albanese et 
al., 2000; Niikura et al., 2000) including gene therapy in neurons (Deuschle et 
al., 1995; Ma et al., 2010), however, there has been no move into preclinical 
models in primates. As hormones, the activating ligand may have off-target 
effects in cells and this needs to be fully elucidated. Furthermore, because these 
molecules may be present in humans through consumption of crop plants 
(Deuschle et al., 1995; Freundlieb et al., 1999; 1999; Dinan et al., 2001; Dinan 
and Lafont, 2006), unwanted activation of the system may occur in a clinical 
setting. Similarly to the tet-systems, the chimeric EcRs still incorporate elements 
of viral proteins, which could lead to immunogenic responses. 
1.2.3 Cre/LoxP 
The Cre/LoxP system is one of the most well known methods to conditionally 
control a transgenic protein. In this system, the gene of interest is flanked by 
motifs recognized by a DNA recombinase “Cre”. When the recombinase makes 
contact with the DNA motifs the DNA is rearranged. The Cre-LoxP site specific 
recombinase was originally found in the P1 bacteriophage (Sternberg and 
Hamilton, 1981). The Cre recombinase binds to the 34bp LoxP DNA motif 
comprised of two 13bp inverted repeat regions separated by 8bp (Hoess et al., 
1982). Depending on the relative orientation of the motifs, the result will either 
be a reversal of the flanked DNA, or the removal of a DNA minicircle 
(Abremski et al., 1983; Hamilton and Abremski, 1984). This tool can be used to 
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produce deletions (Ramirez-Solis et al., 1995; Dolan et al., 2011), gene 
replacements (Hanks et al., 1995), insertions (Sauer and Henderson, 1990), or by 
flanking a stop codon it could be used as a conditional activator (Lakso et al., 
1992). The system was later developed to induce transient gene expression and 
conditional knockouts in mice (Lakso et al., 1992; Orban et al., 1992; Ramirez-
Solis et al., 1995). In order for tissue specific DNA alterations to occur, Cre 
driven by tissue specific promoters is typically used in double transgenic mice 
(Gu et al., 1994). While the Cre/LoxP system has been used extensively in this 
field of transgenics, it is very limited in the context of gene therapy. Once the 
LoxP-flanked gene of interest is delivered to cells, silencing the gene would 
require the unlikely event of all the cells that had been transduced in the first 
instance to be transduced a second time. Also, the requirement of a second 
delivery of vector is disadvantageous. Attempts to remedy this shortcoming have 
been attempted by creating inducible forms of Cre, such that they can be 
delivered at the same time of the therapeutic gene and activated through the use 
of small molecules. 
Metzger and colleagues fused the ligand-binding domain of the oestrogen 
receptor (Metzger et al., 1995) to yield a constitutively expressed hybrid Cre-ER 
that is sequestered by heat shock proteins in the cytosol of cells in the absence of 
activating ligand. When 4-hydroxytamoxifen is supplied to cells, the hybrid Cre 
is released and can mediate recombination evens in the nucleus. The system was 
updated by using a mutated ER ligand-binding domain (forming Cre-ER
T
). 
Validation in living mice (Feil et al., 1996), suggests that nearly 100% 
recombination occurs within 3 days of tamoxifen administration in some cell 
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types (Brocard et al., 1997). Other forms of regulatable Cre have also been 
developed by hybridizing the ligand binding domain of progesterone receptor 
activated by synthetic molecule RU486 (Kellendonk et al., 1996). Despite these 
and many on going improvements, this system still does not fulfil many of the 
criteria desirable to regulate gene therapy agents, such as dose-dependency, 
rapidity and especially reversibility. While the brief requirement for tamoxifen 
means it can even be used in pregnant mice (Danielian et al., 1998), some 
studies indicate incomplete or ligand independent recombination (Schwenk et 
al., 1998; Kellendonk et al., 1999) and there are reports of toxicity by Cre 
(Hameyer et al., 2007; Thanos et al., 2012). More recent developments using 
Cre/LoxP such as the Brainbow project indicate its power as a investigative tool 
(Livet et al., 2007), yet do not increase its suitability to clinical applications. 
1.2.4 Regulation by affecting protein function 
Protein function can also be conditionally controlled at the level of translated 
proteins. In these systems, the proteins are usually constitutively expressed and 
whether a protein will have an effect is mediated by controlling its location, 
degradation, or ability to fold correctly. Traditionally, small molecules have 
been used to target specific proteins. These must be screened and individually 
tested for safety and therefore do not have a general applicability. Furthermore, 
cross-reactivity can affect one or several off target proteins (Davies et al., 2000; 
Bain et al., 2003).  
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1.2.4.1 Destabilisation domain technology 
Another method of creating a regulatable system that can be applied to many 
proteins is to create a fusion protein that can be conditionally altered. 
Varshavsky and colleagues discovered that the half life of a protein depends, in 
part, on its N-terminal residue (Bachmair et al., 1986; Bachmair and 
Varshavsky, 1989). Szostak and colleagues developed this idea to discover that a 
N-terminal fusion of a small peptide could confer instability onto a protein of 
interest (Park et al., 1992). However, this “degron” did not offer conditional 
control and gave a similar outcome to that of a genetic knock out. Varshavsky 
used this approach to develop a mutant dihydrofolate reductase (DHFR) that 
could be temporally regulated by temperature (Dohmen et al., 1994). An N-
terminally fused arginine (to form Arg-DHFR) residue resulted in a temperature 
sensitive (TS) mutant that was maintained in cells growing at 23
o
C, but degraded 
at 37
o
C. Fusing this to other proteins conferred the phenotype onto them 
(Dohmen et al., 1994; Kanemaki et al., 2003), meaning that the Arg-DHFR 
could be used to produce TS mutants without searching for TS mutations. While 
this temperature sensitive regulation is of no use for in vivo studies, it was an 
interesting proof of concept that it is possible to target many different GOIs to be 
degraded by fusing one conditionally regulated protein to it. The next 
development was to find a fusion protein that could be conditionally regulated 
by a small molecule. This breakthrough came when it was fortuitously 
discovered that a mutated domain of the mTOR (mammalian target of 
rapamycin) protein named FRB* (FKBP-rapamycin binding domain) was 
unstable until it was bound and stabilized by a rapamycin analogue MaRap 
(Liberles et al., 1997). Furthermore, proteins fused to FRB* were also degraded 
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and rescued in response to MaRap in living mice (Stankunas et al., 2003; 2007). 
While this system provided dose dependent stabilization of a protein of interest, 
the stabilising ligand MaRap made this system unsuitable for wide spread 
adoption, as it is difficult to formulate, expensive and exhibits poor 
pharmacokinetics in vivo (Bayle et al., 2006).  
However, it acted as a proof of principle that a conditionally stabilized fusion 
protein partner can be used to regulate a protein of interest. Recognising the 
potential of this approach, Wandless and colleagues set out to develop an 
improved system, by engineering a protein specifically to be unstable 
(“destabilisation domain”) and allowing fusion partners to be destabilised until 
stabilized by a ligand.  
The studies that had revealed the FRB*-MaRap protein ligand pair had been 
focused on other aspects of the ternary complex formed between rapamycin, 
FRB and FKBP12 (FK506-binding protein, 12kDa, hereafter FKBP). In light of 
these studies, they selected the FKBP protein to develop into a destabilisation 
domain, as it had already been investigated as a fusion partner, and a range of 
high affinity ligands had already been developed (Yang et al., 2000; Pollock and 
Clackson, 2002). They created a library of mutants of the FKBP protein fused to 
fluorescent reporter protein and screened it to find individual mutations that 
were stabilized by the synthetic ligand for FKBP (SLF) (Banaszynski et al., 
2006). They isolated mutants that conferred dose dependent regulation of the 
fusion partner, with low basal expression levels in the absence of ligand and 
rapid, reversible induced expression in the presence of ligand.  
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To avoid targeting the endogenous FKBP, they used a F36V mutant of FKBP. 
This form has a cavity that ligands bearing a “bump” can bind with over 1000 
fold selectivity. Small modifications of SLF yielded the novel ligand Shield1 
with improved stabilising effects and better cell permeability. (Maynard-Smith 
et al., 2007). Similar ligands tested in humans had not provoked undesired side 
effects (Iuliucci et al., 2001). 
This group have since tested the ability of the system to regulate several 
different classes of proteins by fusing the DD to the N-terminus of proteins: 
including GTPases (Rac1, RhoA, Cdc42), Kinases (GSK-3b), and cell cycle 
regulatory proteins (Securin, p21); and the C-terminus of proteins: a 
transcription factor (CREB), small GTPases (Arf6 and Arl7) and a 
transmembrane protein (CD8a) (Banaszynski et al., 2006). This range of protein 
sizes, folds, function and cellular localization indicated the versatility of the 
system.  To test the system in vivo, they xenographed living mice with cells 
expressing a destabilisation domain-luciferase fusion protein. Administration of 
Shield1 caused dose dependent accumulation of luciferase activity in the 
tumours (Banaszynski et al., 2008). One other study has used this system in mice 
to regulate malonyl-CoA decarboxylase (Rodriguez and Wolfgang, 2012). It has 
also been implemented extensively when studying parasite proteins. Shield1 
regulated proteins have been studied in Plasmodium (Balabaskaran Nina et al., 
2011; Farrell et al., 2012), Trypanosome (Ma et al., 2012), Apicomplexa (Brooks 
et al., 2010; Limenitakis and Soldati-Favre, 2011), and Leshmania (Madeira da 
Silva et al., 2009); reviewed by de Azevedo et al., 2012). 
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While the FKBP-Shield1 system proves that a destabilisation domain can be 
engineered in this way, this system is of little use in the CNS, as Shield1 is 
predicted to have poor pharmacokinetic properties across the blood brain barrier. 
Recognising this, Wandless and colleagues have subsequently developed two 
further destabilisation domains, the first derived from the E. coli DHFR 
(Iwamoto et al., 2010), and the second from the estrogen receptors (Miyazaki et 
al., 2012).  
The DHFR system is stabilized by trimethoprim, a widely available molecule 
that has excellent pharmacokinetic properties. Trimethoprim is readily absorbed 
from the gut and penetrates the blood brain barrier (BBB), meaning that this 
system can be used in the CNS. There are few publications using this relatively 
new system and none investigating its potential to conditionally regulate proteins 
in the CNS. 
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Figure 1-2 Illustration of the destabilisation domain technology, stabilising ligands and configurations 
in fusion proteins 
 
1.2.4.2 SURF 
The Muir group recently developed SURF (split ubiquitin for the rescue of 
function) technology (Pratt et al., 2007). In this system, the protein of interest is 
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fused to the C-terminal half of ubiquitin and FRB that targets the fusion to the 
proteasome. The N-terminal half of ubiquitin is fused to FKBP. In the presence 
of rapamycin, the FKBP and FRB are brought together, allowing the split 
ubiquitin to refold into a function molecule. The advantage of this system is that 
the FRB-FKBP-Rapamycin is then removed by endogenous deubiquitinating 
enzymes, releasing the protein of interest unhindered by other protein moieties.  
1.2.4.3 PROTACs 
Another system that uses endogenous proteolytic pathways to target proteins for 
degradation is the Protac (proteolysis-targeting chimeric protein) system, 
developed by the Deshiaes laboratory (Sakamoto et al., 2001). Protacs are 
heterobifunctional cell permeable molecules that contain a ligand that recognizes 
the target protein, yet also specifically bind to a specific ubiquitin ligase 
(Schneekloth et al., 2004). Therefore, these molecules bring the E3 ligase into 
proximity with the target protein and the resulting polyubiquitination tags it for 
degradation. This approach has been validated with several endogenously 
expressed proteins including methionine aminopeptidase-2 and the aryl 
hydrocarbon receptor (Sakamoto et al., 2001; Lee et al., 2007; Rodriguez and 
Wolfgang, 2012). Although this could be extended to protein expressed in gene 
therapy vectors, the system is limited by the fact that a binding ligand (usually a 
peptide) for the protein of interest must be developed. However, Protacs do offer 
a broader range of application than small molecule inhibitor systems that must 
functionally inhibit an enzymatic site to cause an effect, particularly as a greater 
proportion of proteins do not have enzymatic activity (Arakaki et al., 2006). 
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However, the lack of understanding of the proteasome system means this 
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1.3 CNS diseases that have been targeted by gene therapy 
approaches 
The central nervous system presents a unique challenge to gene therapy 
approaches as it is physically enclosed by a skeletal system and the blood brain 
barrier (BBB). Therefore, the routes of access to the CNS are limited to direct 
injection of gene therapy vectors into the parenchyma or direct delivery to 
cerebrospinal fluid (CSF) through injection into lateral ventricles or into the 
intrathecal space. Some examples of gene therapy approaches that have been 
applied to specific CNS diseases include motor neuron disease, Alzheimer’s 
disease, Huntington’s disease, spinal cord injury and Parkinson’s disease, and 
these will be discussed briefly below.  
1.3.1 Motor neuron disease 
Motor neuron disease is characterized by progressive motor neuron dysfunction 
and death, leading to muscular weakness and wasting. The two most common 
examples of motor neuron diseases are amyotrophic lateral sclerosis (ALS) and 
spinal muscular atrophy (SMA). Approximately 10% of ALS cases are familial 
(fALS) and recently a number of genes have been found to be associated with 
fALS. Gene therapy approaches for ALS have centered on delivery of growth 
factors such as insulin growth factor-1 (IGF-1) (Kaspar et al., 2003; Dodge et al., 
2010) and vascular endothelial growth factor (VEGF) (Azzouz et al., 2004b; 
Dodge et al., 2010), and RNAi-based silencing of mutant SOD1 alleles in 
transgenic ALS mouse models (Ralph et al., 2005; Raoul et al., 2005; Xia et al., 
2006). In most cases, these studies have extended the lifespan of the transgenic 
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mice, but have not prevented disease progression completely. SMA is an 
autosomal recessive disease caused by loss of function of the “survival of motor 
neuron” gene SMN1, which leads to degeneration of motor neurons and infant 
mortality. Gene therapy strategies that have been tested experimentally include 
using AAV9 to deliver SMN1 cDNA to the spinal cord in a mouse model of 
SMA (Foust et al., 2010; Dominguez et al., 2011) or using EIAV-based 
lentiviral vectors to deliver SMN2 to spinal cord motor neurons following vector 
injection into muscles of neonatal SMA mice (Azzouz et al., 2004a). 
1.3.2 Alzheimer’s disease 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by 
severe memory loss and cognitive impairment following the loss of basal 
forebrain cholinergic neurons. One strategy to prevent further cholinergic neuron 
loss is to supply neurotrophic factors such as nerve growth factor (NGF) via 
retrovirus-transduced fibroblast grafts in lesioned rodents and aged non-human 
primates In an initial phase I clinical trial of ex vivo NGF gene therapy, no 
detrimental side effects were observed at 22 months post-engraftment and the 
rate of cognitive decline slowed (Tuszynski et al., 2005). More recently, 
Ceregene are conducting phase I and phase II clinical trials using an AAV vector 
express NGF. 
1.3.3 Huntington’s disease 
Huntington’s disease is caused by progressive death in specific collections of 
striatal neurons and cortical degeneration, leading to lack of muscle 
coordination, cognitive decline and psychiatric illness. It is caused by an over-
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expanded polyglutamine (CAG) tract in exon 1 of the huntingtin gene, htt. To 
date there are no effective cures for Huntington’s disease. Examples of gene 
therapy approaches that have been tested in mouse models of Huntington’s 
disease include using AAV vectors to deliver brain derived neurotrophic factor 
(BDNF) (Gharami et al., 2008; Kells et al., 2008), adenoviral vectors and 
lentiviral vectors to deliver ciliary derived neurotrophic factor (CNTF) (Mittoux 
et al., 2002; Zala et al., 2004), AAV vectors to deliver GDNF (McBride et al., 
2003; 2006) and neurturin (Ramaswamy et al., 2009), as well as RNAi 
approaches to knock down huntingtin proteins (Harper et al., 2005; Boudreau et 
al., 2009; Drouet et al., 2009). While RNAi approaches remain an attractive 
option in HD therapy (where the cause of the disease is completely genetic), the 
studies that have been described thus far decrease expression of both wild-type 
and mutant huntingtin proteins, and the effects of decreased htt expression on 
normal cellular function is unclear. Researchers are therefore currently pursuing 
strategies of allele-specific targeting in which only mHtt expression would be 
down-regulated and this may be a promising approach in the future for treating 
HD. 
1.3.4 Parkinson’s disease 
Parkinson’s disease is a chronic, neurodegenerative disorder characterised by 
shaking, rigidity, slowness of movement and difficulty with walking, due to the 
loss of dopaminergic neurons in the substantia nigra. To date a large number of 
gene therapy approaches to target this disease has been tested in experimental 
models; the success of these studies have resulted in several preclinical trials that 
are currently being conducted in this patient group. The etiology of Parkinson’s 
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disease and gene therapy strategies will be described in more detail in Section 
1.5. 
1.3.5 Spinal cord injury 
Traumatic nerve injuries such as spinal cord injury can produce devastating and 
long-lasting effects in patients, with symptoms ranging from loss of sensation, 
paralysis, chronic pain, incontinence and loss of sexual function. Currently there 
are limited effective treatments for spinal cord injury. Recent breakthroughs in 
spinal cord research have increased our understanding of the problems 
underlying adult nerve regeneration and have facilitated the development of 
experimental therapies for spinal cord injury. These will be described in more 
detail in the next section. 
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1.4 Spinal cord injury 
1.4.1 Pathophysiology of spinal cord injury  
Primary spinal cord injury (SCI) describes the initial traumatic events that can 
results from contusion, compression, penetration or maceration of the spinal 
cord. The immediate events that occur after injury include necrotic cell death of 
neural and endothelial cell tissue and rupturing of blood vessels leading to 
ischemia around the injury site (Dumont et al., 2001). Secondary SCI describes 
the physiological changes that occur in the cord after the initial primary injury 
event. Within a few hours after injury, there is an immunological response to 
SCI. Endothelial cells within the damaged tissue release chemo attractants 
recruiting neutrophils and macrophages to the site of damage. They release 
oxidative and proteolytic enzymes that can lead to damage of spared tissue 
(Taoka et al., 1997), while also releasing pro-inflammatory cytokines that 
exacerbate inflammation by triggering leukocyte invasion (Jones et al., 2005). 
Both neutrophils and macrophages phagocytose debris which can help to clear 
the site of debris, but also leads to reactive oxygen species being released 
(Carlson et al., 1998; Satake et al., 2000)  
Glutamate, the major excitatory neurotransmitter of the CNS (Gasic and 
Hollmann, 1992), is also released at the site of injury, leading to excitotoxic 
effects (Xu et al., 2005) (McAdoo et al., 1999). Neurons and oligodendrocytes 
are particularly susceptible to excitotoxicity as they express a full range of 
glutamate receptors (McTigue, 2008). Excitotoxicity initiates a cascade of events 
that results in the generation of reactive molecules that kill neurons through a 
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 ATPase activity, direct inhibition of mitochondrial 
respiratory chain enzymes, and other modifications to key proteins (Dawson and 
Dawson, 1996; Dumont et al., 2001). Furthermore, lipid peroxidation leads to 
breakdown of cell membrane and mitochondria dysfunction (Sullivan et al., 
2007) and contributes to calcium influx causing damaging changes in cell 
physiology and cell necrosis (Schanne et al., 1979; Xiong et al., 2007).  
Many of the proteins and molecules released either by immune cells or from 
excitotoxicity can trigger apoptosis of neighbouring cells, contributing to further 
loss of neurons, oligodendrocytes and microglia (Crowe et al., 1997; Liu et al., 
1997; Shuman et al., 1997; Beattie et al., 2000). Chronic loss of 
oligodendrocytes from the spinal cord leads to demyelination of spared neurons, 
slowing or blocking the electrical transmission ability of these neurons (Guest et 
al., 2005; McTigue, 2008). Furthermore, demyelinated neurons are more 
vulnerable to attack by the hostile environment in the lesion, leading to further 
cell death (Oyinbo, 2011). 
These processes result in the formation of a cavity, surrounded by a progressive 
glial scar. Initially the scar is formed from myelin and oligodendrocytic debris, 
and some spared oligodendrocytes (Perry and Gordon, 1991). Activated 
microglia and macrophages begin to remove this debris and the site is still 
permissive to axon growth (Fawcett and Asher, 1999). However, as the scar 
progresses it leads to the deposition of molecules that inhibit axonal regrowth. 
Invading immune cells and oligodendrocyte precursors express surface markers 
Chapter 1 - Introduction 
 - 38 - 
NG2 – an inhibitory chondroitinase sulphate proteoglycan (CSPG) (Jones et al., 
2002). Non-CNS cells such as fibroblasts and Schwann cells also migrate to the 
lesion site (Grimpe and Silver, 2002) . Over time the scar becomes a 
predominantly astrocytic mesh held together by many tight junctions and gap 
junctions (Fawcett and Asher, 1999). Astrocytes also produce CSPGs (Lemons 
et al., 1999; Jones et al., 2003) meaning the scar forms a physical and chemical 
barrier to neurite outgrowth and regeneration.  
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1.4.2 Current cellular approaches for treating spinal cord injury 
After spinal cord injury (SCI), the severe loss of cells (including neurons and 
oligodendrocytes) at the lesion site and the formation of the glial scar results in 
permanent barrier through which spared axons cannot regenerate to recover 
spinal cord function. Cell-based therapy has been touted as a promising avenue 
for SCI therapy, as cellular interventions can bridge the cavities with in the 
lesion, replace cells that have been lost, or provide a more permissive 
environment to axon regeneration. 
Unlike the CNS, the PNS has regenerative properties in the adult. To try to 
exploit this, peripheral nerve grafts have been used in the injured spinal cord to 
encourage regeneration. Although regeneration from supraspinal axons was not 
seen when used alone (Richardson et al., 1980); when used in combination with 
other therapies such as anti-inflammatory drugs, vertebral wiring and fibrin glue, 
axons were observed to regenerate down the spinal cord, through and beyond 
grafts in rodents (Cheng et al., 1996; Lee et al., 2004). However when this 
approach was test in nonhuman primates, no functional recovery was detected 
(Levi et al., 2002). There has been very limited experimentation of this idea in 
humans and the outcomes have been inconclusive (Cheng et al., 2004; Steeves et 
al., 2004).  
Olfactory ensheathing cells (OECs) have been hailed as a promising cellular 
therapy for SCI, due to reported successes in rats and non-human primate 
studies. OECs are glial cells derived from the embryonic and adult olfactory 
bulb or mucosa and support growth of olfactory neurons in adults. The use of 
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OECs in SCI was tested in human phase I clinical trials, many of which have 
reported success (reviewed by Radtke et al., 2008). These results should be 
viewed with caution as the lab-to-lab variation in cell biopsy and cell 
preparation, the lack of international standards for safety and efficacy and 
incomplete understanding of how OECs can contribute to axonal regeneration 
suggests that more research in this area is warranted before this strategy is 
implemented in the clinic. 
The embryonic and fetal CNS can regenerate after injury and when fetal spinal 
cords were transplanted into the damaged adult cord, researchers observed some 
functional recovery, but the regenerating axons did not penetrate beyond the 
transplant border (Jakeman and Reier, 1991) (Bregman et al., 1997). 
Furthermore, ethical and resource limitations restrict the wider application of 
this therapy.  
Progress in the field of neural stem cells has made it possible to expand neural 
progenitor cells (NPCs) obtained from a small amount of fetal tissue or 
embryonic stem cells as floating cell aggregates called neurospheres (Reynolds 
and Weiss, 1992). When NPCs were transplanted into rat models of SCI, they 
were observed to differentiate into neurons, astrocytes and oligodendrocytes 
accompanied by function recovery (McDonald et al., 1999; Ogawa et al., 2002). 
Human neural stem cells have also been shown to promote functional recovery 
in mouse and primate models of SCI (Cummings et al., 2005; Iwanami et al., 
2005) and clinical trials are underway (reviewed by Sandner et al., 2012). 
Human embryonic stem cells that have been pre-differentiated into 
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oligodendrocyte progenitor cells demonstrated tremendous efficacy in a rat 
model of cervical spinal cord injury (Keirstead et al., 2005) and this led to a 
Geron-funded phase I trial to test these cells in thoracic spinal cord injuries, 
however the trial was halted due to financial reasons. More recently, Lu and 
colleagues grafted neural stem cells into fibrin matrices containing growth factor 
cocktails into spinal cord lesions and showed axonal extension over remarkable 
distances (Lu et al., 2012). 
For many of these cell-based therapies, chronic immuno-suppression is often 
required in order stop immune-rejection of the transplanted cells. Induced 
pluripotent stem cells (iPSCs), derived from the cells of patients using four 
reprogramming factors (Takahashi and Yamanaka, 2006) should abrogate this 
need and reduce ethical concerns. Neural stems derived from iPSCs were 
initially tested in a mouse model of SCI (Tsuji et al., 2010) and functional 
recovery was observed, although the tumourogenicity of these cells was an 
important factor to consider. Neurospheres generated from human iPSC have 
been generated and tested in a mouse model, and have shown to form functional 
synapses (Nori et al., 2011). However, the safety and immunogenicity generated 
by these cells is not fully understood (Miura et al., 2009; Gore et al., 2011; Zhao 
et al., 2011b). 
Other sources of stem cells that can be utilised for SCI therapy include cells 
derived from adult bone marrow. Bone marrow contains several different 
populations of stems cells, including haematopoietic stem cells (HSCs) and bone 
marrow stromal cells (BMSCs). Both have been seen to improve functional 
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recovery in mouse models of SCI (Wu et al., 2003; Koshizuka et al., 2004; Koda 
et al., 2005). Clinical trials of BMSCs are on going and the clinical efficacy is as 
yet unknown (reviewed by Wilcox et al., 2012). Neural stem cells can also been 
harvested from adult CNS. Active NSCs are found in the dentate gyrus of the 
hippocampus and the subventricular zone (SVZ). They have been shown to self 
renew and be multipotent after transplantation into the CNS. In vivo, adult 
mouse brain SVZ-derived NSCs were able to elicit functional recovery in a rat 
model of SCI when transplanted within a therapeutic window after injury, but 
not a chronic model of SCI (Karimi-Abdolrezaee et al., 2006). Other studies 
with neural stem cells from the spinal cord give mixed results (reviewed by 
Tetzlaff et al., 2011). 
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1.4.3 Molecular therapies for spinal cord injury 
In the past decade, there has been significant breakthroughs in understanding 
why injured nerves, particularly that of the adult mammalian CNS, fail to regrow 
after injury. One main reason is the hostile environment in the spinal cord that is 
generated by the injury and significant progress has been made to identify the 
factors that contribute to this inhospitable environment. Another reason for 
regenerative failure is the poor intrinsic growth potential of the injured nerves. 
This section will aim to briefly describe some examples of experimental 
therapies have been targeted at neutralising the inhibitory growth environment of 
the lesion site or to increase the intrinsic growth potential of injured neurons, 
thus providing a snapshot of the strategies that are currently being explored to 
develop clinical medicines for spinal cord injury. 
1.4.3.1 Chondroitinase. 
CSPGs built up during secondary SCI become a long lasting inhibitory boundary 
that has been shown to hinder regenerative growth and synaptogenesis (reviewed 
by Silver and Miller, 2004). CSPGs consist of a core protein with one or more 
covalently attached chondroitin sulphate glycosaminoglycan (CS-GAG) side 
chains, which are important for the biological function of the CSPGs. 
Administration of the bacterial enzyme chondroitinase ABC can degrade the CS-
GAG from CSPG molecules (Yamagata et al., 1968) reducing their inhibitory 
effect. Lemons and colleagues first demonstrated that ChABC applied to 
contusion-injured rats could degrade CSPGs in vivo (Lemons et al., 1999), 
indicating the therapeutic potential of ChABC. Studies assessing the 
regeneration, functional connectivity, locomotion and proprioception of injured 
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rats revealed that ChABC promoted functional repair and regeneration 
(Bradbury et al., 2002). Subsequent studies have indicated ChABC is 
polyfaceted in promoting repair, including regeneration of lesioned axons, 
sprouting and enhanced connectivity of intact remaining pathways, and 
neuroprotection of injured neurons (reviewed by Bradbury and Carter, 2011). 
Currently, ChABC therapy requires infusion of protein directly into the spinal 
cord. A gene therapy would have advantages, such as a long lasting effect with a 
single injection, while lowering the risk of further trauma and infection. 
Secretion of bacterial ChABC from mammalian cells is hindered by 
glycosylation events, so Muir and colleagues created ChABC mutants that 
retained enzymatic activity, but allowed the protein to be fully secreted when 
overexpressed form a lentiviral vector (Muir et al., 2010). These vectors are now 
being tested in a rat model of spinal cord injury. While there was no test of 
behavioural recovery at this stage, injection to either the CST neurons in the 
sensory motor complex or the spinal cord directly lead beneficial effects similar 
to those seen by direct infusion of ChABC protein (Zhao et al., 2011a) 
A number of studies have investigated the possibility of combining ChABC 
treatment with other interventions that target different challenges for repair. For 
example, combining ChABC administration with peripheral nerve graft 
implantation gave increased regeneration (Yick et al., 2000) and ChABC 
infusion at the interface of a Schwann cell bridge enhanced re-growth into host 
tissue (Chau et al., 2004). 
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1.4.3.2 Anti-Nogo therapeutics 
In the normal CNS, myelin plays a critical role in solidifying connections 
established in development but in the adult mammal, myelin-derived molecules 
are critical inhibitors of axonal growth/regeneration after SCI. The main myelin-
derived inhibitors present at the lesion site are Nogo (a component of central 
myelin), myelin-associated glycoprotein (MAG) and oligodendrocyte myelin 
glycoprotein (OMgp). All three signal through a common Nogo receptor 
complex consisting of NgR, low-affinity neurotrophin receptor p75, LINGO-1 
and TAJ/TROY. Upon activation, the complex activates the GTPase RhoA 
which subsequently recruits Rho kinase and activates downstream events to 
remodel the actin cytoskeleton to inhibit regeneration (reviewed by Zörner and 
Schwab, 2010). Following the identification of Nogo-A as a potent inhibitor, 
Schwab and colleagues demonstrated that neutralization of Nogo-A with 
antibodies (IN-1) increased functional regeneration of injured CNS neurons 
(Schnell and Schwab, 1990). Since this study, new anti-Nogo-A antibodies such 
as 11C7 and 7B12, the NgR blocking peptide NEP1–40, soluble NgR-Fc and 
Lingo-Fc fusion proteins have been developed and tested in animal models 
(reviewed by Zörner and Schwab, 2010).  
1.4.3.3 Increasing the intrinsic growth potential of injured spinal cord neurons 
In addition to identifying the inhibitors that present a major obstacle to axon 
regeneration in the injured CNS, researchers have also attempted to uncover 
factors that can promote intrinsic growth pathways within injured spinal cord 
neurons. For example, cAMP has been shown to induce axonal sprouting of 
cultured neurons in vitro and of injured adult rat spinal sensory neurons in vivo 
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when prophylactically applied (Neumann et al., 2002; Qiu et al., 2002). 
Researchers have also used peripheral nerve injury models to identify neuron-
intrinsic regeneration-associated genes (RAGs) that play a role in axon 
regeneration. A number of these RAGs include transcription factors such as 
Atf3, c-Jun, Stat3 and Sox11 and it has been proposed that transcription factor 
hubs may potentially coordinate the regenerative response via a regeneration-
associated gene network (reviewed by van Kesteren et al., 2011). Indeed, gene 
transfer of transcription factors such as CREB (cAMP response element binding 
protein) (Gao et al., 2004), ATF3 (activating transcription factor 3) (Seijffers et 
al., 2006), or  RARβ2 (retinoic acid receptor β2) (Wong et al., 2006; Yip et al., 
2006) has been shown to enhance axonal outgrowth. The study of RARβ2 in 
nerve injury models will be described in more detail in Chapter 5. 
1.4.4 Combinatorial approaches to treating spinal cord injury 
It is becoming increasingly clear that given the complexity of obstacles to axonal 
regeneration following spinal cord injury, it is quite likely that combinatorial 
approaches that address both the intrinsic and extrinsic cues will be the best 
strategy forward to achieve axonal growth sufficient for robust functional 
recovery after spinal cord injury. Gene therapy can provide a means of achieving 
one or more of these goals. An example of such a combinatorial approach is the 
use of sciatic nerve conditioning lesion, mesenchymal stem cells and NT-3 
expressing lentiviral vector to facilitate successful bridging regeneration of adult 
CNS axons following dorsal column transection at the C3 level (Kadoya et al., 
2009). Indeed, gene transfer to provide neurotrophic factors such as NT-3 and 
BDNF in combination with cell grafts (to bridge the lesion site) have been 
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explored in a large variety of animal models of axon injury (reviewed by Franz 
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1.5 Parkinson’s disease 
Parkinson’s disease (PD) is a neurodegenerative disease characterised by the 
progressive loss of dopaminergic neurons in the substantia nigra pars compacta 
(SNPC) and the presence of intraneuronal proteinaceous cytoplasmic inclusions, 
called Lewy bodies. As striatal dopamine is lowered, motor deficits symptomatic 
of PD emerge, namely rigidity, tremor, brady-kinesia, gait impairment and 
postural instability (Forno, 1996). The cause of PD is unknown in the majority 
of cases: only 10% of cases can be directly linked to genetic mutations. 
Environmental factors, or combinations of environment and genetic 
susceptibility are proposed to play a role in sporadic cases. Though as yet poorly 
understood, the death of dopaminergic neurons has been linked to mitochondrial 
dysfunction, oxidative stress, neuro-inflammation and insufficient proteasomal 
protein degradation (Dauer and Przedborski, 2003; Hirsch and Hunot, 2009) 
The current standard treatment for PD is based on restoration of striatal 
dopamine (DA) neurotransmission by supplying the DA precursor L-3,4-
dihydroxyphenylalanine (L-DOPA) through oral medication to provide relief 
from motor symptoms. In the early stages of PD this approach is very effective, 
but declines in efficiency as the disease progresses. Many patients develop side 
effects such as dyskinesias and hallucinations, which can limit the dose of L-
DOPA that can be tolerated (Obeso et al., 2000). Therefore the search continues 
for an alternative treatment that requires only a single administration to safely 
provide symptomatic relief, halting or even reversing the progression of the 
disease. 
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1.5.1 Models of Parkinson’s disease 
In order to study Parkinson’s disease, several pre-clinical models have been 
developed that replicate aspects of the pathology seen in human patients. These 
can be broadly divided in two categories: neurotoxic and genetic models. Of the 
neurotoxic models, the most widely used are the rodent 6-hydroxydopamine 
(6OHDA) lesion model and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) non-human primate model. 
The 6OHDA model has been developed for the study of PD since the late 1960s 
(Ungerstedt, 1968). In the brain, 6OHDA is preferentially taken up by the 
dopamine transporter expressed by the DA cells projecting from cell bodies 
residing in the SNPC (Luthman et al., 1989). In the cytosol, 6OHDA generates 
reactive oxygen species leading to oxidative stress related cytotoxicity (Saner 
and Thoenen, 1971; Graham, 1978). 6OHDA does not cross the BBB so it must 
be delivered directly into the brain, usually at either the SNPC, the striatum or 
medial forebrain bundle (MFBB). Injection of 6OHDA to the SNPC or MFBB 
leads to significant and rapid degeneration of DA neurons and striatal terminals 
within days (Faull and Laverty, 1969; Jeon et al., 1995). In contrast, and 
potentially indicating a more relevant model of PD, striatal injection of 6OHDA 
produces a slower, progressive, partial lesion of DA neurons in the SNPC (Sauer 
and Oertel, 1994; Kirik et al., 1998).  
This model has a major advantage in that it can be used to produce quantifiable 
asymmetric rotation behaviour in unilaterally lesioned animals. Subsequent to 
lesion, this behaviour is triggered by the injection of either dopamine receptor 
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agonists (such as apomorphine) or dopamine releasing compounds (such as 
amphetamine). The number of rotations, due to the imbalance of striatal 
dopamine signalling between lesioned and non-lesioned hemispheres, correlates 
with the magnitude of the SNPC lesion and DA neuron loss. (Ungerstedt, 1968; 
Ungerstedt and Arbuthnott, 1970). A disadvantage is that the 6OHDA model 
does not produce proteinaceous aggregates or Lewy bodies. Despite this, the 
model has been extensively utilized as a preclinical model for screening the 
efficacy of novel treatments for PD.  
The MPTP model was developed from the accidental finding that drug users 
unintentionally using drugs contaminated with MPTP, developed severe 
symptoms similar to those of PD patients (Langston et al., 1983). Indeed, their 
motor deficits were successfully treated with L-DOPA, suggesting a common 
underlying pathology, and postmortem studies confirmed the loss of the 
nigrostriatal pathway in these patients (Davis et al., 1979; Langston et al., 1999). 
Although this pathology can be applied to many higher mammals, it is perhaps 
best represented in the non-human primate MPTP model that has become the 
gold standard of pre-clinical testing.  
MPTP toxicity arises from its metabolite MPP+, produced by astrocyte and 
released in the vicinity of DA neurons. Upon accumulation in DA neurons, 
MPP+ inhibits complex 1 of the mitochondrial electron transport chain, leading 
to ATP depletion and increased oxidative stress (Nicklas et al., 1985; Mizuno et 
al., 1987). The neurotoxic effect of the nigrostriatal system and behavioural 
evaluations of motor deficits have been well characterized, and it has even been 
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suggested that Lewy bodies may be formed in primates using this model (Fornai 
et al., 2005).  
1.5.2 Genetic models of Parkinson’s disease 
The first gene to be linked to familial PD is α-synuclein. α-Synuclein is a small 
(140 amino acids) but abundant neuronal protein that is particularly enriched in 
pre-synaptic terminals. Three missense mutations (A53T, A30P and E46K) 
cause dominantly inherited PD (Gasser, 2009; Lees et al., 2009). Furthermore, 
simple duplication or triplication of α-synuclein itself is sufficient to cause PD, 
suggesting that the level of expression of α-synuclein is a critical determinant of 
PD progression (Singleton et al., 2003; Singleton, 2005). A number of animal 
models of α-synuclein induced neurodegeneration have been generated; these 
include transgenic mice overexpressing wild-type A53T or A30P α-synuclein 
under the control of Thy1 or PrP promoters (reviewed by Dawson et al., 2010) 
or more recently, AAV-mediated overexpression of human α-synuclein in rats 
(Decressac et al., 2011). Interestingly, GDNF did not exert any neurotrophic 
factor effects in the latter PD model, as opposed to positive results described in 
previous studies involving the more commonly used neurotoxin models of PD. 
The difference in these results raises the importance of testing experimental 
therapies in both chemical and genetic preclinical models of PD. 
The increasing number of genetic associations that have been identified with PD 
have also led to the development of other genetic models of PD. These include 
transgenic mice overexpressing leucine rich repeat kinase 2 (LRRK2) and mice 
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that are deficient for Parkin, DJ-1, phosphatase and tensin homolog (PTEN)-
induced novel kinase 1 (PINK1) (reviewed by Dawson et al., 2010). 
1.5.3 Gene therapy and Parkinson’s disease. 
Gene therapy is a promising approach for the treatment of Parkinson’s disease 
for several reasons. It does not require indwelling hardware, yet therapeutic 
factors can be consistently delivered directly into the required area, abrogating 
dose fluctuations and the requirement for agents to pass the blood-brain-barrier 
(BBB). There are several therapeutic genes that have entered clinical trials, 
briefly discussed below. 
1.5.3.1 Glutamic decarboxylase (GAD) 
In PD, the subthalamic nucleus (SN) become disinhibited due to decreased 
GABA input leading to excessive activation, potentially giving rise to the 
symptoms of PD. Delivering GAD (glutamic decarboxylase, a catalyst for the 
inhibitory GABA) to the SNPC using AAV2 vectors is an approach to restore 
normal function. Indeed, in phase I clinical trials, improvements in motor 
function were seen without any observable adverse side effects (Kaplitt et al., 
2007; LeWitt et al., 2011). However, this approach is not neuroprotective or 
restorative, nor does it address PD symptoms outside of motor circuitry. 
1.5.3.2 Aromatic L-amino acid decarboxylase (AADC) 
Aromatic L-amino acid decarboxylase (AADC) is an enzyme involved in the 
dopamine synthesis pathway, converting L-DOPA (L-3,4-
dihydroxyphenylalanine) to dopamine. Levels of AADC activity, mRNA and 
protein have been found to be lower in the postmortem brains of PD patients 
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(Lloyd et al., 1975; Nagatsu and Sawada, 2007), potentially contributing to the 
need for increased frequency and dosage of levodopa in advanced stages of PD. 
By re-introducing AADC using AAV vectors, local conversion of levodopa to 
dopamine can be increased; meaning the dose of levodopa can be lowered to 
reduce side effects. Pre-clinical data in rats (Leff et al., 1999) and primates 
(Bankiewicz et al., 2006) indicated long term expression of AADC lead to 
increased striatal DA levels. Two phase I trials have been carried out 
(Muramatsu et al., 2010; Mittermeyer et al., 2012), and although improvement in 
motor function have been observed, side effects experienced by some patients 
indicate that more investigation is needed to determine the safety and clinical 
relevance of this approach. 
1.5.3.3 AADC, GTP-cyclohydrolase-1 (GCH-1) and tyrosine hydroxylase (TH) 
These enzymes are all members of the dopamine synthesis pathway. Tyrosine 
hydroxylase (TH) catalyses the synthesis of L-DOPA from L-tyrosine, which is 
then converted to dopamine by AACD. GTP cyclohydrolase 1 (GCH1) is the 
late limiting enzyme in the formation of tetrahydrobiopterin (BH4), an essential 
cofactor for TH (Kumer and Vrana, 1996; Elsworth and Roth, 1997) that is also 
reduced in PD (Nagatsu and Ichinose, 1997). Re-introducing these genes into the 
striatum can increase dopamine production at the site of injection; yet avoid 
excessive production in areas where dopamine is not depleted. Furthermore, the 
continuous production of dopamine, compared to pulsatile levodopa, may 
prevent levodopa-induced dyskinesia (Olanow and Obeso, 2000). 
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Pre-clinical studies co-transducing three individual AAV vectors expressing 
these enzymes in rat and primate models of PD (Shen et al., 2000; Muramatsu et 
al., 2002) decreased motor deficits. Tricistronic EIAV vector expressing these 
genes was also successful in preclinical studies (Azzouz et al., 2002; Jarraya et 
al., 2009) and dose escalation studies are underway, so far indicating reduction 
of motor deficits in patients. 
1.5.4 Neurotrophic factors for Parkinson’s disease 
The strategies discussed so far aim to treat the symptoms of PD. A further 
reaching strategy is to delay symptoms by providing protection to, or even 
stimulating restoration of SNPC neurons, by providing additional trophic 
support. 
1.5.4.1 Glial derived neurotrophic factor (GDNF)  
Interest in using GDNF (Glial derived neurotrophic factor) as a potential therapy 
for PD stems from in vitro studies, where it was found that embryonic ventral 
mesencephalon (VM) DA cell survival was increased in the presence of GDNF 
(Lin et al., 1993). Subsequent studies revealed the potent dopaminotrophic 
effects of GDNF protein infusions that lead to both neuroprotection and 
neurorestoration in animal models (Gash et al., 1996; Shults et al., 1996; 
Björklund et al., 1997; Rosenblad et al., 1998; 1999). However, studies reported 
that improvements in symptoms were lost after cessation of treatment (Zhang et 
al., 1997), suggesting chronic infusion of GDNF is required. However, long term 
direct infusion of GDNF into the brain can lead to problems, including 
complications associated with the chronically implanted infusion device (Kirik 
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et al., 2004). Gene therapy offers an alternative method to supply specific 
regions of the brain with GDNF long term. Indeed, in many studies, this 
approach was efficacious using AD, AAV and lentiviral vectors (reviewed by 
Hong et al., 2008). However, some reported a decrease in TH levels and aberrant 
neuronal sprouting, raising concerns about the long-term high levels of delivery 
(Georgievska et al., 2002; 2004b). Furthermore, GDNF fails to exert 
neuroprotection in a α-synuclein rat model of Parkinson’s disease, indicating 
GDNF may not be able to modulate metabolic cell death due to abnormal protein 
aggregation (Bianco et al., 2004; Decressac et al., 2011). Clinical trials using 
GDNF have focused on the infusion of protein rather than gene therapy 
approaches. Results of these trials have given mixed results. PD symptoms were 
not reduced in two trials delivering GDNF to the ventricles (Kordower et al., 
1999; Nutt et al., 2003) and while one reported improvements following 
Intraputamenal delivery (Gill et al., 2003; Patel et al., 2005), further studies have 
failed to validate these findings (Lang et al., 2006).  
1.5.4.2 Neurturin 
Neurturin is a neurotrophic factor in the GDNF family (Kotzbauer et al., 1996) 
and has been shown to enhance the survival of dopaminergic neurons both in 
vitro and in rodent (Horger et al., 1998; Rosenblad et al., 2000; Oiwa et al., 
2002) and non-human primate models of PD (Li et al., 2003; Kordower et al., 
2006). Furthermore, there have been indications that it can aid restoration of DA 
neurons in rodent lesion models (Oiwa et al., 2002). In the preclinical studies, 
AAV2-Neuturin vectors were injected into the striatum of non humans primates, 
resulting in an increase of neurturin in the striatum and SNPC, along with an 
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increase in tyrosine hydroxylase in DA neurons (Herzog et al., 2007; 2008). In 
phase I clinical trial, there were no adverse effects and measures of motor 
function showed improvement (Marks et al., 2008). However, in a phase II 
double blind randomized clinical trial, analysis 12 months post injection of 
vector showed there was no difference in motor function between treated and 
sham operated groups. Subsequent analysis suggested that although neurturin 
was being adequately expressed a the site of injection (putamen), it was not 
transferred back to the SNPC (Bartus et al., 2011). This indicated that further 
trials were required, including an additional intranigral injection of vector, which 
are now underway. 
1.5.4.3 Conserved dopamine neurotrophic factor and Mesenchymal astrocyte 
derived neurotrophic factor (CDNF/MANF)  
CDNF and MANF are members of the novel family of neurotrophic factors 
(Lindholm et al., 2007). In vitro studies revealed that MANF could promote the 
survival of DA neurons in ventral midbrain (VM) cultures (Petrova et al., 2003). 
Subsequently, MANF protected DA and there was a reduction in rotation 
behaviour in the 6OHDA model of PD (Voutilainen et al., 2009). Similar 
benefits have been seen with CDNF, where a single pre-treatment with CDNF 
protein prevented 6OHDA-induced degeneration of DA neurons. (Lindholm et 
al., 2007) Furthermore, chronic administration starting two weeks post-lesion 
inhibited the 6OHDA induced loss if DA neurons in the SNPC, and TH fibres in 
the striatum (Voutilainen et al., 2011). 
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1.6 Aims and Objectives 
Gene therapy is a powerful tool for delivering therapeutic factors into the CNS. 
However, there is an unmet need for systems to regulate the levels of transgenes 
in a clinical setting. Existing methodologies for regulating gene therapy agents 
have disadvantages that make them unsuitable for the clinic, so novel regulatory 
systems are of interest. 
Destabilisation domain (DD) technology, developed by the Wandless laboratory 
at Stanford University, is a novel approach that is receiving considerable 
interest. This technology is composed of a protein domain engineered to be 
unstable until stabilised by a ligand. When fused to a protein of interest, the 
conditional stability of the domain is conferred to the fusion partner.  
 In this study, we will assess two different DD technologies to determine which 
is best suited to regulating the levels of therapeutic genes in the CNS. We will 
begin this process by attempting to regulate levels of reporter proteins (such as 
green fluorescent protein (GFP) and luciferase) delivered using viral vectors to 
cell lines and primary cultured neurons. After testing and identifying the 
constructs that yield the most efficacious results, we will proceed to test the 
ability of the vectors to regulate reporter genes in vivo. 
Next, we will determine if this regulatory system is able to regulate genes that 
may of interest in the treatment of nerve injuries or Parkinson’s disease.  
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Retinoic acid receptor β2 (RARβ2) has been shown to mediate pro-regenerative 
retinoic acid outgrowth programs in neurons. When delivered to the 
sensorimotor cortex in rat models of SCI, the increased sprouting of new 
projections correlated with a reduction in motor deficits, suggesting it may have 
potential as a therapy for spinal cord injury. We will develop a regulatable 
RARβ2 vector and test it in vitro to determine if the appropriate downstream 
pathways can be stimulated in DRG neurons to encourage neurite outgrowth. 
We will then determine the efficacy of the vector in vivo, in a rat model of SCI. 
CDNF has recently been identified as a potential candidate for protecting and 
restoring dopaminergic neurons of the substantia nigra pars compacta (SNPC) 
that are lost in Parkinson’s disease. Here we will investigate a gene therapy 
approach to deliver a regulatable form of CDNF to the SNPC. After preliminary 
testing of the vector in vitro, we will implement it in a rat model of Parkinson’s 
disease.  
Overall, we aim to add to the modest body of evidence so far collected on 
destabilisation domain systems, to help predict if these systems could be of 
clinical relevance in the future. 
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Chapter 2 Methods 
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2.1 DNA manipulation techniques 
2.1.1 Polymerase chain reaction (PCR) 
Double stranded DNA fragments were produced using the Fast start high fidelity 
PCR kit (Roche). The reaction conditions were the following: 
High fidelity PCR 
 AMOUNT SUPPLIER 
Template 20-40ng  
Forward primer (10µM) 1µ l MWG operon 
Reverse primer (10µM) 1µ l MWG operon 
10X Reaction Buffer (+Mg
2+
) 2.5µ l Roche 
10mM dNTPs 4µ l Invitrogen 
DMSO 2µ l Roche 
Taq 0.5µ l Roche 
ddH2O Up to 25µ l Sigma 
2min at 95ºC   
30s at 95ºC   
30s at 55-65ºC* X 40 cycles 
60s at 72ºC   
10min at 72ºC   
   
Figure 2-1 High fidelity PCR using Fast start high fidelity PCR kit (Roche) 
*Cloning PCR primers were typically run on a gradient of annealing temperatures between 55-65
o
C.  
PCR products were typically separated by electrophoresis on a 1% agarose gel at 
75V. Annealing temperature was changed to match specific primer pairs, usually 
between 55 and 65ºC. 
2.1.2 Agarose gel electrophoresis 
DNA fragments were separated and purified using agarose gel electrophoresis. 
Electrophoresis-grade agarose (Invitrogen) was dissolved in 1x TAE (40mM 
tris-acetate, 1mM EDTA) by boiling briefly in a microwave oven. Once the 
agarose solution (usually 1% [w/v]) had cooled, ethidium bromide (EtBr) was 
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added (final concentration of 0.5µg/ml), before the mix was poured into a 
suitably sized casting tray with an appropriate comb. Once the gel had set, it was 
submerged into 1x TAE buffer in a horizontal gel electrophoresis tank (Jencons). 
Prior to loading, the DNA sample was mixed with 0.2 volumes of a 6x DNA 
loading buffer (Invitrogen). Appropriately sized molecular weight markers were 
run alongside the samples (e.g. the ‘1kb DNA ladder’ (NEB)). The gel was run 
at a constant voltage of between 5–10V/cm for sufficient time to allow the 
different DNA bands the separate. The bands were visualised using a ultra-violet 
illumination source (Ultra-Violet Products, Cambridge, UK) and images 
captured using a Gel-Doc image capture system (Bio-Rad, Hercules, CA, USA).  
2.1.3 DNA extraction from agarose gels 
To extract DNA from gel, the band was excised from the gel using a scalpel. The 
QIAquick gel extraction kit (QIAGEN) was used to extract the DNA from the 
gel according to the manufacturer’s instructions. Briefly, 3 volumes of buffer 
QG were added to 1 volume of gel and dissolved at 50ºC. Isopropanol (1 gel 
volume) was added to the tube and mixed and the resulting sample loaded onto a 
QIAquick column and centrifuged at 17,900 RCF for 1 minute. The flow-
through was discarded and 750µl buffer PE was added to the column and 
centrifuged at 17,900 RCF for 1 minute. Again, the flow through was discarded 
and the column was centrifuged again for 1 minute to remove residual PE. DNA 
was eluted in 30-50µl ddH2O.  
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2.1.4 Quantification of DNA 
DNA was quantified using agarose gel electrophoresis and the intensity of the 
sample band was compared with the intensity of bands of known concentration 
from the molecular marker (1KB ladder, NEB). In addition, DNA concentration 
may be determined using spectrophotometry. The 260/280 ratio used to 
determine the quality of the sample, with ratios in the range of 1.8-2.1 
considered high quality DNA. 
2.1.5 Desphosphorylation of DNA fragments 
Prior to ligation, vector backbones were dephosphorylated to prevent self-
ligation of the cut ends (thus reducing empty vector clones) using the Rapid 
DNA Dephosphorylation kit (Roche). rAPid Alkaline Phosphatase Buffer (10x - 
Roche) was diluted to 1x in DNA sample and 1µl (1U) Rapid Alkaline 
Phosphatase (Roche) was added after making a total reaction volume of 20µl 
with ddH2O. The sample was incubated for 10 minutes (5’ overhangs) or 30 
minutes (3’ extensions) at 37ºC before heat inactivating the enzyme at 75ºC for 2 
minutes.  
2.1.6 Ligation of DNA fragments 
Vector and insert DNA were ligated together using the Rapid DNA Ligation Kit 
(Roche) according to the manufacturer’s protocol. Briefly, 5x DNA dilution 
Buffer was diluted to 1x in a total reaction volume of 10µl containing DNA 
fragments (200ng total) and ddH2O. To calculate the volumes of DNA required 
to give either a 3:1 or 5:1 ratio between insert DNA and vector DNA, the 
following equation was used:  
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After mixing, 10µl of 2x DNA Ligation Buffer was added and mixed, before the 
addition of 1µl (5U) of T4 DNA Ligase. The reaction was allowed to proceed for 
5 minutes at room temperature before transformation into chemically competent 
Escherichia coli.  
2.1.7 Transformation of chemically competent Escherichia coli 
Escherichia coli strains DH5α or Stbl3 (Invitrogen) were used for all 
transformations. DH5α cells were used for all cloning until such time as the 
DNA was required for lentivirus production, at which point Stbl3 cells were 
used. All transformations were performed according to the manufacturer’s 
instructions, using aseptic techniques. Briefly, between 1-10ng of DNA was 
added to 50µl cells thawed on ice (without vortexing). The cells were incubated 
on ice for 30 minutes prior to heat shock at 42ºC for 20 seconds (DH5α) or 45 
seconds (Stbl3). The tube was incubated on ice for 2 minutes and then 950 µl LB 
media (25g/L LB-Broth Miller (Fisher), 1mM NaOH) (DH5α) or 250µl SOC 
medium (Invitrogen) - Stbl3) was added to the cells. Cells were incubated for 1 
hour at 37
o
C with shaking before plating on onto pre-warmed LB agar plates 
(25g/L LB-Broth Miller (Fisher), 1mM NaOH, 1.5% agar [w/v], 1mM NaOH) 
containing the appropriate antibiotic. Cells were either plated directly (20-200µl 
of incubated cells), or briefly centrifuged (2000 RCF) before resuspension in 
20µl media, depending on the expected efficiency of the ligation reaction. LB 
agar plates contained either 100µg/ml ampicillin (Sigma) for pRRL series 
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were incubated overnight at 37ºC and colony growth examined the following 
day. 
2.1.8 Small scale preparation of plasmid DNA 
Single bacterial colonies were picked from agar plates using a sterile pipette tip. 
The tip was dropped into 5ml LB broth (25g/L LB-Broth Miller (Fisher), 1mM 
NaOH) containing appropriate antibiotic selection, and incubated at 37˚C with 
shaking for 12-16 hours. 1-2ml of the bacterial broth was transferred into a 
microcentrifuge tube and centrifuged at 5000 RCF for 2 minutes. The 
supernatant was discarded and the cell pellet was processed using the QIAprep 
miniprep kit (QIAGEN). The cell pellet was resuspended in 250 µl buffer P1 and 
then 250 µl lysis buffer P2 added to the cells. The tube was inverted to mix the 
contents. Buffer N3 (350 µl) was added to the tube and inverted to neutralise the 
lysis reaction. The tube was centrifuged at 17,900 RCF for 10 minutes at room 
temperature and the resulting supernatant transferred to a QIAprep spin column. 
The spin column was centrifuged for 1 minute and then washed by adding 500µl 
buffer PB and centrifuging again for another minute. The flow-through was 
discarded and a further wash step was carried out by the addition of 750µl buffer 
PE. The column was centrifuged for 1 minute, the flow-through discarded and 
the column was centrifuged again for 1 minute. Purified DNA was eluted in 30-
50µl ddH2O. 
2.1.9 Confirmation of ligation by restriction enzyme digest 
To evaluate whether the ligation of the insert into the vector backbone had been 
successful, DNA was restriction digested with appropriate restriction enzymes 
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using the appropriate reaction buffer for a minimum of 3 hours at 37˚C. Digested 
DNA was electrophoresed on a 1% agarose gel and bands visualised under UV 
light.  
2.1.10 DNA sequencing 
 Plasmid DNA obtained in either small or large scale preparations were sent for 
sequencing to Value Read Tube Sequencing service at Eurofins Genetic Service 
London (Ltd.), or the Single Run Sequencing Service at GATC Biotech, 
Germany, or the SpeedREAD service at Sourcebioscience (Oxford). Sequencing 
primers were selected to allow maximal coverage of a newly inserted DNA 
fragment (Table 2-1). ClustalW online software was used to compare the desired 
sequence to that obtained from sequencing 
(http://www.ebi.ac.uk/Tools/clustalw2/).   
 
 
Table 2-1 Sequencing primers  
CMV 3’ forward binds to the 3’ end of the CMV promoter and extends downstream into genes of interest. 
WPRE 5’ reverse bid and the 5’ of WPRE and extends upstream into genes that precede the WPRE. By 
using either or both of these primers, transgenes can be fully sequenced provided they are not longer than 
1400kb. 
2.1.11 Large scale preparation of plasmid DNA 
The double-caesium chloride (CsCl) density gradient technique was used to 
purify large quantities of DNA of high enough purity for transfection reactions. 
Confluent bacterial cultures (1ml) were used to inoculate 500ml LB broth 
Primer Name             Primer Sequence (5’-3’)
CMV 3’ forward           ATCCACGCTGTTTTGACCTC   
WPRE 5’ reverse            GGCATTAAAGCAGCGTATCC  
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containing appropriate antibiotics (usually 100µg/ml ampicillin), and incubated 
at 37ºC with shaking for 12-16 hours. Cell suspensions were centrifuged at 3,434 
RCF for 20 minutes at room temperature. The supernatant was discarded and the 
pellet was resuspended in 18ml Solution 1 (25mM Tris-HCl pH8.0, 10mM 
EDTA pH8.0, 50mM glucose). Following resuspension, 2ml Lysozyme solution 
(1% lysozyme [w/v] (Sigma), 10mM Tris pH8) was added along with 40ml 
Solution 2 (0.2M NaOH; 1% [w/v] SDS) and incubated for no longer than 10 
minutes at room temperature. Ice cold Solution 3 (5M potassium acetate; 11.5% 
glacial acetic acid) was then added and mixed by inversion 6 times. The lysate 
was then incubated for 10 minutes on ice before centrifugation at 3,434 RCF for 
20 minutes at 4˚C. The supernatant was filtered through Whatman filter paper to 
remove protein contamination, before the addition of 0.6 volumes isopropanol. 
The solution was left at room temperature for at least 10 minutes before 
centrifugation at 4,020 RCF for 20 minutes at room temperature. The 
supernatant was discarded and the pellet air dried, before re suspension in 3 ml 
TE buffer (10mM Tris pH 8, 1mM EDTA pH 8) followed by purification in a 
caesium chloride (CsCl) gradient centrifugation.  
An equal amount of CsCl [w/v] was added to the DNA followed by ethidium 
bromide (EtBr) (200µg/ml final concentration) before centrifugation at 12,000 
RCF for 10 minutes at room temperature. The supernatant was transferred into 
an OptiSeal Ultracentrifuge tube (Beckman) and topped up with TE/CsCl 
solution (1:1) prior to centrifugation at 400,670 RCF (NVT65 Rota, Optimal LE-
80K Ultracentrifuge, Beckman Coulter) for 12-16 hours at 20ºC. The resulting 
DNA band was excised and placed into a fresh OptiSeal Ultracentrifuge tube 
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taking care not to carry over any ‘nicked’ DNA (visible as a smaller band higher 
up in the tube).  Again, the volume was topped up using TE/CsCl and 
centrifuged for 400,670 RCF for 6 hours. The DNA band was excised and EtBr 
removed using butanol saturated with H2O. CsCl was removed from DNA by 
adding 10ml ddH2O followed by 45ml 100% ethanol and incubating at 4˚C for 
20 minutes. DNA was centrifuged at 12,000 RCF for 20 minutes at 4˚C. The 
supernatant was discarded and the pellet washed in 70% ethanol (200µl) prior to 
centrifugation for 5 minutes at 12,000 RCF. The pellet was dried using suction 
and resuspended in ddH2O. 
2.1.12 Transfection of HEK293T cells with plasmid 
To test DNA constructs before lentivirus production, plasmids were transfected 
into human embryonic kidney cells, bearing the large T antigen of SV40 virus 
(HEK293T) cells. Cells were plated at 75,000 cells/well in a 12 well plate in 1ml 
of DMEM culture medium 24 hours prior to transfection. 1µg of DNA was 
transfected in each well using Fugene6 transfection reagent (Roche). Reaction 
ratio was 1µg DNA: 3.6µl Fugene6. Briefly, for one well, 3.6µl Fugene6 reagent 
was added to 36.4µl serum free medium (DMEM with no supplements), mixed 
well and incubated for 5 minutes at room temperature. DNA was then added and 
mixed thoroughly before incubation at room temperature for 30 minutes. The 
media volume on the cells was reduced to 0.5ml before addition of 
DNA/Fugene6 mix. After 3 hours, wells were topped up with 1ml DMEM and 
incubated for a further three days, before harvesting for analysis via flow 
cytometry or Western blot. 
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2.2 Lentivirus production and titration  
2.2.1 Generation and amplification of recombinant lentiviral vectors 
8x10
6
 low passage (<40) HEK293T cells were plated into 15cm
2
 plates (12 
plates required per virus for concentrated preparations, 3 for unconcentrated) in 
20ml medium (DMEM supplemented with 10% FBS (Sigma), 2mM L-
glutamine, 100 units/ml penicillin 100µg/ml streptomycin and 1x MEM non-
essential amino acids (Sigma)) before incubation at 37˚C in a humidified 
atmosphere containing 5% carbon dioxide and 20% oxygen for 24 hours. 
Cells were co-transfected with the genome plasmid (10µg), pMDLgp-RRE 
(gag/pol, 10µg), pMD2-VSV-G (Env, 3.4µg) and pRSV-Rev (2µg). Briefly, 
DNA added to a sterile polypropylene container and made up to 1125µl with 
ddH2O. 140µl 2M Calcium chloride was added to the DNA solution and mixed. 
1125µl Hepes-buffered saline (HBS; 50mM HEPES, 280mM NaCl, 1.5mM 
Na2HPO4) was added to the DNA drop wise with mixing and the solution left to 
incubate at room temperature for 30 minutes. Transfection mix (2.4ml/plate) was 
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 1x 3.5x 12.5x 
genome 10µg 30µg 125µg 
gag/pol 10µg 30µg 125µg 
env 3.4µg 11.9µg 42.5µg 
rev 2µg 7µg 25µg 
H2O up to 1.125ml up to 3.938ml up to 14.063ml 
2 M CaCl2 140µl 490µl 1.75ml 
HBS (added drop-wise) 1.125ml 3.938ml 14.063ml 
Table 2-2 Scale up of transfection reactions 
Reaction mixture required for one, three or twelve 15cm
2
 plates. Three plates were used for unconcentrated 
preparations, 12 plates for concentrated preparations. 
Table 2-2 shows how the reactions mixture is scaled up for multiple pates. The 
following morning, all media was replaced with fresh medium containing 10mM 
sodium butyrate (NaBu). Medium was harvested 6 hours later and replaced with 
16ml fresh medium (no NaBu). Cells were returned to the incubator and the 
harvested medium was stored at 4
o
C for concentrated preparations. For 
unconcentrated preparations this harvest was discarded. 
The following morning the rest of the medium was harvested and pooled 
together with the first harvest. Culture plates were discarded at this point. 
Harvested medium was centrifuged for 5 minutes at 1200 RCF (Megafuge-20R; 
Heraeus Sepatech) before the supernatant was filtered through a 0.45µm filter 
unit (Nalgene) using a vacuum pump. The cell-free supernatant was stored at -
20
o
C if an unconcentrated preparation. For concentrated preparations, the 
supernatant was centrifuged at 6337 RCF (SLA 3000 rotor - Sorvall Evolution 
RC) overnight at 4˚C.  To further concentrate the viral particle suspension, the 
resulting pellet was resuspended in 5ml of ice-cold PBS and transferred into a 
14ml thin-wall polyallomer tube (Beckman-Coulter) and centrifuged at 70952 
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RCF (SW40 Ti ultra-Rotor, Beckman) for 90 min. The supernatant was 
discarded and pellets left to drain for several minutes. 100µl of TSSM buffer 
(20mM tromethamine (Sigma), 100mM NaCl (Melford), 10g/L sucrose (Sigma) 
and 10g/L D-mannitol (Sigma)) was added to the pellet and left on ice for 2 
hours. The pellet was then resuspended by gently pipetting and the final 
resuspension volume was adjusted to 192µl with TSSM (this corresponds to a 
2000x concentration of the original culture medium). Concentrated viral 
preparations were aliquoted and stored at -80ºC. 
2.2.2 Lentiviral titering by fluorescent activated cell sorting (FACS) 
HEK293T cells were seeded at a density of 7.5 x 10
4
 cells/well in a 12 well plate 
and incubated overnight. The following day, cells were transduced with the 
lentiviral vectors in serial dilution (1 x 10
-3
 - 1 x 10
-6
) in a total volume 500µl. 
An untransduced control was also included. Cells were returned to the incubator 
and the media topped up to a total volume of 1.5ml 5-6 hours later. Cells were 
counted in one representative well at the time of transduction, in order to 
subsequently calculate the titre. Cells were harvested after a further 72 hours. To 
titre lentiviral vectors expressing GFP fused to a destabilisation domain, media 
was exchanged for 1ml DMEM containing either 500nM Shield1 (FKBP12-
based DD) or 50µM Trimethoprim (DHFR-based DD) 24 hours prior to 
harvesting for FACS analysis (Method 2.3). After recording the percentage of 
GFP positive cells, the titre was calculated using the formula:  
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2.2.3 Titering of Lentivirus by Taqman 
Taqman QPCR was performed to determine the titre of non-GFP expressing 
lentiviruses by analysing the number of HIV integration sites. HEK293T cells 
were plated at a density of 7.5 x 10
-4
 cells per well of a 12 well plate and 
transduced with lentivirus at a dilution of 1:250 and 1:1000. As a control, a 
lentivirus with a known biological titre was also transduced at concentrations of 
1:250 and 1:1000. Cells were passaged 1:5 every 3 days for 12 days and 
genomic DNA was extracted using a wizard DNA extraction kit (Promega), 
following manufacturers instructions. PCR reactions were set up in triplicate: 
12.5µl Taqman 2x master mix, 1µl HIV Forward primer, 1µl HIV Reverse 
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2.3 Fluorescent activated cell sorting (FACS) 
To harvest cells for FACS, media was aspirated and the cells gently washed with 
PBS. After aspirating the PBS, 200µl trypsin/EDTA was added to the cells and 
incubated at 37ºC for 5 minutes. Once cells detached from the plate, the trypsin 
was neutralised by adding 800µl complete DMEM medium, while 
simultaneously triturating the cells to break up clumps. Cells were held on ice 
until ready for analysis using the FACS machine (FACSCalibur, Becton 
Dickenson). Using Cellquest Pro software, the population of single whole cells 
was gated using side and forward scatter measurements. Further gating of this 
population according to the fluorescence of the cells allowed determination of 
the percentage of GFP positive cells and the mean fluorescent intensity. 
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2.4 Western Blot 
2.4.1 Protein extraction from cultured cell lines 
Cell culture medium was aspirated and cells washed once with ice cold PBS. 
Cells were lysed in 100µl RIPA buffer per well (50mM Tris-HCL pH 7.4, 
150mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium 
dodecyl sulphate (SDS) supplemented with protease inhibitors (Complete Mini 
(1 tablet per 10ml RIPA buffer) (Roche)). Cells were scraped from the surface of 
the well to ensure complete removal, before homogenisation with a needle and 
syringe in an Eppendorf tube. Lysates were incubated on ice for 20 minutes and 
then centrifuged at 17,900 RCF for 20 minutes at 4˚C. The pellet was discarded 
and protein concentration of supernatant was determined using the BCA Protein 
Assay kit (Pierce) according to the manufacturer’s protocol (see 2.4.2). Cell 
lysates were stored at -20ºC or -80ºC for long-term storage. 
2.4.2 BCA Protein Assay 
BCA assay (Pierce) was performed according to the manufacturers protocol. 
Briefly, protein standards were prepared by diluting 2mg/ml bovine serum 
albumin to concentrations ranging from 2000µg/ml to 25µg/ml. Protein samples 
from cell lines were typically diluted 1:5 before assay, samples from primary 
cell cultures were used neat. BCA working reagent is prepared by diluting BCA 
Reagent B 1:50 into BCA reagent A. Samples and standards were added to a 96 
well plate (5µl) before adding BCA Working Reagent (95µl), and incubating at 
37ºC until purple colouration had sufficiently developed (approximately 30 
minutes). Plate was read in a plate reader at a wavelength between 540-590nm.  
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2.4.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
PAGE gels (10-12%) were prepared using Mini Protean II apparatus (Bio-Rad). 
A 4% stacking gel was cast on top of the running gel. Prior to loading, cell 
lysates were boiled for 5 minutes in 2x reducing sample buffer (100mM Tris-
HCl pH6.8, 200mM dithiothreitol (Sigma), 4% [w/v] SDS, 0.3% [w/v] 
bromophenol blue (Sigma), 20% [v/v] glycerol (Melford)). Samples were loaded 
onto the gel along with standard protein markers (Precision Rainbow markers, 
Biorad) and run in tris-glycine buffer (25mM Tris; 250mM glycine; 0.5% [w/v] 
SDS) at 100v until proteins had migrated sufficiently through the gel. 
 
Components 8% 10% 12% 
H2O 9.3ml 7.9ml 6.6ml 
30% acrylamide mix 5.3ml 6.7ml 8.0ml 
1.5M Tris pH8.8 5.0ml 5.0ml 5.0ml 
10% SDS 0.2ml 0.2ml 0.2ml 
10% ammonium 
persulphate 
0.2ml 0.2ml 0.2ml 
TEMED 0.012ml 0.008ml 0.008ml 
Table 2-3 Solutions for preparing resolving gels for Tris-glycine SDS-Polyacrylamide gel electrophoresis 
Total volume is suitable for casting two resolving gels at the indicated percentage of acrylamide. 
Components Volume 
H2O 5.5ml 
30% arcylamide mix 1.3ml 
1.0M Tris p6.8 1.0ml 





Table 2-4 Solutions for preparing stacking gels for Tris-glycine SDS-Polyacrylamide gel Electrophoresis 
Total volume is suitable for casting two stacking gels. 
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2.4.4 Transfer of proteins onto polyvinylidene difluoride (PVDF) membrane 
Proteins were transferred onto PVDF membrane using a wet trans-blot cell (Bio-
Rad). Two pieces of thick filter paper (Biorad) were soaked in transfer buffer 
(150mM glycine; 20mM Tris Base, 0.038% SDS, 20% methanol). The PVDF 
membrane was briefly soaked in methanol to activate it and rinsed in transfer 
buffer prior to transfer. The transfer ‘sandwich’ was assembled: filter paper, 
PVDF membrane, gel, filter paper. Sufficient transfer buffer was used to wet the 
transfer sandwich. The transfer was performed for 90 minutes at 220Amps. 
2.4.5 Immunodetection of proteins 
Following protein transfer, membrane was blocked 5% milk powder 
(Marvell)/PBS for at least 1 hour at room temperature with gentle agitation. The 
membrane was incubated in primary antibody (1:1000 anti-GFP raised in mouse 
(Roche)) diluted in 5% milk powder/PBS, overnight at 4˚C with gentle agitation. 
The next day the membrane was washed 3 x 10 minutes in PBS-T (1xPBS; 
0.01% Tween20) before being incubated in horseradish peroxidase (HRP)-
conjugated secondary antibody (typically anti-mouse (Roche) at 1:5000 dilution 
in 5% milk powder/PBS) for at least 1 hour at room temperature with gentle 
agitation. The membrane was washed again for 3 x 10 minutes in PBS-T before 
protein detection. 
2.4.6 Enhanced chemiluminescence (ECL) detection of bound antibodies  
Bound antibody was detected using ECL Western Blotting Detection Reagent 
(Amersham) Autoradiograph film (Amersham) was exposed to the membrane 
and developed using a Kodak film processor. 
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2.4.7 Quantification of proteins 
Western blots were scanned and the density of bands quantified using ImageJ 
software. Data from ImageJ was then normalised for protein loading, by dividing 
the density of each band of GOI/treament by the density of corresponding bands 
of a protein loading control. α-tubulin was used as a loading control in all 
Western blots, probed on the same membrane, by stripping other antibodies and 
reprobing using an anti-α-tubulin antibody. α-tubulin was used as a loading 
control due to its abundance in cells, ease of detection with highly specific 
antibodies and unchanging expression profile in response to treatments used in 
similar experiments already optimised in our laboratory. 
2.5 HEK293T cell culture 
2.5.1 Cell culture technique 
All cell culture techniques were performed using sterile tissue culture conditions 
in a category 2 laminar flow hood.  
2.5.2 General maintenance of HEK293T cultured cell line 
HEK293 cells were maintained in Dubecco’s Modified Eagle medium (DMEM, 
Sigma) supplemented with 10% foetal bovine serum (FBS, Sigma), 2mM L-
glutamine, 100units/ml penicillin and 100µg/ml streptomycin. Cells were 
incubated at 37˚C in a humidified atmosphere containing 5% carbon dioxide 
(CO2).  
Cells were sub-cultured once they reached around 70-80% confluence. Briefly, 
after aspirating the culture medium cells were washed with phosphate buffered 
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saline (PBS, Gibco). Following aspiration of PBS, ~1-3ml trypsin/EDTA 
(500µg/mL trypsin; 200µg/mL EDTA in PBS, Sigma) was added and incubated 
at 37˚C for approximately 2 minutes. Cells were detached from the flask by 
gentle rocking and topped up to 10ml using the appropriate pre-warmed culture 
medium before triturating to break up clumped cells. 1ml of cell suspension was 
placed into a fresh culture flask containing fresh medium. A haemocytometer 
was used to count the remaining cells if required. 
2.5.3 Transduction of HEK293T cells with lentiviral vectors 
HEK293T cells were seeded at a density of 7.5 x 10
4
 cells/well in a 12 well plate 
and incubated overnight. The following day, cells were transduced with the 
lentiviral vectors (usually at MOI1) in a total volume 500µl. An untransduced 
control was also included. Cells were returned to the incubator and the media 
topped up to a total volume of 1.5ml 5-6 hours later. Typically on day 5, 
photomicrographs were taken prior to harvesting for Western blot analysis or 
cells were fixed using 4% paraformaldehyde in preparation for 
immunocytochemistry. 
2.6 E18 rat cortical neuron culture 
2.6.1 Preparation of plates 
Poly-D-Lysine solution (0.1 mg/ml (Sigma)) was added to each well of a 24-
well plate (Nunc), followed by incubation at room temperature for at least 4 
hours, or at 4
o
C over night.  The solution was then removed and wells washed 
three times with sterile ddH20, for 15 minutes per wash.  After the final wash, 
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the water was removed and the plates left open to dry in laminar flow hood for at 
least 1 hour.   
2.6.2 Dissection of cortex 
This method is an adaptation of the hippocampal culture methods of Brewer et al 
(Brewer et al., 1993;Brewer, 1997). All surgical instruments were cleaned and 
sterilised by autoclave. Pregnant Wistar rats at E18 gestation were obtained from 
the central animal facility (University of Bristol).  The animal was swabbed with 
100% ethanol and the embryos removed into a 90mm petri dish containing 5ml 
Hanks Balanced Salt Solution without calcium and magnesium (HBSS, Gibco).  
Foetal heads were removed, washed in HBSS and the dissection performed 
under a MZ6 dissection microscope (Leica, Switzerland) with a K1500 
electronic light source (Schott, USA). The skin and soft bone tissue were 
removed using forceps and the brain transferred into another dish containing 
10ml fresh HBSS. Next the cerebellum was removed and the two brain 
hemispheres separated. Each hemisphere was placed on its side to enable 
removal of the thalamus, followed by the complete removal of the meninges. 
Finally the cortex was dissected out and placed into fresh HBSS medium on ice. 
2.6.3 Trituration and plating of cortical neurons 
Once the cortex had been collected they were cut into smaller pieces using the 
fine forceps before being placed in 5ml of HBSS medium containing 0.05% 
(w/v) trypsin (Sigma) and incubated for 20 minutes at 37
o
C.  The cortex were 
then washed three times in HBSS and triturated with a flame-polished Pasteur 
pipette in 1ml of Cortical Neuron plating medium (Neurobasal medium (Gibco) 
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supplemented with 2% (v/v) B-27 supplement (Gibco), 0.5mM L-glutamine, 
100U/ml Penicillin and 0.1mg/ml Streptomycin, 25uM Glutamic acid).  
Following trituration, additional plating medium was added to the cell 
suspension so that cells were plated at a density of 100,000 cells per 500µl 
aliquots.   
2.6.4 Culture maintenance and transduction 
After three days in vitro, one third of the volume of medium in each well was 
removed and replaced with fresh feeding medium (Neurobasal medium 
supplemented with 2% (v/v) B-27, 100U/ml Penicillin and 0.1mg/ml 
Streptomycin). Two days later (5 days in culture), cells were transduced with 
lentivirus (MOI2). To increase the efficiency of transduction, one third of the 
media was removed prior to addition of virus. After incubation in the reduced 
media volume for at least 6 hours, the deficit was filled with fresh media. Media 
was changed (as above) after a subsequent two days, followed by media changes 
every three days. If appropriate, the final feed (day 12) contained stabilising 
ligands (Shield1, trimethoprim) at a range of dilutions, in triplicate. On day 15, 
photomicrographs were taken prior to harvesting for Western blot analysis or 
fixed using 4% paraformaldehyde in preparation for immunocytochemistry.  
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2.7 In vivo  
2.7.1 Animals, housing and licence 
Adult male Wistar rats weighing between 250-275g were obtained from either 
B&K Universal or Charles River, and kept for a minimum of one week to 
acclimatize before surgery. All animal work was performed under the license 
numbers: PIL: 30/8693 and PPL: 30/2537. All procedures were carried out using 
sterile instruments, drapes, gloves and solutions in accordance with the Animals 
(Scientific Procedures) Act 1986. 
2.7.2 Stereotactic surgery 
Animals were anaesthetised with a mixture of 1mg/Kg medetomidine (Dormitor, 
Pfizer) and 75mg/Kg ketamine (Vetalar, Pfizer) by IP injection. Confirmation of 
anaesthesia was obtained by footpad pinch test, before shaving the site of 
incision and placing the animal into a stereotactic frame. After cutting through 
skin using a scalpel and retracting to the skin to facilitate localisation of bregma, 
holes were drilled at the appropriate stereotactic coordinates relative to bregma, 
according to the brain atlas of Paxinos and Watson. A Hamilton 700 series 
syringe and 33G gauge-15mm needle was loaded with 2µl (plus a surplus) of 
concentrated vector preparation. Vectors were typically infused at rate of 
0.2µl/min and the needle left in place for 5 minutes afterwards. At the end of 
procedure, the wound was closed using absorbable sutures and the animal 
recovered by subcutaneous administration of 0.2mg/Kg atipamezole (Antisedan, 
Pfizer). Additional post-operative analgesia was not used in these studies in 
accordance with techniques in project licence PPL 30/2537 indicating that 
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ketamine has analgesic properties that persist after surgery. In experiments 
modelling either Parkinson’s disease or spinal cord injury in vivo, it has to be 
noted that the trauma to the tissues of rats is substantial and that in future work 
we would seek to administer additional post-operative analgesia. This would  
2.7.3 Transcardial perfusions and brain harvesting 
Animals were terminally anaesthetised with 150mg/Kg
 
pentobarbital (Euthatal, 
Merial animal Health Ltd). Adequate anaesthesia was determined by footpad 
pinch test.  After cessation of breathing, an incision was made through the 
sternum and the heart exposed by retracting the rib cage retracted. After removal 
of pericardium, blunted needle (19 gauge for rats) was introduced into the left 
ventricle and clamped in place using a pair of mosquito-haemostats. The right 
atrium was pierced to allow the drainage of the perfusate. PBS-Heparin (1U/ml, 
Sigma) was injected using a peristaltic pump 200ml at a rate of 40ml/min were 
used for rats. This was followed by perfusion with 4% [w/v] PFA, again, 200ml 
at 40ml/min for rats. The animals were then decapitated, the brains harvested, 
and post-fixed in 4% [w/v] PFA overnight, before being transferred into a 30% 
[w/v] sucrose solution until sectioning.  
2.8 Sectioning tissue 
2.8.1 Brain harvesting and section using cryostat 
After perfusion fixing the animal firstly with Heparin-0.9% Saline, then 4% 
Paraformaldehyde (PFA) (pH7-7.4), the brain was harvested, and post-fixed for 
24 hours in 4% PFA. It was then transferred to a 30% sucrose solution for three 
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days, or until the brain sank in the tube. Brains were then mounted into OCT 
mounting matrix (Thermo) and frozen to -20
o
C in a Leica CM190 cryostat for 
cutting typically 40µm sections. Sections were kept free floating in PBS until 
immunohistochemical staining and mounted onto glass coverslips in Fluorosave 
(Calbiochem). 
2.8.2 Spinal cord sectioning using a vibratome 
After perfusion fixing the animal firstly with Heparin-0.9% Saline, then 4% 
Paraformaldehyde (PFA) (pH7-7.4), the brain was harvested, and post-fixed for 
24 hours in 4% PFA. It was then transferred to a 30% sucrose solution for three 
days. 10% gelatin (Sigma) was warmed until melted, then cooled to 40
o
C. In a 
shallow tray, sections of cord were submerged into the gelatin and left to set. 
The cord could then be cut out incorporating a border of gelatin and mounted 





2.9.1 Immunofluorescent staining of brain sections 
Sections were washed three times in 0.1% TritonX-100/PBS, before blocking 
against non-specific binding using 10% normal goat serum (NGS) in 0.1% 
TritonX-100/PBS for 1 hour at room temperature. Primary antibodies were 
added in a volume of 500µl 10% NGS/0.1% TritonX-100/PBS, and incubated at 
4
o
C over night. Sections were washed 3x with PBS (5min per wash) before 
adding secondary antibodies diluted in PBS and incubating for 2-4 hours at room 
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temperature in the dark. After washing 3x in PBS (5 minutes per wash) sections 
were mounted on glass slides using Fluorosave (Calbiochem). Slides were kept 
at 4
o
C in the dark. 
2.9.2 DAB staining of brain sections 
Brain sections were transferred into staining pots and washed as described in 
method 2.9.1. Blocking, incubation with primary antibodies and washes were 
also as method 2.9.1, but were performed using TBS (100mM Tris-HCl 
(Melford); 154mM NaCl (Melford)) instead of PBS as the presence of phosphate 
groups can inhibit the activity of HRP.  After binding primary antibody, sections 
were incubated with a biotinylated secondary antibody diluted (typically 1:400) 
in 500µl of TBS-0.1%Tx100 containing 5% [v/v] serum, 1% [w/v] BSA. 
Sections were blocked on a horizontal rocker at 10rpm (Stuart Scientific), 4ºC, 
overnight. The following day, sections were washed with TBS-0.1%Tx100 3 
times and treated with HRP-conjugated avidin (ABC-Kit, Vector Labs) 
following manufacturer recommendations. Briefly, 0.5% [v/v] “Solution A” and 
0.5% [v/v] “Solution B” were pre-mixed in 500µl of TBS and placed on ice for 
30min, then added to the pots and incubated on a horizontal rocker at 10rpm, 
4ºC, for 2h. ABC-solution was then washed twice with TBS and once with TNS 
(Tris non-saline buffer, 100mM, Melford). The HRP-substrate 3-3’-
diaminobenzidine (DAB Substrate Kit for peroxidase, Vector Laboratories) was 
prepared following manufacturer’s instructions. Briefly, 2 drops of buffer 
solution were added to 5ml of ddH2O and mixed, followed by 4 drops of DAB 
solution and 2 drops of H2O2 solution. 750µl of this mixture were added to each 
pot and incubated on a horizontal shaker at 40rpm at room temperature until a 
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suitable staining developed (usually between 5 to 10 minutes). The sections were 
then washed once in ddH2O and kept in TBS at 4ºC until mounting.  
 
Antibodies used in immunostaining  
Antibody  Species Supplier  Typical dilution 
Anti-βIII tubulin Mouse Roche  1:1000   
Anti-CDNF   Rabbit ProSciInc  1:500   
Anti-ChickenALEXA488 Goat Invitrogen  1:500   
Anti-GFAP   Rabbit Dako 1:1000   
Anti-GFP  Chicken Roche  1:1000   
Anti-Mouse-Cy3  Goat Jackson Labs 1:500   
Anti-MouseALEXA660 Goat Invitrogen 1:400   
Anti-MouseBiotinylated Goat Vector 1:400   
Anti-NeuN  Mouse Chemicon 1:500   
Anti-PKCγ  Rabbit Santa Cruz 1:500   
Anti-RabbitALEXA405 Goat Invitrogen 1:400   
Anti-RabbitALEXA568 Goat Invitrogen  1:500   
Anti-RabbitBiotinylated Goat Vector 1:400   
Anti-RARβ2  Rabbit Santa Cruz 1:50  
Anti-TH  Mouse Covance 1:600   
 
Table 2-5 Antibodies used in immunostaining  
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3.1 Introduction 
Destabilization domain technology comprises a small, inherently unstable 
domain that confers instability to any protein it is fused to. The destabilization 
domain (DD) utilized in this chapter has been developed from the 107-residue 
FKBP12 protein (FK506-binding protein, 12kDa, hereafter FKBP) and is 
stabilized by the ligand Shield1. In humans, the FKPB protein is an abundant 
cytosolic protein that acts as the intracellular receptor for the 
immunosuppressive drugs FK506 and rapamycin. It was chosen for development 
into a DD as it has been widely studied by the Wandless Lab and others, often in 
the context of fusion proteins. Furthermore, a range of high affinity binding 
ligands were already available (Yang et al., 2000; Pollock and Clackson, 2002). 
To combat the potential issue of off target effects via interaction with 
endogenous FKBP, they utilised an FKBP-F36V mutant. This mutation forms a 
cavity in the ligand binding domain, enabling ligands bearing a “bump” to bind 
with over 1000 fold increased selectivity to the mutant over the wild type protein 
(Clackson et al., 1998; Yang et al., 2000). Promisingly, undesired responses to 
highly similar ligands had not been seen in cultured cells, animals, or humans 
(Iuliucci et al., 2001). 
To create a destabilization domain, FKBP-F36V was further mutated using an 
error-prone PCR strategy (Banaszynski et al., 2006). A library was formed by 
cloning the random mutants in frame upstream of the yellow fluorescent protein 
(YFP) reporter gene. After transducing the library into cells using a retroviral 
delivery system, it was screened using flow cytometry to select mutants that 
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were destabilising to YFP in the absence of ligand, yet also stabilising in the 
presence of ligand (Banaszynski et al., 2006). Initially the ligand SLF* 
(Synthetic ligand for FKBP) was used, before a range of SLF* derivatives were 
synthesised (Maynard-Smith et al., 2007) revealing the cell permeable Shield1 to 
be most effective at stabilising the fusion proteins. Genomic DNA was extracted 
to enable identification of potential clones. Further testing revealed the FKBP-
F36V/L106P clone to be most destabilising to YFP, yet rescued to high levels by 
Shield1. To ensure that the system could be applied to other genes of interest 
(GOI), such as proteins that have a cellular function, the system was tested on a 
range of classes of proteins, including GTPases, kinases, and cell cycle 
regulatory proteins (Banaszynski et al., 2006). 
DD fusion proteins produced in the absence of stabilising ligands are thought to 
be degraded by the proteasome, due to the presentation of the unfolded domain. 
Cells expressing DD-YFP fusions in the presence of Shield1 before treatment 
with proteasome inhibitors Lactacystin (Maynard-Smith et al., 2007) and 
MG132 (Banaszynski et al., 2006) failed to degrade the fusions when Shield1 
was withdrawn. Furthermore, a destabilized green fluorescent protein reporter 
(DD-zsGFP) colocalised with subunits of the proteasome in the absence of 
Shield1 (Leong et al., 2012). Most recently, ubiquitin chains have been found 
associated with DD within minutes after withdrawal of Shield1 from cells 
(Egeler et al., 2011). 
At the time of our study, the authors had investigated the DD system in living 
mice, firstly observing the conditional expression of a luciferase reporter in pre-
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transduced xenografted cancer cells, when Shield1 was supplied intravenously. 
Secondly, the tumour burden of cancerous xenografts expressing destabilised 
Interleukin-2 could be conditionally reduced in the presence of Shield1 
(Banaszynski et al., 2008). There were no studies investigating the use of the DD 
system in the central nervous system (CNS) and as such we undertook to test 
this system in the CNS. 
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In this chapter, we will describe our design of DD/GOI fusion cassettes. These 
constructs are formed of the DD fused to the N- or C-terminus of GFP, separable 
using unique restriction sites to facilitate exchange of GOIs. Initially we will test 
the ability of the Shield1 to regulate the levels of GFP in cells transduced with 
lentiviral vectors bearing these constructs. To ensure that the system is versatile, 
and also to investigate the kinetics of the system, we will clone a luciferase 
reporter to replace GFP. If these studies are efficacious, we will then attempt to 
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3.2 Methods 
3.2.1 Restriction site optimised destabilisation domain construct design 
Two DD GOI fusion constructs were designed. One contained the destabilisation 
domain at the N-terminus of GFP (DD-GFP) and the other at the C-terminus 
(GFP-DD). In order to facilitate exchange of reporter (GFP) genes for other 
genes of interest and insertion of the cassette into two different lentiviral vector 
backbones while maintaining a very similar genetic construction, restriction 
enzyme sites were chosen with care to be unique in both the cassette and the 
parental plasmids. The parental EIAV (equine infectious anaemia virus) based 
vector plasmid was pONYK-CMV-GFP and the parental HIV (human 
immunodeficiency virus) based vector plasmid was pRRL-CMV-GFP (both 
obtained from Oxford Biomedica Plc. Oxford, UK).  
In both parental plasmids, there was a unique AgeI site upstream of GFP. Down 
stream, SalI and KpnI were unique to the pRRL and pONYK plasmids, 
respectively. Neither pRRL nor pONYK (or DD/GFP cassette) contained an 
NheI or PspOMI site, meaning that these sites could be implemented in the 
boundary between the GOI and DD. Selecting unique enzyme sites in this way 
will facilitate exchange of the GOI, as only one digestion/ligation cycle is 
required for directional cloning of new GOIs. The DD/GFP constructs were 
supplied in a pMA plasmid by GeneArt gene synthesis services (Germany) 
(Figure 3-1 and Figure 3-2). After transforming into E. coli, DNA was harvested 
from an overnight culture via maxi prep (Method 2.1). 
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Figure 3-1 Sequence of DD-GFP and GFP-DD cassettes  
Restriction enzyme sites are indicted by red nucleotides (AgeI, accggt; PspOMI, gggccc; NheI, gctagc; 
KpnI, ggtacc; SalI, gtcgac). Blue nucleotides code for the destabilisation domain. Green nucleotides code 
for GFP. Black nucleotides indicate either the Kozak sequence (gccacc) or nucleotides required to mention 
translation frame (tc). 
3.2.2 Cloning DD constructs into pRRL and pONYK lentiviral genomes  
pONYK and pRRL backbones were prepared by digestion with restriction 
enzymes AgeI and KpnI, or AgeI and SalI respectively. The DD/GFP inserts 
were prepared by digestion with appropriate enzyme pair for the destination 
backbone. Digestions (1ug DNA, 2µl 10X Buffer, 1µl Enzyme, up to 20µl 
Water) were incubated at 37
o
C for a minimum of 2 hours, before purifying 
correct band via gel electrophoresis (Method 2.1.2). After desphosphorylation of 
the backbone, ligation, transformation and plating bacteria, individual colonies 
were picked, grown overnight at 37
o
C so DNA could be harvested by miniprep 
and sequenced to confirm DNA sequence. Subsequently, larger volumes of high 
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Figure 3-2 Design and cloning strategy for producing lentiviral genome plasmids containing DD/GFP 
cassettes 
[A/B] Schematic of the location of restriction sites selected for DD-GFP and GFP-DD respectively. AgeI 
and KpnI/SalI allow insertion into lentiviral genome plasmids, but can be used in conjunction with PspOMI 
or NheI to exchange GFP for other GOI. [C/D] pMA plasmids containing DD/GFP cassettes supplied by 
GeneArt. [E/F] After restriction digest of pMA and parental pRRL or pONYK plasmids with appropriate 
enzyme pairs, lentiviral genome plasmid and DD/GFP cassette were ligated. 
3.2.2.1 PCR amplification of Luciferase 
PCR was performed as described (Method 2.1.1) using the primers listed in 
Table 3-1 and the template pRRL-CMV-Luciferase. 
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Table 3-1 Primers designed for the amplification of luciferase from pRRL-CMV-Luciferase 
Annotated sequences indicate RE sites, while sequences shown in bold represent regions of template 
complementarity. 
3.2.2.2 Cloning pRRL-DD-Luciferase and pRRL-Luciferase-DD 
PCR products were separated in a 1% agarose gel, the correct band was excised 
and DNA recovered (Methods 2.1). Backbone plasmid pRRL-DD-GFP and 
luciferase (to be N-terminally tagged) were digested with the REs PspOMI/SalI; 
pRRL-GFP-DD and luciferase (to be C-terminally tagged) with the AgeI/NheI 
pair. After agarose gel electrophoresis, band excision and DNA recovery, 
products were quantified and backbone-insert pairs ligated, transformed and 
sequenced. 
3.2.3 Lentiviral production, titration and use 
Lentiviral vectors were produced and titred (Method 2.2). In all in vitro 
experiments in this chapter, vectors were used at MOI1. HEK293T cells and E18 
rat cortical neurons seeded and transduced (Methods 2.5.3 and 2.6.4 
respectively). Shield1 (Clontech) is purchased at 1mM and diluted to a range of 
doses usually below 1µM. 
Primer Name             Primer Sequence (5’-3’)
DD-Luciferase forward        TAGCATGGGCCCTCGAAGACGCCAAAAACATA   
DD-Luciferase reverse         TATAATGTCGACGGTACCTCACTCGAGCAATTTGG  
Luciferase-DD forward        TAGCATACCGGTGCCACCATGGAAGACGCC      
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3.2.4 Stereotactic injection of HIV-DD-GFP and HIV-GFP into the CNS of 
adult rats 
In all in vivo experiments in this chapter, adult male Wistar rats (250-300g) 
received 2µl of vector via stereotactic injection (0.2µl/min infusion rate) into the 
striatum at the coordinate (AP/ML/DV relative to bregma) 0/±3.5/-4.75 (Method 
2.7). HIV-DD-GFP was infused into the left hemispheres; HIV-GFP control was 





tfu/ml. Titres were not matched for in vivo experiments. 
 
3.2.5 Injection of Shield1 to the striatum and ventricles 
Vector was allowed to transduce for three weeks before injecting 2µl of the 
stabilising ligand Shield1, diluted to an appropriate concentration in 0.9% 
Saline, at a rate of 0.2µl/minute, either into the striatum, using the above co-
ordinate, or into the ventricles, at the co-ordinate (AP/ML/DV relative to 
bregma) -0.8/1.5/-3.9, on the left side (the side with DD-GFP). 0.9% saline was 
infused into the same coordinates on the right hand side. 
The animals were euthanized 24 hours later and brains were harvested after 
perfusion fixation using 4% paraformaldehyde. After cryoprotection 30% 
sucrose, the brains were sectioned to 40µm in a cryostat and kept free floating in 
PBS until immunohistological staining (Method 2.9 and Table 2-5 for details of 
antibodies).  
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3.3 Result 
3.3.1 Designing an optimized cassette to express DD-GOI in lentiviral 
vectors 
Published literature suggested that the domain had regulatory properties when 
fused to either the N or C terminus of the gene of interest (GOI). Two constructs 
(DD-GOI and GOI-DD) were therefore designed. Design of the constructs began 
by looking for conveniently located single cutting restriction enzyme (RE) sites 
in the parental lentiviral genome plasmids (pRRL-CMV-GFP and pONYK-
CMV-GFP. Any REs that cut within the DD sequence or GOIs (GFP, Luciferase 
or RARβ2) were discounted (See methods for full details). The completed 
constructs comprised a GFP gene with one construct bearing the DD fused to the 
N-terminus of GFP, and the other construct bearing DD fused to the C-terminus 
fusion of GFP. DD-GFP and GFP-DD were synthesised by GeneArt and 
delivered in a minimal pMA plasmid. After digestion with appropriate RE 
enzymes, the DD/GFP cassette could be ligated into either a pRRL or pONYK 
series plasmid that had been digested with the same enzyme pair. This resulted 




Figure 3-3 Schematic diagram of the viral insert of DD-GFP and GFP-DD 
 
WPRECMV GFPDD dLTRdLTR RRE cPPT/CTSDD-GFP
WPRECMV GFP DD dLTRdLTR RRE cPPT/CTSGFP-DD
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3.3.2 HEK293T cells transduced with EIAV DD-GFP or EIAV GFP-DD 
accumulate GFP in the presence of Shield1 
To begin initial assessments of the regulatable system, unconcentrated EIAV-
based lentiviral vector preparations of pONYK-DD-GFP, pONYK-GFP-DD and 
pONYK-GFP (control) were produced, and used to stably transduce individual 
populations of HEK293T cells. A range of Shield1 concentrations ranging from 
0 to 5µM was applied in duplicate to the transduced cells for 48 hours prior to 
FACS analysis (Figure 3-4 [A]). GFP production from both DD-GFP and GFP-
DD constructs, as indicated by mean fluorescence, was dependent on the dose of 
Shield1 supplied. Mean fluorescence from the GFP protein was observed to 
increase with increasing Shield1 concentrations. Shield1 did not affect the 
fluorescence of an untagged GFP control. 
To confirm these findings and evaluate the system further, HEK293T cells 
transduced with the three constructs were subjected to Shield1 concentrations of 
an optimised range – 0, 1, 10, 100, 200, 500, 1000nM – in triplicate, 48 hours 
prior to microscopy and FACS analysis. Again, GFP fluorescence dose-
dependently increased with increasing Shield1 concentration (Figure 3-4 
[B/C/D/E]). FACS data indicated that cells expressing either DD-GFP or GFP-
DD showed a 30- or 4-fold greater amount of GFP respectively in the presence 
of 500nM Shield1, compared to untreated cells. Western blotting of cell lysates 
from each treatment group showed that the increase in fluorescence is due to an 
increase in the amount of GFP protein present in the cells. This technique also 
suggested that the N-terminally tagged GFP exhibited less basal activity, as there 
was no detectable GFP protein present from 0 to 10nM of Shield1. The C-
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terminally tagged GFP construct showed a 22-fold increase in fluorescence with 
the 500nM dose of Shield1 in Western blot analysis. Furthermore, it was clear 
the basal expression of the C-terminally tagged system was higher than that of 
the N-terminally tagged construct. 
 
Figure 3-4 HEK293T cells transduced using EIAV vector of DD-GFP, GFP-DD or GFP control, treated 
with Shield1 
[A] HEK293T cells transduced with EIAV lentiviral vectors expressing DD-GFP, GFP-DD or GFP control, 
were treated with a range of Shield1 doses 48h before FACS analysis (n=2). [B/C/D/E] Following the same 
procedure, a different range of Shield1 doses were applied 48h before imaging [B] (Scale bar=400µm) and 
[C] FACS analysis. [D/E] Triplicate samples were pooled for Western blot analysis. Blots were probed with 
anti-GFP primary antibody, and α-tubulin as a loading control. [D] Densitometry was performed using 
ImageJ software. [E] Shield1 doses (left to right): 0, 1, 10, 100, 200, 500 and 1000nM. 
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3.3.3 HEK293T cells transduced with HIV-DD-GFP or HIV-GFP-DD show 
dose dependent accumulation of GFP to Shield1 
To determine if the destabilisation domain system is comparable between 
different lentiviral vector delivery systems, a similar experiment was performed 
with HIV vectors produced from using pRRL-DD-GFP, pRRL-GFP-DD and 
pRRL-GFP plasmids. The results obtained were similar to those obtained with 
the EIAV lentiviral vector constructs. FACS analysis indicated that there was a 
37 fold greater amount of GFP produced by the DD-GFP construct, and 4 fold 
greater amounts by the GFP-DD construct, when treated with 500nM Shield1, 
compared to untreated cells (Figure 3-5). When the samples were analysed by 
Western blot, the DD-GFP construct again showed very tight regulation, with 
basal levels of GFP being 234 fold lower than that of cells treated with 500nM 
Shield1, although this much larger range of induction may be due to variations 
in the α-tubulin loading control. This variation has not been seen in other 
experiments using Shield1, suggesting that this is most likely due to 
experimental error, not Shield1 affecting the levels of α-tubulin in high 
concentrations. 
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Figure 3-5 HEK293T cells transduced using unconcentrated HIV vector of DD-GFP, GFP-DD or GFP 
control, treated with Shield1. 
[A] HEK293T cells transduced with unconcentrated HIV vector of DD-GFP, GFP-DD, or GPF, exposed to 
a range of Shield1 concentrations. Scale bar=200µm. [B] FACS analysis of imaged cells (n=3). MFI=mean 
fluorescent intensity. [C/D] Triplicate samples were pooled for Western blot analysis. [D] Blots were 
probed with anti-GFP primary antibody and subsequently α-tubulin as a loading control. [C] Densitometry 
was performed using ImageJ software. [D] Shield1 doses (left to right): 0, 1, 10, 50, 100, 200 and 500nM. 
3.3.4 Concentration of HIV vector preparations does not affect regulation 
In vivo experiments require the use of a concentrated preparation of lentiviral 
vector. To test if the destabilisation system would be affected by the 
concentration process (involving several spin steps, and possible concentration 
of contaminating factors from cell culture) a further replicate of the experiment 
described above was performed by transducing HEK293T cells with 
concentrated HIV virus preparations of pRRL-DD-GFP, pRRL-GFP-DD and 
pRRL-GFP. FACS data and Western blot analysis for the DD-GFP construct 
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indicated a 44-fold and 19-fold increase in the amount of GFP respectively, upon 
exposure to 500nM Shield1 (Figure 3-6). Both FACS and western blot analysis 
indicated a 5-fold induction for the GFP-DD construct. 
 
 
Figure 3-6 HEK293T cells transduced using a concentrated preparation of HIV vector of either DD-
GFP or GFP-DD, treated with Shield1. 
[A] HEK293T cells transduced with concentrated HIV vector of DD-GFP, GFP-DD, or GPF, exposed to a 
range of Shield1 concentrations. FACS analysis of cells (n=3). MFI=mean fluorescent intensity. [B/C] 
Triplicate samples were pooled for Western blot analysis. [C] Blots were probed with anti-GFP primary 
antibody, and α-tubulin as a loading control. [B] Densitometry was performed using ImageJ software. [C] 
Shield1 doses (left to right): 0, 1, 10, 50, 100, 200, 500 and 1000nM. Approximate molecular weight: 
DD-GFP, 39kDa; GFP-DD, 39kDa; α-tubulin, 50kDa. 
3.3.5 E18 rat cortical neurons transduced with HIV vectors of DD-GFP and 
GFP-DD show dose dependent regulation 
To determine the efficacy of the system in a neuronal cell type, E18 rat cortical 
neurons were transduced using concentrated HIV viral vector preparations of 
pRRL-DD-GFP, pRRL-GFP-DD and pRRL-GFP. A range of Shield1 
concentrations was applied in triplicate to the transduced cells – 0, 1, 10, 100, 
500nM – prior to imaging. Subsequently, the triplicate wells were pooled, a 
protein extraction performed, and analysed in Western blot. Again, there was no 
detectable GFP in cells overexpressing the DD-GFP construct at in the presence 
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of 0, 1, or 10nM Shield1, while ample GFP in cells treated with 100 and 500nM, 
suggesting tight regulation (Figure 3-7).  
 
Figure 3-7 E18 rat cortical neurons transduced with HIV vector of either DD-GFP or GFP-DD, treated 
with Shield1. 
[A] E18 cortical rat neurons cultured for a total of 18 days after transduction with (MOI10) HIV vector 
containing pRRL-CMV-DD-GFP, pRRL-CMV-GFP-DD and pRRL-CMV-GFP. Fed at day 15 with media 
containing a range of Shield1 dilutions (n=3). [B/C] After imaging (representative wells shown, n=3), 
triplicate samples were pooled for Western blot, probed with anti-GFP primary antibody. [B] Shield1 doses 
(left to right): 0, 1, 10, 100 and 500nM. Approximate molecular weight: DD-GFP, 39kDa; GFP-DD, 
39kDa; α-tubulin, 50kDa. [C] Densitometry was performed using ImageJ software. 
3.3.6 Cloning destabilised luciferase vectors for transduction of HEK293T 
cells: Dose response to Shield1 and Shield1 over a time course 
A destabilised luciferase construct was made for two reasons. First, to test that 
the regulatory characteristics exhibited by the DD-GFP construct can be applied 
to other GOI. Second, to facilitate studies on the kinetics of the activation and 
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inactivation of the system. The much shorter half life of luciferase 
(approximately 3 hours (Kafri	  et	  al.,	  1998),) compared to that of GFP (26 hours 
(Corish and Taylor-Smith, 1999) may mean that a destabilised luciferase 
reporter will better reflect changes in levels of activation of the system (Wang et 
al., 2002). Thus, the firefly luciferase reporter gene was cloned to replace the 
GFP reporter. PCR primers (Table 3-1) were designed to amplify the Luciferase 
gene from the parental plasmid (pRRL-CMV-Luciferase-WPRE) such that the 
stop codon, or the transcription start sequence (ATG) was removed, to enable 
formation of the DD-Luciferase and Luciferase-DD fusion proteins, 
respectively. Unconcentrated preparations of HIV lentivirus containing pRRL-
DD-Luciferase and pRRL-Luciferase-DD were produced and used to transduce 
HEK293T cells. Shield1 was applied at a range of concentrations 48 hours prior 
to cell lysis in preparation for luminometry. In both DD-Luciferase and 
Luciferase-DD transduced cells, there was a dose dependent increase in 
Luciferase activity with increasing Shield1 concentration (Figure 3-8 [A/B]), 
becoming significant with a minium dose of 100nM (Dunnetts posthoc test). A 
desirable characteristic of a regulatory system is rapidity. To test the time taken 
to reach maximal induction levels, Shield1 was applied to cells transduced with 
the DD-Luciferase construct over a time course before harvesting for 
luminometry (Figure 3-8 [C]). Luciferase activity was significantly increased 
within the forth hour of Shield addition (Dunnetts posthoc test), and reached 
maximal levels within 24 hours after Shield addition, with no significant 
increase observed after this time.  
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Figure 3-8 HEK293T cells expressing DD-Luciferase or Luciferase-DD - Dose response and time course 
[A/B] HEK293T cells transduced with concentrated HIV vector of DD-Luciferase or Luciferase-DD, 
exposed to a range of Shield1 concentrations 48h before harvesting (n=4). After cells lysis, a luciferase 
assay was performed. [A] Luciferase activity increases with Shield1 dose: One way ANOVA: *** 
p<0.0001, (f=71.23, R
2
=0.9703); Stars indicate Dunnett posthoc test: 0vs100nM, ** p<0.01, (q=3.712). [B] 
Luciferase activity increases with Shield1 dose: One way ANOVA: *** p<0.0001, (f=49.44, R
2
=0.9577); 
Stars indicate Dunnett posthoc test: 0vs100nM, * p<0.05, (q=3.596); 0vs250nM, ** p<0.01, (q=5.603) [C] 
HEK293T cells transduced with concentrated HIV vector of DD-Luciferase were treated with Shield1 over 
a time course before harvesting (n=4). After cell lysis, a luciferase assay was performed. Luciferase activity 
increases after Shield1 addition: One way ANOVA: *** p<0.0001, (f=23.78, R
2
=0.879); Stars indicate 
Dunnett posthoc test: 0vs4hrs ** p<0.01, (q=4.065). [Inset] One way ANOVA * p=0.0237, (f=3.129, 
R
2
=0.4720); Stars indicate Dunnett posthoc test: 0vs60mins, ** p<0.01, (q=3.760). 
3.3.7 Evaluation of the DD system to the central nervous system of adult rats  
From the experiments we have performed so far, the DD-GFP construct has 
consistently exhibited lower basal accumulation of GFP in cells that have not 
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been treated with Shield1, thus suggesting that this is the best candidate for use 
in vivo. To test the efficacy of the system in vivo, concentrated preparations of 
pRRL-DD-GFP and pRRL-GFP were injected stereotactically into the left and 
right striatum of rats respectively and incubated for 3 weeks before stereotactic 
administration of Shield1. Shield1 was injected into either the striatum at 500nM 
or the lateral ventricle at 500nM on the left side of the brain 24 hours before 
harvesting. The right hemisphere received a mock treatment of saline. After 
sectioning and immunohistochemical analysis, animals that received striatal and 
ventricular delivery of Shield1 had only very weakly GFP positive cells in the 
left striatum (DD-GFP) that co-stained for the neural marker (NeuN) (Figure 
3-9). In fact, expression was not considerably greater than animals that had 
received a mock treatment, where there were also low levels of GFP expression 
in areas surrounding the infusion needle tract. In contrast, the right striatum had 
considerably more GFP expression due to the constitutively expressing GFP 
vector. Dose response experiments (Figure 3-4) indicate that when the system is 
fully activated, DD-GFP levels approach that of a constitutive GFP reporter, 
therefore suggesting that the system was not being activated to its maximum 
potential. To investigate further, animals receiving the same virus injection 
regimen received a one hundred times higher dose (50µM) of Shield1 into the 
ventricles. Again, only very weak expression was observed in areas surrounding 
DD-GFP infusion needle tract (Figure 3-9). 
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Figure 3-9 HIV DD-GFP vector transducing neurons in adult rat brain 
Stereotactic injections of concentrated HIV constructs of pRRL-CMV-DD-GFP (LHS) and pRRL-CMV-
GFP (RHS) to the striatum of rat brain were performed three weeks before injection of either 2µl of 500nM 
Shield1 solution to striatum (n=2), 2µl of 50µM Shield1 solution to striatum (n=3), or 2µl of 50µM Shield1 
solution to the ventricles (n=2), on the LHS. A vehicle (Mock) treatment of 0.9% NaCl was also included 
(n=1). Brain were harvested 24 hours later and prepared for cryosection to 40µm slices. Scale bar=200µm. 
GFP. [Right-hand confocal image]. Close up of neurons transduced with DD-GFP vector. 
GFP/NeuN/GFAP. Scale bar=10µm. 
3.3.8 Administration of Shield1 via permanent cannulation of the lateral 
ventricles 
The pharmacokinetic properties of Shield1 in the brain are unknown. Following 
injection of Shield1 into the striatum/ventricles, the ligand can potentially be 
washed away from the transduced area and DD-GFP expression may return to 
minimal basal levels. For longer term stabilisation of GFP expression we sought 
to deliver Shield1 to the brain over a longer time course using cannulas that were 
implanted into the lateral ventricles. Animals received stereotactic injections of 
vector as before. At the time of vector injection, a guide cannula was 
permanently implanted into both right and left lateral ventricles. At three weeks 
post implantation, Shield1 was administered through an infusion cannula twice a 
day for three days, before being harvested 6 hours after the final infusion. 
Immunohistochemistry did not indicate a build up of GFP in the striatum of rats 
(data not shown). 
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3.3.9 HEK293T cells transduced with DD-GFP accumulate GFP in the 
absence of Shield1 at high MOI 
It was thought that the weakly GFP positive cells in mock treated could be due 
to high basal expression caused as a result from some cells receiving a higher 
number of vector copies than others, producing much more fusion protein, 
thereby overloading the degradation machinery and leading to accumulation of 
the protein. Cells surround the needle tract would be more likely to come into 
contact with more viral particles, explaining why the weakly GFP expressing 
cells were found in this area. To test this idea in vitro, HEK293T cells were 
transduced at a range of MOIs with the same DD-GFP vector preparation used 
for the in vivo experiments. At high MOIs (above 5), GFP can be seen 
accumulating the in the cells in the absence of Shield1 (Figure 3-10). 
 
 
Figure 3-10 HEK293T cells transduced with HIV vector of DD-GFP at a range of MOI 
HEK293T cells were transduced over a range of MOI using concentrated HIV vector of DD-GFP, and 
either mock treated, or treated with Shield1 48 hours before imaging and harvesting for Western blot. MOIs 
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3.4 Discussion 
These results show that it is possible to design and construct lentiviral vectors 
that tightly and dose-dependently regulate the expression of a GOI in vitro using 
the DD technology. 
The DD was originally isolated via a screen of random mutants cloned at the N-
terminus of YFP (Banaszynski et al., 2006). C-terminal fusions also exhibited 
destabilizing characteristics and this arrangement may be useful for situations 
where an N-terminal fusion would be non viable, indicating the importance of 
testing both construct designs with each new GOI. In dose response experiments 
the DD system displayed dose dependent levels of induction between 0-100nM 
Shield1. Similar dose responsiveness has been reported by others (Dolan et al., 
2011; Skafte-Pedersen et al., 2012). In our hands the DD-GFP construct 
exhibited preferential characteristics such as a higher maximal level of induction 
and lower basal accumulation.  
This may be explained by the order in which the DD is translated in the context 
of the fusion protein. When placed at the N-terminus, the DD will be translated 
before the GFP. When the protein is being produced in the absence of Shield1, it 
will not fold correctly and may already be targeted for degradation at this early 
stage, meaning that as soon as the remaining GFP portion of the fusion protein is 
produced it will also already be targeted for degradation. Conversely, when the 
DD is fused to the C-terminus, the GFP will be translated first and may fold 
correctly until the DD domain is released. GFP would therefore be present in the 
cell for longer before being degraded in the absence of Shield1. However, it 
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must also be noted that the difference in basal expression between N- and C-
terminal DD fusions was considerably lessened when Luciferase is the fusion 
partner, and, in following chapters it will be seen that C-terminal fusions of other 
DDs out perform N terminal. This implies the environment surrounding the DD 
is important in determining the regulatory profile of the system.  
Reporter proteins have been widely used in molecular biology for their stability 
and reliability promoting their utilisation in initial testing of this system. Here 
we have not evaluated the system using more complex proteins, however, this 
system has been used to regulate many other classes of proteins such as kinases, 
cell cycle regulatory proteins, GTPases, transmembrane proteins and secreted 
proteins (Banaszynski et al., 2006; 2008), suggesting that it may be of use for 
studying other GOI. We were able to use both HIV and EIAV lentiviral vectors 
to transduce the DD/GOI cassette in 293T cells and HIV viral vector to 
transduce cultured E18 cortical neurons and striatal neurons in vivo. Other cell 
types (Banaszynski et al., 2006) had been successfully transduced using other 
vector systems (Rodriguez and Wolfgang, 2012), suggesting that the DD system 
could be highly versatile. 
The luciferase reporter was cloned not only to test the ability of the DD system 
to regulate a different reporter in our hands, but also to facilitate studies in the 
kinetics of activation and deactivation. Luciferase has a much shorter half-life 
(approximately 3h) (Thompson	  et	  al.,	  1991;	  Kafri	  et	  al.,	  1998) than GFP (26h) 
(Corish	   and	   Taylor-­‐Smith,	   1999) in mammalian cells, suggesting that 
luciferase levels may better reflect the changes in levels of activation (Wang	  et	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al.,	   2002). Other studies have taken a similar approach, using the DD with a 
PEST tagged luciferase (Imanishi	   et	   al.,	   2011). The PEST peptide sequence 
(rich in proline, glutamic acid, serine, and threonine), acting as a signal for 
protein degradation (Rogers et al., 1986; Rechsteiner, 1990), reduced the half-
life to under one hour (Leclerc	  et	  al.,	  2000), meaning accumulation of residual 
luciferase was at a minimum.  
We hoped these properties could give insight into the deactivation kinetics of the 
DD system. However, an attempted on-off kinetic study was not been reported 
here, due to very high variability in the data obscuring any trend in Luciferase 
levels. Experimental procedure is mostly likely the cause of this variation. It was 
considered that a simply exchanging Shield1 media for Shield1-free media 
would not sufficiently remove Shield1 as media would remain in the cell layer, 
and Shield1 would remain bound to protein in the cell. We therefore replaced the 
media several times, resulting in cells being dislodged. Subsequent unpublished 
data from the original authors indicate that doping the media with unliganded 
FKBP12 would result in more reliable experimental data. However, producing 
the protein in house as they suggest was outside the time scale of this project. 
We reported an off-on time course (Figure 3-8) suggested that the system is fully 
activated within 24h after the addition of Shield1. Similar induction kinetics 
have been reported in other studies (Banaszynski et al., 2006; Schoeber et al., 
2009) 
We have shown that HIV lentiviral vectors can successfully transduce cultured 
cortical neurons with the DD system, and dose-dependently regulate levels of a 
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GFP reporter. Other groups have not reported this and it suggests the system 
maybe of great use for controlling levels of GOI in cultured neuronal cells.  
At the time of study, one in vivo study had been performed, and no information 
regarding the pharmacokinetics of Shield1 passing the blood brain barrier (BBB) 
was available. In an unpublished communication, the original investigators 
suggested that Shield1 would not enter the brain after intravenous injection. Cost 
considerations regarding Shield1 - the in vivo study by Banaszynski et al used 
relatively large amounts (5-10mg/kg mouse) of Shield1 - meant it was not 
feasible to investigate this. We decided to test this regulatable system in the CNS 
in vivo by directly injecting the ligand into the environs of cells overexpressing 
the regulatable GFP fusion protein. While we saw strong GFP expression in the 
striatum infused with a constitutively expressing GFP control (confirming that 
our experiment procedures were efficacious), we could not stimulate GFP from 
the DD-GFP infused striatum, either when infusing Shield1 to the striatum or 
ventricles at a higher dose. At the current time we cannot deduce a reason for the 
lack of activation, however, it is unknown how long the Shield1 ligand will 
remain biologically active in the striatum. The brain is constantly washed by 
cerebrospinal fluid (CSF). It is formed in the ventricles at a rate of 3.7µl/min 
(Harnish and Samuel, 1988) to a total volume of CSF in rat of 300-400µl 
(Bergman et al., 1998), therefore turning CSF over 13-18 times per day. Small 
molecules injected into the ventricles are quickly cleared (Nagaraja et al., 2005), 
which may prevent them from entering the tissue and maintaining high local 
concentrations. The in vitro work suggested that the system could be fully 
induced after 24 hours of exposure to Shield1, however, if the Shield1 is being 
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cleared and diluted, there may not be sufficient concentration in the striatum to 
see a significant effect. Furthermore, injecting the brain will result in glial 
scarring around the injection site. Glia cells are highly metabolically active, and 
may increase the removal of Shield1 in the vicinity of the transduced neurons. 
We sought to achieve longer-term stabilisation by delivering Shield1 twice a day 
via cannula permanently implanted into the lateral ventricles. Unfortunately we 
did still not observe a significant increase in GFP expression. While cannulation 
of the brain and microinjection of Shield1 may have improved the experimental 
design by potentially prolonging the availability of Shield1 to transduced 
neurons, the technique for actually inserting the infusion cannula into the guide 
cannula was very difficult and resulted in frequent breakages to the infusion 
apparatus. While the apparatus was always checked before re-attempting it is 
possible that due to the difficulties of performing the technique, that reliability 
may have been lost. Furthermore, it is possible that the permanently implanted 
guide cannula became blocked, preventing the Sheild1 from reaching the correct 
location. 
By transducing HEK293T cells at a range of MOI (Figure 3-10), we may have 
provided some explanation for the existence of individual GFP positive cells 
present in mock treated DD-GFP rats. In some of the brain sections, we observed 
that these cells occur in the area surrounding the needle tract. These cells would 
be transduced at the highest MOI and therefore have the most potential for 
overwhelming the proteasome, thereby accumulating GFP in the absence of 
Shield1. 
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If Shield1 is unable to easily activate the system in the rat brain, the FKBP-
Shield1 system has limited scope for future use in neuronal systems. The 
sensitivity of the brain to damage means that invasive surgery must be kept to a 
minimum, yet there is no long-term therapy using this system possible without 
either continuous reinjection, or cannulation. In contrast to these difficulties, a 
new system obtained from the Wandless research group (Iwamoto et al., 2010) 
offers a system with a ligand that is already well characterized in vivo, is more 
cost efficient, can cross the BBB, and can therefore potentially cheaply and non-
invasively regulate GOI in the brain. This system will be investigated in the next 
chapter. 
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4.1 Introduction 
The FKBP12 derived destabilisation domain system (Chapter 3) had been 
successfully used to conditionally regulate the levels of transgenes in vivo 
(Banaszynski et al., 2008), but the poor predicted pharmacokinetics and expense 
of the ligand made it unsuitable for long term delivery to the CNS. The 
Wandless group identified the need to develop a second destabilisation domain 
(DD) system capable of regulating levels of transgenes in the central nervous 
system (CNS). The full-length Escherichia coli (E. coli) dihydrofolate reductase 
(DHFR) protein was chosen to be engineered into a DD with these properties. 
DHFR is a ubiquitously expressed 159-residue enzyme that catalyses the 
production of tetrahydrofolate (THF) from dihydrofolate. THF derivatives are 
required for purine and thymidylate synthesis and therefore necessary for cell 
growth and proliferation (Schnell et al., 2004). As rapidly dividing cells such as 
bacteria or tumour cells require more of these molecules, DHFR has been 
targeted in the development of bacteriostatic antibiotics and chemotherapy 
agents, creating many high affinity ligands already optimised as therapies for 
humans (Schweitzer et al., 1990).  
Trimethoprim (TMP) is an example of a DHFR inhibitor developed for use as an 
antibiotic in humans. It has properties that make it highly suitable to activating 
the DD system in the CNS. As TMP binds to E. coli DHFR 3000-fold more 
tightly than to vertebrate DFHR (Matthews et al., 1985), adverse effects due the 
inhibition of endogenous DHFR are minimized. It is commercially available, 
inexpensive, and its pharmacokinetics have been studied in rats, (Meshi and 
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Sato, 1972; Tu et al., 1989), lending insight to potential in vivo studies. 
Importantly, it can cross the blood brain barrier (Barling and Selkont, 1978), and 
is rapidly absorbed from the gastrointestinal tract (Meshi and Sato, 1972). 
The parental DHFR gene isolated from E. coli K12 (folA) already encoded two 
mutations (R12H/G67S) from the wild type sequence. To develop DDs, a library 
of clones with further random mutations was generated using error prone PCR. 
This library was fused to a yellow fluorescent protein (YFP) reporter so that 
flow cytometry could be used to identify clones that responded to TMP, by 
assessing YFP fluorescence. Previous work by the Wandless Lab (Banaszynski 
et al., 2006) suggested DDs have different efficiencies when used at the N- or C-
terminus of YFP. Therefore, two fusion libraries were created - one fusing the 
DHFR DD library to the N-terminus of YFP, and another fusing the DD library 
to the C-terminus of YFP. We were supplied one DD from the N-terminal-DD 
screen, bearing the engineered mutations R12Y/Y100I, and one DD from the C-
terminal screen, with mutations N18T/A19V. The N-terminal DD therefore has 
three mutations (hereafter 3mut) in total - R12Y/G67S/Y100I - while the C-
terminal DD has four (hereafter 4mut) - R12H/N18T/A19V/G67S. At the 
initiation of our studies, detailed description of the properties of the DHFR DD 
system had not been published by the Wandless laboratory. We therefore tested 
both domains at both the N- and C-terminus of our genes of interest (GOI). 
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In this chapter, we will evaluate the DHFR destabilisation domains at both the 
N- or C-terminus of GFP, to find the best construct for further investigation. We 
will assess the versatility of the system by cloning a luciferase reporter, also 
enabling study of the induction kinetics once TMP has been supplied. To 
confirm the suitability of the system for regulating levels of GOI in neurons, 
further characterization of induction kinetics will be performed in cultured 
primary neurons. Finally, the system will be tested in vivo with the aim of 
optimizing the delivery, dose and timing of TMP administration, potentially 
providing a robust strategy for regulating therapeutic genes in the CNS.  
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4.2 Methods 
4.2.1 Optimised DD-GOI/GOI-DD cassette used in combination with PCR 
strategy 
Two constructs were obtained from the Wandless laboratory – pBMN-3mutDD-
YFP and pBMN-YFP-4mutDD. The pBMN plasmid is a Moloney Murine 
Leukaemia Virus based vector, therefore cloning into a pRRL series backbone 
will be necessary so the constructs can be used with our HIV based lentiviral 
vector system (Dull et al., 1998). Restriction enzyme (RE) site optimised 
constructs had already been designed for investigating the FKBP12 DD system 
(See Chapter 3). A PCR based strategy would facilitate the exchange of the 
FKBP12 for the new DHFR destabilisation domains in constructs pRRL-DD-
GFP and pRRL-GFP-DD. 
4.2.1.1 Sequences of 3mut and 4mut DHFR DD 
 
Figure 4-1 Sequence of 3mut and 4mut DHFR DD compared to mutant-free folA 
Numbers above text indicate the amino acid number in the native folA sequence. Blue nucleotides indicate 
mutations present in the parental E. coli K12 folA clone. Red nucleotides indicate mutations introduced 
using error-prone PCR. Green nucleotides indicate silent mutations. Stars indicate nucleotide 
complementarity in the alignment. Start and stop codons have been omitted, as only one is present, 
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4.2.1.2 PCR amplification of DHFR DD from pBMN-3mutDD-YFP and 
pBMN-YFP-4mutDD 
PCR was performed (Methods 2.1.1) using the primers listed in Table 4-1. The 
same primer pair could be used to amplify both 3mut and 4mut DD sequences. 
N-terminal form PCR products (for forming pRRL-3/4mutDD-GFP) were 
505bp, C-terminal form products (for forming pRRL-GFP-3/4mutDD) were 




Table 4-1 Primers designed for the amplification of DHFR DD domains from 3mutDD-YFP and YFP-
4mutDD. 
Annotated sequences indicate RE sites, sequences shown in bold represent regions of template 
complementarity. 
4.2.1.3 Cloning pRRL-3mutDD-GFP, pRRL-4mutDD-GFP, pRRL-GFP-
3mutDD and pRRL-GFP-4mutDD 
PCR products were separated, typically in a 1% agarose gel, the correct band 
was excised and DNA recovered (Method 2.1). Backbone plasmid pRRL-DD-
GFP and N-terminal form DDs were digested with the REs AgeI/PspOMI; 
pRRL-GFP-DD and C-terminal form DDs with the NheI/SalI pair. After agarose 
gel electrophoresis, band excision and DNA recovery, products were quantified, 
and backbone-insert pairs ligated, transformed and sequenced. 
Primer Name             Primer Sequence (5’-3’)
N-terminal-form forward       TATATTACCGGTGCCACCATGATCAGTCTGATTGCGGCG  
N-terminal-form reverse        TAGGTTGGGCCCGCCGCTCCAGAATCTC  
C-terminal-form forward       TAGCGTGCTAGCATCAGTCTGATTGCGGCG      
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4.2.1.4 Cloning pRRL-Luciferase-3mutDD 
A luciferase reporter gene had already been cloned into the RE optimised 
cassette for investigating the FKBP12 derived DD system (Chapter 3). The REs 
AgeI/NheI were used to extract the Luciferase fragment from pRRL-Luciferase-
DD. GFP was removed from pRRL-GFP-3mutDD using the same enzyme pair. 
After gel purification and extraction, DNA fragments were ligated to form 
pRRL-Luciferase-3mutDD.  
4.2.2 Preparation and use of HIV lentiviral vectors 
Lentiviral vectors were produced and titred (Method 2.2). In all in vitro 
experiments in this chapter, vectors were used MOI1. HEK293T cells and E18 
rat cortical neurons seeded and transduced as described in (Methods 2.5.3 and 
2.6.4 respectively). TMP was supplied at a range of doses – 0, 0.5, 5, 50µM – to 
both cell types. 






were not matched for in vivo experiments. 
 
4.2.4 Preparation of trimethoprim stock solutions 
For use in vitro, TMP (Sigma) was dissolved in neat DMSO (Sigma) to make a 
200mM solution, and typically used at dilutions below 50µM. In vivo, when 
directly infusing TMP into the striatum, 2µl of stock solution was used (116µg 
TMP). TMP was used as a powder and disseminated in powdered normal rat 
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chow before mixing with water and flavouring agents to make a mash - final 
concentration 0.2% TMP. 
4.2.5 Stereotactic injection of HIV-GFP-3mutDD into the CNS of adult rats 
In all in vivo experiments in this chapter, adult male Wistar rats (250-300g) 
received 2µl of HIV-GFP-3mutDD vector via stereotactic injection (0.2µl/min 
infusion rate) to the striatum of the right hemisphere at the coordinates 
(AP/ML/DV relative to bregma) 0/3.5/4.75 (Method 2.7). TMP dosing regimen 
commenced three weeks later. At the end of the feeding regimen, the animals 
were euthanized,  
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4.3 Results 
4.3.1 Cloning the DHFR destabilisation domain into GFP reporter cassette. 
To test the efficacy of the different domains to destabilize a GFP reporter, both 
the 3mut and 4mut DD had to be cloned at both N and C-terminus of GFP. We 
utilised the restriction enzyme (RE) optimized cassettes that were already being 
used to study the FKBP12 DD (See chapter 3). PCR primers containing the 
appropriate RE sites (See 4.2.1.2) were used to amplify the new DHFR DDs, 
facilitating cloning into the DD-fusion cassette in an HIV-based lentiviral vector. 
This strategy enabled the formation of two N-terminally fused constructs - 
pRRL-3mutDD-GFP, pRRL-4mutDD-GFP – and two C-terminally fused GFP-
DD constructs - pRRL-GFP-3mutDD and pRRL-GFP. These plasmids could 
then be used to produce HIV lentiviral vectors. 
 
 
Figure 4-2 Schematic diagram of the viral insert of 3mutDD-GFP, 4mutDD-GFP, GFP-3mutDD and 
GFP-4mutDD constructs 
 
4.3.2 HEK293 cells transduced with HIV lentiviral vectors expressing DHFR 
DD fusions to GFP accumulate GPF in the presence of TMP 
HIV lentiviral vector preparations of the four constructs were made and used to 
transduce HEK293T cells. TMP doses ranging from 0 - 50µM were applied 48h 





WPRECMV GFPDD dLTRdLTR RRE cPPT/CTSDD-GFP
WPRECMV GFP DD dLTRdLTR RRE cPPT/CTSGFP-DD
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[A/B/C/D]).  All four constructs showed an accumulation of GFP when treated 
with TMP. The 4mutDD applied at either the N- or C-terminus achieved 
maximal levels of GFP at low doses of TMP, however, basal expression was 
high in the absence of TMP. The 3mutDD form (fused to either N or C-terminus 
of GFP) exhibited the most favourable characteristics, with low basal expression 
in the absence of TMP and dose dependent increase of GFP when treated with a 
range of TMP doses. Using flow cytometry techniques to assess mean 
fluorescence intensity, the 3mutDD-GFP construct showed a 16-fold induction 
upon exposure to 50µM TMP while the GFP-3mutDD construct showed a 42-
fold induction, with maximal levels comparable to that of a constitutively 
expressed GFP control. This indicates that the 3mutDD used at the C-terminus is 
the most desirable construct, and this will therefore be used for further 
investigations. There was no change in fluorescence when the same range of 
TMP was applied to cells expressing a constitutive GFP reporter, indicating that 
TMP does not affect GFP fluorescence or CMV promoter activity. 
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Figure 4-3 HEK293T cells transduced with DHFR DD constructs accumulate GFP in the presence of 
TMP. 
[A] HEK293T cells transduced with unconcentrated HIV preparations of DHFR DD tagged GFP constructs, 
treated to a range of TMP doses 48h before imaging. Scale bar=400µm. [B] Analysis of GFP MFI (mean 
fluorescent intensity) by FACs analysis (n=3). [C] Western blot analysis of pooled samples, TMP doses 
(left to right): 0, 0.1, 0.2, 0.5, 5 and 50µM. Approximate molecular weight: 3/4mutDD-GFP, 45kDa; GFP-
3/4mutDD, 45kDa; α-tubulin, 50kDa. [D] Densitometry of blots performed using ImageJ software. 
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4.3.3 HEK293T cells transduced with HIV-Luciferase-3mutDD accumulate 
luciferase in the presence of TMP, over time-course 
To investigate the versatility and kinetics of the DD system, a firefly Luciferase 
reporter was employed. Luciferase has a much shorter half-life (≈3h) (Thompson 
et al., 1991) than GFP (≈26h) (Corish and Taylor-Smith, 1999), meaning that a 
DD tagged luciferase may better reflect the changes in levels of system 
activation in cells being treated with TMP (Wang et al., 2002). pRRL-
Luciferase-3mutDD was developed as described (See 4.2.1.4). An 
unconcentrated HIV vector preparation was produced (4.2.2) and used to 
transduce HEK293T cells. TMP doses ranging from 0 - 50µM were applied 48h 
prior to cell lysis in preparation for luciferase assay (Figure 4-4 [A]). TMP 
caused a dose-dependent increase in luciferase activity, requiring a minimum 
dose of 0.25µM TMP to be significant (Dunnetts posthoc test). To assess the 
induction kinetics of the system, TMP (50µM) was supplied to HIV-Luciferase-
3mutDD transduced HEK293T cells over a range of time points before 
harvesting (Figure 4-4 [B]). Luciferase activity increases significantly within the 
second hour after TMP addition Dunnetts posthoc test, reaching a maximal level 
within 24h. 
  
Chapter 4 - DHFR Destabilisation Domain 
 - 127 -
 
 
Figure 4-4 HIV-Luciferase-3mutDD transduced HEK293T cells accumulate luciferase activity over a 
range of TMP doses. Luciferase activity increases over time post TMP addition. 
[A] HEK293T cells transduced with concentrated HIV vector of Luciferase-3mutDD, exposed to a range of 
TMP concentrations 48h before harvesting (n=3). A luciferase assay performed on cell lysates indicates 
significant increase in luciferase activity when analysed: One way ANOVA: *** p<0.0001, (f=26.35, 
R
2
=0.9584); Stars indicate Dunnett posthoc test: 0vs0.25µM, ** p<0.01 (q=4.863) [B] HEK293T cells 
transduced with concentrated HIV vector of Luciferase-3mutDD were treated with TMP over a time course 
before harvesting (n=3). A luciferase assay performed on cell lysates indicates significant increase in 
luciferase activity, One way ANOVA: *** p<0.0001, (f=24.11, R
2
=0.9156); Stars indicate Dunnett posthoc 
test: 0vs2hrs, * p<0.05 (q=2.997); 0vs3hrs ** p<0.01 (q=3.806). [Inset]: One way ANOVA: ** p=0.0028 
(f=8.649, R
2
=0.7758); Stars indicate Dunnett posthoc test: 0vs45mins, ** p<0.01 (q=4.121). 
4.3.4 E18 rat cortical neurons transduced with HIV GFP-3mutDD treated 
with TMP accumulate GFP in the presence of TMP 
When testing this system in vivo, successful transgene regulation in neural cells 
is essential if this system is to be used in the CNS in vivo. As we do not require 
the short half-life properties of luciferase, we will therefore use HIV-GFP-
3mutDD vector. To test the efficacy of the system in neuronal cells, E18 rat 
cortical neurons were transduced in vitro with HIV-GFP-3mutDD, and treated 
with a range of TMP doses 96 hours before harvesting for 
immunocytochemistry. Photomicrographs indicate that neuronal cells 
accumulate GFP in a dose dependent manner, due to colocalisation of NeuN and 
GFP staining in higher TMP doses (Figure 4-5 [A]). To confirm that the system 
could be activated in neurons in a similar time scale to that seen in HEK293Ts 
cells, E18 rat cortical neurons transduced with HIV-GFP-3mutDD were treated 
with 50µM TMP at time points between 96h and 1h before harvesting (Figure 
4-5 [B]). Immunofluorescent staining suggests that GFP accumulation reached a 
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maximum within 24h of exposure to TMP, and was maintained until at least 96h. 
Staining for NeuN (neurons) was not included in this experiment, as it has 
previously been established in our laboratory that E18 cortical cultures contain 
over 90% neurons (approximately 6% glia), and immunostaining in Figure 4-4 
[A] already indicates that the system is functional in neurons. 
 
 
Figure 4-5 HIV-GFP-3mutDD transduced E18 rat cortical neurons accumulate GFP over a range of 
TMP doses. Accumulation occurs over time post TMP addition. 
[A] E18 rat cortical neurons seeded at 10000 cells/well were transduced with HIV-GFP-3mutDD at day 5, 
then treated with 50µM TMP from day 8 (96h) to day 12 (0h) before harvesting for immunostaining. βIII-
Tubulin/GFP/DAPI. Scale bar=100µm. [B] E18 rat cortical neurons seeded and transduced as before were 
treated with TMP over a time course ranging from 1 hour to 96 hours prior to harvesting for 
immunostaining. A control that did not have TMP added was included (0h). GFP/DAPI. Scale bar=100µm. 
4.3.5 Testing the efficacy of HIV-GFP-3mutDD vector in adult rat CNS 
Adult male Wistar rats received a stereotactic injection of pRRL-GFP-3mutDD 
in the striatum of the right hemisphere. Three weeks later, TMP solution (116µg 
TMP total) was infused into the striatum, 6h before the brain was harvested in 
preparation for cryosectioning and immunohistochemistry. Control rats did not 
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receive any injection of TMP, and consequently there was minimal GFP 
immunoreactivity in sections from these animals (Figure 4-6 [A]). However, rats 
that received TMP had a large area of cells positively stained for GFP in the 
striatum (Figure 4-6 [B]). Higher magnification images reveal that GFP and 
NeuN (neuronal marker) immunostaining is co-localised (Figure 4-6 [D/E]). 
This confirms that the HIV-GFP-3mutDD system can be regulated in neurons in 
vivo. However, in some of the sections, it was observed that the TMP infusion 
had led to damage in the striatum, possibly due to the high local concentration of 
DMSO or TMP, or both. Furthermore, this method of activation requires animals 
to undergo at least two rounds of invasive surgery, which should be kept to a 
minimum. 
TMP is readily absorbed when orally ingested (Meshi and Sato, 1972). 
Administration of TMP via either the chow or drinking water of rats would be 
highly advantageous, as it would eliminate the need for invasive surgery, while 
providing a more constant supply that could be maintained over weeks if 
required. To investigate this possibility, adult male Wistar rats received a 
stereotactic injection of HIV-GFP-3mutDD vector in the striatum of the right 
hemisphere. After three weeks, normal chow was replaced with a mashed chow 
containing 0.2% TMP (On average 230mg/kg TMP eaten per day) for three 
days, before harvesting the brain for cryosection and immunostaining. Rats 
eating a control diet did not have an accumulation of GFP (as seen before - 
Figure 4-6 [A] is representative), while rats eating a TMP supplemented diet had 
a large area amount of positively GFP stained neurons in the striatum (Figure 
4-6 [C]). Again, higher magnification images confirm that this method of 
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activating the system leads to increased levels of GFP in neurons (Figure 
4-6 [F/G]), without the need for invasive surgery to deliver TMP. 
 
 
Figure 4-6 Two TMP delivery methods to adult rat CNS transduced with HIV-GFP-3mutDD vector leads 
to accumulation of GFP. 
[A/B/C] HIV-GFP-3mutDD lentiviral vector was stereotactically injected in the striatum of adult male 
Wistar rats (n=3). [A] Control rats without TMP administration. [B] TMP was stereotactically delivered 
directly into the striatum 3 weeks post vector injection, brain harvested after 6h. [C] TMP was supplied at 
0.2% of diet (≈250mg/kg/day) for 4d before harvesting. Scale bar=1mm. [D/E] Enlarged area outlines in 
[B/D] respectively. [F/G] Enlarged area outline in [C/F] respectively. NeuN/GFP/DAPI. Scale bar=50µm. 
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4.4 Discussion 
When our study of the DHFR based DD system was commenced, data 
describing the system had yet to be published. The Wandless Lab supplied us 
with two constructs without clarification that they were the product of two 
independent library screens. Therefore, we cloned both domains at both N- and 
C-terminus of GFP to fully test which would be best at regulating GFP in our 
hands. As discussed in chapter 3, in our experience, the efficiency of the DD is 
altered by the GOI that it is fused to. Therefore, ideally, for each new GOI, all 
four possible constructs should be investigated. However, in the initial test of the 
four DD GFP fusions (Figure 4-3) the 4mutDD constructs did not exhibit 
desirable regulatory characteristics, so we did not use it for further experiments. 
GFP levels dose dependently increased when increasing TMP dose was supplied 
to cells transduced with HIV-GFP-3mutDD, and the maximum accumulation 
level was approximately double that shown by cells transduced with HIV-
3mutDD-GFP. Basal expression in the absence of ligand was also lower when 
using GFP-3mutDD. Both properties are important when considering the 
potential of this system to regulate therapeutic genes in vivo. Higher levels of 
maximal induction will provide higher levels of therapeutic GOI when the 
system is activated. That this can be achieved over a large range of TMP doses 
may make it possible to tune the level of activation in vivo, where controlling the 
TMP dose precisely may be difficult. When the therapeutic window has passed, 
unwanted effects from the continued expression of the GOI will be abrogated as 
far as possible if basal expression (in the absence of ligand) is minimal. Bearing 
in mind that these properties would initially be assessed in vivo using a GFP 
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reporter, we decided to use the GOI-3mutDD form when investigating another 
GOI (Luciferase). 
The HIV-Luciferease-3mutDD vector was produced to assess the ability of the 
system to regulate other GOI, as well as gain an understanding of the kinetics of 
the system activation/deactivation. Luciferase has a much shorter half than GFP, 
meaning that immediate changes in levels of activation in the DD system will be 
more accurately reported, particularly when looking at deactivation (or “turning 
off”) kinetics. As we reported, luciferase activity increased dose dependently 
with increasing TMP concentration, and supplying TMP over a time course 
indicated that the system is fully activated within 24h, however, the deactivation 
kinetics were not assessed as intended. Removing the TMP ligand from the 
transduced cells proved to be technically challenging, as washing cells with new 
media in a 96 well plate format resulted in the removal of patches of cells, 
causing highly variable readings in luciferase activity (result not shown). It has 
subsequently been suggested in unpublished communication from the Wandless 
Lab, that doping cell culture media with unliganded DHFR would improve the 
experimental result, as this will sequester free TMP away from the cells. 
Reported deactivation times suggest that levels of GOI can be reduced to basal 
levels between 4h (Iwamoto et al., 2010) in cell lines (Muralidharan et al., 2011) 
to 17h in P .falciparum after withdrawal of TMP.  
The in vivo efficacy of the DHFR DD system had not been published when our 
in vivo studies began. Therefore we had to optimise the procedure used to 
deliver TMP to the animals. The initial approach involved direct stereotactic 
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infusion of TMP into the CNS (Figure 4-6 [B]) and harvesting 6h later. This 
time point was chosen, first because it was apparent from the time course studies 
in vitro (Figure 4-4 [B], Figure 4-5 [B]) that the system could be activated 
within 6h, and second, that over time the TMP may be removed from the 
injection site by the clearing effects of cerebral spinal fluid (CSF), potentially 
deactivating the system again. We administered the maximal dosage (116µg 
TMP) permitted, which resulted in robust activation of the system. However, 
this procedure requires two rounds of invasive surgery into the CNS, and does 
not provide a method of long-term delivery of TMP. Also, damaged areas were 
observed in the striatum, possibly due to the double injection, or high DMSO or 
TMP concentration at that site. However, it did indicate that the system had 
efficacy to regulate GOI in the CNS. 
In an intermediate study (not reported), two methods avoiding the need for direct 
delivery of delivered TMP into the CNS were tested: A twice-daily 
intraperitoneal (IP) injection of TMP for three days, and delivery via the 
drinking water for three days. Both aimed to deliver 50mg/kg/day TMP, chosen 
partly because dose had been used by others when studying TMP as an antibiotic 
in rats (Kluge et al., 1978). Both experimental procedures were suboptimal. 
First, twice-daily IP injection was distressing to the animals, and long-term 
delivery of TMP would lead to the abdominal skin becoming very sensitive due 
to multiple of injection sites. Secondly, rats did not accept the TMP doped 
drinking water. Supplementation with 5% sucrose and 5% Ribena was required 
before drinking would commence. This means that not only is the diet is 
supplemented with sugar, but the sugary water will encourage bacterial and 
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fungal growth, necessitating large wastage of TMP as it is replaced. However, 
over three days after drinking commenced rats consumed an average of 
approximately 55mg/kg/day, indicating that this may be a way of providing 
TMP non-invasively. However, both approaches failed to yield positive results - 
after immunohistochemistry on the brains, only very weakly GFP positive cells 
were observed in the striatum, indicating incomplete activation of the system. 
We hypothesised that the TMP dose supplied to the animals was too low, and as 
such increased the dose by supplying TMP in chow, where the taste would be 
better concealed. However, after this work was completed, the Wandless Lab 
published data showing TMP supplied in drinking water to rats at a dose of 
approximately 20mg/kg/day for three weeks, lead to activation of the system 
(Iwamoto et al., 2010). This is under half the dose our animals received, but it 
supplied for a much longer time, suggesting that the system may need prolonged 
exposure to activate at low doses. However, they did not report findings at 
intermediate time points, leaving the kinetics of activation of the system in vivo 
poorly elucidated. The lower dosing regimen is attractive in monetary terms, and 
would potentially require less flavouring agents to be palatable for animals. 
However, for our intended application of this system (in models of spinal cord 
injury and Parkinson’s’ disease - See Chapter 5/6) we may require that the 
system be activated quickly in a shorter timescale.  
TMP supplied via chow leads to activation of the system within three days 
(Figure 4-6 [C]). On average rats ate a dose of 230mg/kg/day, when the TMP 
(0.2%) powder had been completely disseminated in flavoured powdered chow. 
This dose activated the system within 3 days, while still being well below a toxic 
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levels (Oral rat LD50=5.7g/kg). This feeding procedure will be used when testing 
other therapeutic genes in vivo in the following chapters. In conclusion the work 
in this chapter indicates that the DHFR system has the potential to regulate 
levels of GOI in the brain.  
  
Chapter 5 - RARβ2 
 - 136 - 
Chapter 5 RARβ2 
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5.1 Introduction 
The retinoic acid signalling pathway plays vital roles in development, patterning 
and regeneration in the mammalian central nervous system (CNS). Retinoic acid 
(RA) is a biologically active metabolite of vitamin A. It is obtained in the diet in 
the form of carotenoids (from plant material) or retinyl esters (in animal 
products), and stored in several sites in the body, including the kidneys, bone 
marrow and lungs. It is released into blood plasma as retinol and is transported 
by the plasma retinol-binding protein 4 (RBP4). Retinol can then be taken up 
into cells where it is then bound to the cellular retinol binding protein (CRBP), 
following which it can then be metabolized into all-trans RA by retinol and 
retinaldehyde dehydrogenases. Newly synthesized RA can be bound by cellular 
retinoic acid-binding proteins 1 and 2 (CRABP-1 and CRABP-2) (reviewed by 
Maden, 2007). 
RA exerts physiological effects on cells by binding to nuclear receptors - 
retinoic acid receptor (RAR)/retinoic X receptors (RXR) heterodimers. There are 
three families of both RARs and RXRs - RARα/RARβ/RARγ and 
RXRα/RXRβ/RXRγ - all exhibiting several isoforms resulting from differential 
promoter usage and variable splicing (Leid et al., 1992; Chambon, 1994; 
reviewed by Chambon, 1996) alluding to the pleotropic effects of RA signalling. 
The structure of these receptors is modular and highly conserved across species, 
particularly in the ligand binding domain, suggesting that they play important 
roles in normal physiological and biological processes. Upon activation by the 
ligand, the RAR/RXR heterodimer complex is translocated to the nucleus and 
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with additional phosphorylation and recruitment of a range of cofactors (Taneja 
et al., 1997; Bastien and Rochette-Egly, 2004), it binds to DNA sequences called 
retinoic acid response elements (RAREs) in the promoter regions of genes. RA 
signalling in cells directly affects 27 genes, although more than 500 have been 
observed to be RA responsive, probably due to RARE independent mechanisms 
(Balmer and Blomhoff, 2002).  
RA is classically involved in the development of the embryonic nervous system, 
namely in patterning and neuronal differentiation (reviewed by Maden, 2007). 
RA gradients, together with WNTs and fibroblast growth factors (FGFs), are 
necessary for the organizing the posterior hindbrain and the anterior spinal cord 
(Melton et al., 2004) while RA, in combination with sonic hedgehog (SHH), 
bone morphogenetic proteins (BMPs) and FGFs, is important for establishing 
dorsoventral patterning of the neural plate and neural tube (Novitch et al., 2003) 
(Wilson and Maden, 2005). RA also plays an extensive role in differentiation of 
various neuronal types and glia, through the activation of transcription factors, 
cell signalling molecules, structural proteins, enzymes and receptors. For 
example, RA is known to induce neuronal differentiation of embryonic 
carcinoma cell lines (Jones-Villeneuve et al., 1983) and has been used in 
embryonic neural progenitor cells to derive neurons/glia for transplantation in 
models of neurodegenerative disease (reviewed by Maden, 2007). 
More recently roles for RA signalling have been described in the adult nervous 
system. The RA synthesizing enzymes, binding proteins and RAR/RXR are 
expressed in the adult nervous system. Particularly in the field of axonal 
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regeneration, there is growing evidence that RA signalling may contribute 
significantly to axonal growth processes, possible through the reactivation of 
developmental programs in the adult. For example, in peripheral nerves that 
regenerate (as opposed to central nerves that do not), RA signalling is induced 
upon nerve injury, as evidenced by increased activity in RARE-LacZ reporter 
mice, with peak activity being reported 7 days following injury (Zhelyaznik et 
al., 2003). By comparing the levels of all RAR isoforms in embryonic dorsal 
root ganglion (DRG) cultures extending neurites in response to RA (and isoform 
specific agonists), Corcoran et al. found that RARβ2 was the principal 
modulator of RA based neurite outgrowth (Corcoran et al., 2000). In 
confirmation, they observed a rise in RARβ2 expression when embryonic spinal 
cord explants were treated with RA and this was correlated with an increase in 
neurite outgrowth (Corcoran et al., 2002). However, treating adult spinal cord 
explants with RA did not result in the up-regulation in RARβ2 and neurite 
outgrowth was not induced. This suggested that the differences seen between the 
regenerative ability of the embryonic and peripheral nervous system (PNS) 
compared to the adult CNS were in part due to the lack of RARβ2 levels. 
Furthermore, neurotrophins such as nerve growth factor (NGF) that are 
important in the development of the nervous system have been shown to 
increase retinaldehyde dehydrogenase-2 (RALDH-2) and RARβ2 levels, 
resulting in increased neurite outgrowth from adult mouse DRG (Corcoran and 
Maden, 1999). Finally, So et al. (So et al., 2006) demonstrated that there was 
decreased peripheral nerve regeneration in adult RARβ null mice while 
Puttagunta et al. (Puttagunta et al., 2011) have demonstrated that postnatal 
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cerebellar granule neurons from RARβ null mice failed to extend neurites in 
response to RA. 
The above evidence suggested that RARβ is the primary receptor through which 
RA acts to induce neurite outgrowth in embryonic and adult neurons. Corcoran 
et al. (Corcoran et al., 2002) showed that lentiviral vector-mediated 
overexpression of RARβ2, not RARβ4, induced neurite outgrowth in 
organotypic adult spinal cord preparations. This indicated that re-introducing 
endogenous signalling pathways back into adult tissue could provide a method 
of inducing local neurite outgrowth. Based on these and other observations, 
Wong et al. (Wong et al., 2006) investigated the utility of this lentiviral approach 
to exogenously express RARβ2 in vivo in order to increase axonal regeneration 
after nerve injury. Having confirmed that transducing DRG neurons with a 
lentiviral vector overexpressing RARβ2 induced neurite outgrowth on a 
nonpermissive substrate, adult rat DRGs were transduced in vivo in a dorsal root 
lesion model. The authors observed that lentiviral-mediated overexpression of 
RARβ2 promoted growth of injured DRG neurons into the non-permissive 
dorsal root entry zone (DREZ). Furthermore, improvements in motor deficits 
recorded after a dorsal root crush indicated regenerating sensory neurons could 
reconnect to appropriate targets (Wong et al., 2006). In another CNS lesion 
model, Yip et al. (2006) demonstrated that lentiviral overexpression of RARβ2 
encouraged axonal outgrowth from adult cortical neurons in vitro, and 
transduction of the sensorimotor cortex prior to spinal cord lesion led to axonal 
and functional regeneration of the corticospinal tract (CST) in adult rats (Yip et 
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al., 2006). Finally, a RARβ specific agonist, CD2019, infused into the brain 
following a dorsal column lesion also increased regeneration of CST axons and 
functional forelimb recovery (Agudo et al., 2010). These studies, together with 
the in vitro data, confirm that the RA-RARβ2 signalling pathway is involved in 
promoting growth programs in injured neurons to facilitate functional 
regeneration. 
The downstream targets of RA-RARβ2 signalling are not well studied. The 
study by Wong et al. (Wong et al., 2006) indicated that lentiviral overexpression 
of RARβ2 increased cAMP production and inhibition of cAMP production by an 
adenylate cyclase inhibitor, 2’, 5’-dideoxyadenosine (DDA) attenuated RARβ2-
induced neurite outgrowth from DRG neurons. However, Agudo et al. (Agudo et 
al., 2010) showed that the growth promoting effects of the RARβ agonist 
CD2019 was decreased by a PI3K (Phosphoinositide 3-kinase) inhibitor but not 
a PKA (Protein kinase A) inhibitor. More recently Puttagunta et al. (Puttagunta 
et al., 2011) demonstrated that the RA-RARβ-mediated neurite outgrowth acted 
via suppression of myelin-activated Nogo receptor (NgR) pathway, specifically 
through the transcriptional repression of the NgR complex member Lingo-1. The 
authors demonstrated that that RA treatment recruits binding of RARβ to a 
RARE element found in the Lingo-1 promoter, thereby inhibiting its expression 
in response to myelin. This is particularly relevant as the inhibitory myelin-
associated molecules within the CNS are known to signal through the neuronal 
membrane-bound NgR complex to activate RhoA, which then triggers a chain of 
events that ultimately result in growth cone collapse (He and Koprivica, 2004). 
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So far, no other direct transcriptional targets of RARβ have been identified to be 
involved in mediating neurite outgrowth, although RARβ2 target genes have 
been described in RA-treated F9 wild-type teratocarcinoma cells (Zhuang et al., 
2003).
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The use of the lentiviral vector to deliver the transcription factor RARβ2 in in 
vivo models of central nerve injury suggested that this may be a relevant target 
to pursue further therapeutically. However, in order to improve the appeal of 
gene therapy for CNS injuries such as spinal cord injury, it would be desirable to 
engineer a system whereby exogenous gene expression from the vector can be 
regulated in a dose-dependent manner; making it more acceptable in the clinic. 
In this chapter, we will assess the ability of the DHFR destabilisation domain 
(DD) technology to regulate the levels of RARβ2 in vitro and in vivo. Initial 
testing of the DD at both the N or C terminus of RARβ2 will reveal the best 
construct for further investigation. To confirm the suitability of the system for 
regulating levels of RARβ2 in neurons, further characterization will be 
performed in cultured primary neurons harvested from the cortex and DRGs. 
Using an in vitro model of neurite outgrowth over inhibitory substrates, we will 
discover if the regulatable RARβ2 can induce greater outgrowth when activated. 
Finally, the system will be tested in vivo using a model of spinal cord injury. 
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5.2 Methods 
5.2.1 Cloning DD-RARβ2 construct, a constitutively expressed RARβ2 
construct, and a GFP control construct 
To form a regulatable RARβ2 construct, the restriction site (RE) optimised 
constructs (pRRL-DD-GFP/pRRL-GFP-DD) that had already been designed for 
investigating the DHFR DD system (See Chapter 4) were used. A PCR based 
cloning strategy facilitated the replacement of the green fluorescent protein 
(GFP) gene with the RARβ2 gene. Two sets of primer pairs were used for this, 
one for cloning the RARβ2 so that it is N-terminally tagged by the DD, and one 
so that it is C-terminally tagged. The expression cassette from these constructs 
was then shuttled into a “dual promoter” construct - containing a GFP reporter 
driven by a spleen focus forming virus (SFFV) promoter upstream of the 
cytomegalovirus (CMV) driven DD/RARβ2 - to form pRRL-SFFV-GFP-CMV-
DD-RARβ2, pRRL-SFFV-GFP-RARβ2-DD (hereafter DD-RARβ2 and RARβ2-
DD respectively). This two-stage process was required, due to cloning sites in 
the DD cassette being non unique in the dual promoter vector. 
To form a constitutively expressed RARβ2 construct, a PCR based strategy 
allowed RARβ2 to be inserted directly into the dual promoter vector, forming 
pRRL-SFFV-GFP-CMV-RARβ2 (hereafter RARβ2). 
A control plasmid was made by removing the CMV promoter-driven gene from 
the dual promoter parental construct, leaving only the SFFV-driven GFP gene 
followed by the CMV promoter (pRRL-SSFV-GFP-CMV, hereafter GFP). 
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5.2.1.1 PCR amplification of mouse RARβ2 cDNA from pONYK-FLAGmRAR 
PCR was performed (Method 2.1.1) using the primers listed in Table 5-1. PCR 
products for forming pRRL-DD-RARβ2 were 1388bp, those for forming pRRL-
RARβ2-DD were 1386bp, while those for forming pRRL-RARβ2 were 1413bp 




Table 5-1 Primers designed for the amplification of RARβ2 for insertion into the destabilization domain 
cassette, and also into a constitutively expressing construct. 
Annotated sequences indicate RE sites. Highlighted bold sequences indicate template complementarity. 
5.2.1.2 Cloning pRRL-DD-RARβ2 and pRRL-RARβ2-DD 
PCR products were separated, typically in a 1% agarose gel, the correct band 
was excised and DNA recovered (Method 2.1). Backbone plasmid pRRL-DD-
GFP and RARβ2 (to be N-terminally tagged) were digested with the REs 
PspOMI/SalI; pRRL-GFP-DD and RARβ2 (to be C-terminally tagged) with the 
AgeI/NheI pair. After agarose gel electrophoresis, band excision and DNA 
recovery, products were quantified and backbone-insert pairs ligated, 
transformed and sequenced. To insert the expression cassette into the dual 
promoter construct, the parental dual reporter plasmid (pRRL-SFFV-GFP-CMV-
Primer Name             Primer Sequence (5’-3’)
TAGCATGGGCCCTCGACTACAAGGACGACGAT   
TATAATGTCGACGGTACCTCACTGCAGCAGTGGTG  
TAGCATACCGGTGCCACCATGGACTACAAG      
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NCS1 – a gift from Dr Ping Yip, Kings College London) was digested with XbaI 
(NEB), before creating a blunt end using Klenow polymerase. After running the 
digested backbone through a PCR clean up column (Qiagen), the backbone was 
digested with SalI (NEB) and subsequently dephosphorylated using the rAPID 
dephosphorylation kit (Roche), before separating the products in an agarose gel. 
After band excision and DNA recovery, products were quantified, and 
backbone-insert pairs ligated, transformed and sequenced. 
5.2.1.3 Cloning pRRL-RARβ2 
Backbone plasmid pRRL-SSFV-GFP-CMV-NSC1 and RARβ2 PCR products 
were both digested using REs XhoI and SpeI. After agarose gel electrophoresis, 
band excision and DNA recovery, products were quantified, and backbone-insert 
pairs ligated, transformed and sequenced as described before (Method 2.1). 
5.2.1.4 Cloning pRRL-SFFV-GFP-CMV 
Backbone plasmid pRRL-SSFV-GFP-CMV-NSC1 was digested using REs XhoI 
and SpeI. Klenow DNA polymerase was used to create blunt ends, before 
separating the fragments in an agarose gel. After the correct band had been 
excised and purified, it was ligated (no dephosphorylation), transformed and 
sequenced as described before (Method 2.1). 
5.2.2 Preparation and use of HIV-DD-RARβ2, HIV-RARβ2-DD, HIV-
RARβ2 and HIV-GFP vectors 
Lentiviral vectors were produced and titred (Method 2.2). HEK293T cells and 
E18 rat cortical neurons seeded and transduced as described in (Method 2.5.3 
and 2.6.4 respectively).  
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5.2.3 Dorsal root ganglion (DRG) neuron culture 
5.2.3.1 Preparation of Trimethoprim stock solutions 
For use in vitro, TMP (Sigma) was dissolved in neat dimethyl sulphoxide 
(DMSO, Sigma) to make a 200mM solution, and typically used at concentrations 
below 50µM. For use in vivo, TMP was used as a powder and disseminated in 
powdered normal rat chow before mixing with water and flavouring agents to 
make a mash - final concentration 0.2% TMP. 
5.2.3.2 Preparation of multi-well plates  
Poly-L-lysine solution (0.01% solution (Sigma)) was added to each well of a 24-
well plate (Nunc) containing flame-sterilised glass coverslips, followed by 
incubation at room temperature for at least 4 hours, or at 4
o
C over night. The 
solution was then removed and wells washed three times with sterile ddH20, for 
15 minutes per wash.  After the final wash, the water was removed and the plates 
left open to dry in laminar flow hood for at least 1 hour, before adding 250µl of 
10µg/ml laminin (Sigma) (for DRG neurite outgrowth assay, reduced laminin 
(0.1mg/ml) was used, see Method 5.2.3.5) and incubating at 37
o
C for at least 2 
hours. The laminin solution was removed immediately before plating. 
5.2.3.3 Dissection and plating of DRG neurons 
All surgical instruments were cleaned and sterilised by autoclave. Adult male 
Wistar rats were obtained from Charles River, UK. The animal was swabbed 
with 100% ethanol and the head removed before exposing the spinal column. 
Hemisection of the vertebra allowed the DRGs to be removed into prewarmed 
Ham’s F-12 basal media (Gibco), before the root sleeve membrane and dorsal 
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and ventral roots were carefully removed under a MZ6 dissection microscope 
(Leica, Switzerland) with a K1500 electronic light source (Schott, USA). 
Cleaned DRGs were incubated in 0.125% Collagense F-12 for 2 hours at 37
o
C. 
Collagenase was removed by transferring the DRGs to 15ml of warm Hank’s F-
12, allowing them to sink before removing the media. DRGs were triturated by 
adding 1ml of Bottenstein and Sato’s (BS) media (F-12 (Gibco), 1% N-2 
Supplement (Gibco), 0.3% BSA (Sigma), 10,000U Penicillin/Streptomycin 
(Sigma)) and pipetting up and down using a Gilson P1000 pipette, allowing cell 
clumps to settle before collecting the cell suspension. Twice further triturating 
the non-individualised cells gave 3mls of cell suspension. Three 15% bovine 
serum albumin (BSA) cushions were prepared by mixing (without bubbles) 1ml 
30% BSA solution (Sigma) with 1ml F-12. 1ml cell suspension was applied to 
the top of the cushions very carefully to avoid mixing. DRG neurons were spun 
through the cushion at 600 RCF for 8 minutes with the brake function turned off. 
After removal of the supernatant, the three pellets of DRG cells were 
resuspended in 100µl TID (CMF (1x Hanks Buffered Salt solution (HBSS 
Calcium- and magnesium-free, Gibco), 0.001% Phenol Red (Sigma), 0.0345% 
Sodium bicarbonate (Gibco), H2O) 3mg/ml BSA (Sigma), 50µg/ml 
Deoxyribonuclease type I (Sigma), 250µg/ml Soybean trypsin inhibitor (Type II, 
Sigma), 0.038% Magnesium Sulphate (Gibco)). 8µl of cells was removed, 2µl of 
Trypan blue (Sigma) added and cells counted. The cell suspension could then be 
diluted in an appropriate volume of BS media in preparation for plating. 
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5.2.3.4 Culture of DRG neurons for protein lysates 
DRG neurons were plated at a density of 3000 cells/well in 500µl BS media and 
incubated at 37
o
C 5% CO2. On day 2, 200µl of the media was removed and 
lentiviral vectors (HIV-DD-RARβ2, HIV-RARβ2, and HIV-GFP – all at 
MOI10) were added. After 6 hours the wells were topped up using 250µl BS 
media. On day 3, 50µM TMP was supplied to some of the cells. On day 5, cell 
lysates were harvested in 50µl RIPA buffer (Method 2.4.1). 
5.2.3.5 DRG neurite outgrowth assay 
Plates were prepared as described above using reduced laminin (0.1µg/ml), 
before plating 1500 cells/well in 500µl BS media and incubating the cell at 
37
o
C. On day 2, the DRGs were transduced as described above. On day 3, 50µM 
TMP was supplied to some of the cells. On day 5, the DRGs were gently washed 
with PBS, before fixing in 4% paraformaldehyde for 10 minutes. Fixed cells 
were stored in PBS at 4
o
C before immunocytochemistry. Primary antibodies 
were chicken-anti-GFP (1:1000), mouse-anti-βIII-tubulin (1:1000). Secondary 
antibodies were anti-chicken-ALEXA488 (Goat 1:500) and anti-mouse-Cy3 
(Goat 1:500). DAPI was used to stain DNA (Table 2-5). 
5.2.4 Stereotactic injection of HIV-DD-RARβ2 and HIV-RARβ2 to the CNS 
of adult rats 
In all in vivo experiments in this chapter, adult male Wistar rats (250-300g) 
received infusions of lentiviral vector via stereotactic injection (0.2µl/min 
infusion rate) under anaesthesia detailed in Methods 2.7. Additional post-
operative analgesia was not provided in accordance with PPL 30/2537. 
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However, it must be noted that there is substantial trauma to tissues when 
modeling spinal cord injuries in vivo, and that in the future we would seek to 
administer additional post-operative analgesia, continuing for several days after 
surgical intervention. This would be unlikely to confound behavioural findings if 
all animals received the same dose. It must also be noted that patients receiving 
surgery for spinal cord injuries are treated with analgesia, so this may help to 
improve the efficacy of potential therapies in the rat models of cord injury. At 
the end of experiments, the animals were terminated using 150mg/Kg
 
pentobarbital (Euthatal) and transcardially perfused with PFA (Method 2.7.3) 
and the relevant tissue harvested.  
5.2.4.1 Titres of lentiviral vectors used in vivo 
Lentiviral preparations above 1x10
8
tfu/ml were considered sufficient to provide 








Titres were not matched for in vivo experiments. 
5.2.4.2 Expression study 
Six rats received infusions 2µl of HIV-DD-RARβ2 vector into the cortex of the 
right hemisphere at 4 co-ordinates (AP/ML/DV relative to bregma) -1.5/2.5/2, 
0.5/3.5/2, -1/1.5/2 and 1.5/2.5/2. Three weeks later, 3 rats had normal chow 
replaced with a mashed diet containing 0.2% TMP, 3 rats received mashed chow 
that did not contain TMP. Once feeding began, this diet was continued for 3 
days, recording the amounts consumed daily. The animals euthanized on day 4, 
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and following perfusion fixation with PFA the brains were harvested, and 
prepared for section via cryostat. 
5.2.5 Cervical crush model spinal cord injury 
5.2.5.1 Viral vector delivery to the sensorimotor cortex 
To ensure that a maximal number of neurons in the corticospinal tract were 
transduced, 8 rats received 6 infusions of 2µl of HIV-DD-RARβ2 vector per 
hemisphere into the cortex at coordinates as determined from a microstimulation 
mapping study (Neafsey et al., 1986) (relative to bregma; AP/ML/DV): Left 
hemisphere: -1.5/2.5/2, -0.5/3.5/2, 0.5/3.5/2, -1/1.5/2, 1.5/2.5/2 and 2/3.5/2. 
Right hemisphere: -1.5/-2.5/2, -0.5/-3.5/2, 0.5/-3.5/2, -1/-1.5/2, 1.5/-2.5/2 and 2/-
3.5/2. Rate of infusion: 0.2µl/minute. Wait one minute before slowly removing 
needle. 4 rats began to receive mashed chow containing 0.2% TMP, while 4 rats 
received mashed chow that did not contain TMP immediately after completion 
of surgery.  
5.2.5.2 Dorsal crush of spinal cord 
After three weeks, the animals were re-anaesthetised, the spinal column exposed 
at the level of C4 vertebra, and a bilateral dorsal column crush performed using 
fine forceps (2mm depth). Dr Liang Fong Wong performed this surgical 
technique. Rats were randomly selected to be prepared for surgery by Ben 
Houghton, to blind the surgical procedure. 
5.2.5.3 Behavioural testing 
Animals were trained on apparatus three times a week after recovery from viral 
vector infusions and data was collected once a week for 8 weeks after column 
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crush. Ladder apparatus consisted of 11 small rungs 10cm apart. Animals back 
legs were supported if necessary where motor deficits were severe. 
5.2.5.4 BDA tracer injection 
After 8 weeks post spinal cord lesion, rats were once again anaesthetised to 
inject biotinylated dextran amine (MW10000, Molecular Probes) (BDA). 2µl 
BDA was injected into six sites per hemisphere, using the coordinates listed in 
method 5.2.4.2.  
5.2.5.5 Harvesting tissue 
After animals were euthanized using 150mg/Kg
 
pentobarbital (Euthatal) and 
perfusion-fixed with PFA (Method 2.7.3), the brains were harvested. The spinal 
cord was carefully exposed and the cord very carefully removed.  
The brains were prepared for sectioning using a cryostat (Method 2.8.1). To 
section, the brain was cut in half down the midline. The right hemisphere was 
cut coronally, while the left hemisphere was cut sagittally. 
A small section of lumbar cord was removed and prepared for coronal sectioning 
in the cryostat. A 2cm fragment encompassing lesion site in the cervical region 
was prepared for sectioning longitudinally using a vibratome by embedding into 
10% gelatin (Method 2.8.2). 
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5.2.5.6 Immunohistochemistry 
Refer to Table 2-5 for full details of antibodies. Brain sections were stained in 
two groups. Group 1 sections (1 section in every 5 slices of tissue) were 
prepared for antibody binding as (Method 2.9). Primary antibodies: anti-GFP 
(chicken 1:1000)/anti-RARβ2 (mouse, 1:50), Secondary antibodies: anti-
chicken-ALEXA488/anti-mouse-ALEXA-568 (both mouse, 1:500) and DNA 
was visualized using DAPI. Sections in group 2  (containing another set of 1 in 
every 5 slices of tissue) were stained using primary antibody anti-GFP (chicken 
1:1000), and secondary antibodies anti-chicken-ALEXA488. Neutr-avidin-
TexasRed (without tyramide amplification step) was applied with the secondary 
antibodies, and DAPI used to visualize DNA. 
Longitudinal sections of spinal cord encompassing the lesion site were washed 
3x5 minutes in PBST (0.01M PBS, 0.1% TritonX-100). Sections were incubated 
in 0.3% H2O2 to inactivate endogenous peroxidases, before washing 3x5mins 
with PBST. Sections were then incubated in avidin-biotin peroxidase complex 
(Vectastain ABC Elite Kite, Vector Laboratories) for 30 minutes, washed 3x5 
minutes with PBST, incubated in biotinyl tyramide (1:100, Molecular Probes) 
for 10 minutes and washed again 3x5 minutes PBST, before incubating with 
Neutr-avidin-TexasRed (1:400, Sigma) for 2 hours. Sections were mounted after 
a final wash step. 
Protein Kinase γ (PKCγ) staining was performed to determine whether the 
column crush had completely lesioned the dorsolateral CST. The presence of 
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PKCγ staining in the dorsal funiculus would indicate incomplete lesion of the 
dorsolateral CST (Bradbury et al., 2002; Mori et al., 2004). 
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5.3 Results 
5.3.1 Cloning DD-RARβ2, RARβ2 and GFP reporter constructs 
We began our investigation into regulating RARβ2 expression using the DD 
technology by cloning the mouse RARβ2 gene into the RE optimized cassettes 
previously described (Chapter 4). We chose the ‘3mut’ form of the DHFR based 
DD and applied to the N- and C-terminus of RARβ2. To facilitate experimental 
methodologies used in this chapter, the expression cassette of both regulatable 
and constitutive RARβ2 constructs was shuttled into a dual promoter vector (Yip 
et al., 2010) that constitutively expressed GFP under a SFFV promoter (Method 
5.2.1). The resulting plasmids DD-RARβ2, RARβ2-DD, RARβ2 and GFP could 
then be used to produce HIV based lentiviral vectors. 
 
 
Figure 5-1 Schematic diagram of the viral insert of DD-RARβ2, RARβ2-DD, RARβ2 and GFP 
constructs 
 
5.3.2 HEK203T cells transduced with HIV-DD-RARβ2 accumulate RARβ2 
in the presence of TMP 
HIV lentiviral preparations of DD-RARβ2, RARβ2-DD, HIV-RARβ2 and HIV-
GFP were made and used to transduce HEK293T cells at an MOI1. TMP doses 
ranging from 0 - 50µM were applied 48 hours prior to harvesting the cells for 
either immunocytochemistry, or Western blot analysis (Figure 5-2 [A/B]). Cells 
transduced with HIV-DD-RARβ2 accumulated DD-RARβ2 in response to 
GFP CMVSFFV GFP WPRE dLTRRRE cPPT/CTSdLTR
WPRECMVSFFV GFP DD dLTRdLTR RRE cPPT/CTS
CMVSFFV GFP WPRE dLTRdLTR RRE cPPT/CTS
WPRECMVSFFV GFP DD dLTRdLTR RRE cPPT/CTS
Chapter 5 - RARβ2 
 - 156 - 
increasing TMP dose, with maximal levels similar to RARβ2 levels seen in cells 
expressing RARβ2 constitutively. Basal levels of DD-RARβ2 in cells that had 
not been treated with TMP were as low as the levels of endogenously expressed 
RARβ2 in cells expressing GFP as a control. It can also been seen that 
increasing TMP had no effect on endogenous RARβ2 expression in HEK293T 
cells. RARβ2-DD could not be detected in lysates derived from cells transduced 
with HIV-RARβ2-DD.  
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Figure 5-2 HEK293T cells transduced with HIV-DD-RARβ2 accumulate RARβ2 in the presence of 
TMP 
[A] HEK293T cells transduced with HIV-DD-RARβ2, HIV-RARβ2 and HIV-GFP, treated to a range of 
TMP doses 48h before fixing and immunocytochemistry. RARβ2/GFP/DAPI. Scale bar=50µm. [B] 
Western blot analysis of pooled samples (n=3) with representative blots illustrated below. Densitometry of 
blots performed using ImageJ software. Significant increase in DD-RARβ2 levels with TMP dose. DD-
RARβ2: One way ANOVA: ** p=0.0025 (f=7.180, R2=0.7496); Stars indicate Dunnett posthoc test: 
0vs0.5µM, ** p<0.01 (q=4.769). TMP dose does not affect constitutive RARβ2 over-expression. One way 
ANOVA: ns (p=0.8524). TMP does not affect endogenous RARβ2 expression. One way ANOVA: ns 
(p=0.9985). 
5.3.3 E18 rat cortical neurons and adult DRG neurons transduced with 
HIV-DD-RARβ2 accumulate RARβ2 in the presence of TMP 
Anticipated experimental methodologies would require the DD-RARβ2 
construct to be efficacious in both cortical neurons in vivo and DRG neurons in 
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vitro. To begin testing the efficacy of DD-RARβ2 regulation in a neural cell 
type, E18 rat cortical neuron cultures were transduced in vitro with HIV-DD-
RARβ2 at an MOI1. These cultures have been established in our laboratory to 
contain a high percentage of neurons – between 80-90%. TMP doses were 
applied 96 hours before harvesting for Western blot analysis (Figure 5-3). Again, 
maximal levels of DD-RARβ2 activation are similar to that of constitutively 
expressed RARβ2. Higher basal levels of activation in the absence of TMP 
suggest that regulation may not be as tight in embryonic cortical neural cells as 
in HEK293T cells. There is a 4-fold increase when TMP is supplied to E18 
cortical cells expressing DD-RARβ2.  
To see if these regulatory characteristics would also be seen in DRG neurons, 
HIV-DD-RARβ2 (and the control vectors) were used to transduce DRG neurons 
growing in vitro (Figure 5-4) at an MOI10. Again, there are higher levels of 
basal expression.  Levels of DD-RARβ2 do not reach those of the constitutive 
RARβ2 control when TMP is supplied at 50µM. There is a 1.8-fold increase 
when TMP is supplied to E19 cortical neurons expressing DD-RARβ2. 
 
 
Figure 5-3 Rat E18 cortical neurons transduced with HIV-DD-RARβ2 accumulate RARβ2 in the 
presence of TMP 
HEK293T cells transduced with HIV-DD-RARβ2, HIV-RARβ2 and HIV-GFP, treated to a range of TMP 
doses 96h before harvesting for Western blot analysis. Blots illustrated above graphs including predicted 
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molecular weight. Densitometry of blots performed using ImageJ software; all data normalised to 
endogenous RARβ2 untreated with TMP (n=1, samples pooled from at least 3 separate transductions). 
 
 
Figure 5-4 Adult rat DRG neurons transduced with HIV-DD-RARβ2 accumulate RARβ2 in the 
presence of TMP 
DRG neurons were transduced with HIV-DD-RARβ2 (DR), HIV-RARβ2 and HIV-GFP on day 2 in vitro. 
On day 3, 50µM TMP was supplied to half of the neurons expressing DD-RARβ2 (DR+T), 48h before 
harvesting for Western blot analysis. Blots illustrated below graphs including predicted molecular weight. 
Densitometry of blots performed using ImageJ software; all data normalised to endogenous RARβ2 
untreated with TMP (n=1, samples pooled from 3 separate transductions). 
5.3.4 DRG neurite outgrowth assay  
RARβ2 has already been show to encourage neurite outgrowth from DRG 
neurons grown on inhibitory surfaces (Wong et al., 2006). To test if DRGs 
expressing the regulatable RARβ2 construct could have a similar physiological 
effect in the presence of TMP, adult rat DRGs sparsely plated (1500-2000 
cells/well in a 24-well plate) on a reduced laminin substrate (0.1µg/ml) were 
transduced with HIV-RARβ2, HIV-DD-RARβ2, HIV-DD-RARβ2 and HIV-
GFP vectors at an MOI10. The mean length of the longest neurite, total neurite 
length and number of neurites of individual neurons were analysed from 
pictomicrographs (Figure 5-5). The data indicates that there is a trend of 
increased neurite outgrowth in DRGs accumulating more RARβ2. However, 
while there is significant increase in the total length of neurites and in neurite 
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number, the physiological differences between the different groups is small, 




Figure 5-5 Analysis of neurites sprouting from adult rat DRG neurons growing on a non-permissive 
substrate. 
Fixed DRG cultures were stained using mouse anti-βIII-tubulin and chicken anti-GFP primary antibodies. 
Secondary antibodies anti-mouse-Cy3 and anti-chicken-ALEXA488 allowed selection of transduced 
neurons for analysis. [A/B/C/D] Representative pictomicrographs of neurites, scale bar=100µm. 
Pictomicrographs of between 50-100 individual DRG neurons transduced with [A] HIV-GFP (GFP) [B] 
HIV-DD-RARβ2 (DR), [C] HIV-DD-RARβ2+TMP (DR+T), [D] HIV-RARβ2 (RARβ2) were analysed 
using the NeuronJ plugin for ImageJ Software. All following statistical analysis: One-way Anova. [Total 
length] *** (p=0.0004) [Longest Neurite] ns [Neurite Number] ** (p=0.0035).  
5.3.5 Testing the efficacy of HIV-DD-RARβ2 and HIV-RARβ2 vector in 
adult rat CNS 
Adult male Wistar rats received stereotactic injections of HIV-DD-RARβ2 in the 
cortex of the right hemisphere. As described in method 5.2.4.2 of this chapter, 
four stereotactic coordinates were used, rather than six that would be used in 
models of spinal cord injury. Some rats received stereotactic injections of HIV-
RARβ2 or HIV-GFP to the cortex of the left hemisphere as controls. Three 
weeks later, normal chow was replaced with a mashed chow containing 0.2% 
TMP (On average 185mg/kg TMP eaten per day) for four days before harvesting 
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the brain for cryosection and immunostaining (Figure 5-6). In the cortex of rats 
fed a TMP containing diet, immunohistochemistry revealed greater amounts of 
RARβ2 compared to animals that have not received TMP in the diet.  
 
 
Figure 5-6 Adult rat cortex transduced with HIV-DD-RARβ2 accumulates RARβ2 when diet contains 
TMP 
[A] Adult male Wistar rats received stereotactic infusions of HIV-DD-RARβ2 into the cortex. After three 
weeks, TMP was supplied at 0.2% of diet for 4 days before harvesting the brain for cryosection (40µm 
sections) and immunohistological staining. RARβ2/GFP/DAPI. Scale bar=100µm. [B] Higher 
magnification of layer V pyramidal neurons in animals eating TMP chow. [C] Higher magnification of 
layer V pyramidal neurons in animals eating control chow. RARβ2/GFP/DAPI. Scale bar=25µm. 
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5.3.6 Evaluating DD-RARβ2 in a dorsal column crush model of spinal cord 
injury 
This marked difference suggested that the DD-RARβ2 vectors had the potential 
to regulate the timing and dose of RARβ2 in vivo models of spinal cord injury 
with oral administration of TMP. To begin investigating the use of these vectors 
in a spinal cord injury model, 8 adult male Wistar rats received stereotactic 
injection of HIV-DD-RARβ2 vector to the cortex of both hemispheres. Infusions 
took place at six stereotactic coordinates per hemisphere, determined in a 
microstimulation mapping study (Neafsey et al., 1986) to cover as large an area 
of the sensory motor complex as possible. TMP supplementation of the diet 
began immediately for four rats, while the remaining four ate a control diet that 
did not contain TMP. After spinal cord lesion, behavioural testing, BDA tracer 
infusion and subsequent harvesting of tissue (as described in methods 5.2.5.2 to 
5.2.5.5), immunohistochemical analysis was performed. Two rats had to be 
euthanized during the course of the experiment, leaving three rats in each group. 
PKCγ immunohistochemical staining of lumbar spinal cord sections revealed 
that the dorsolateral CST of all the animals in the study had been completely 
lesioned, as indicated by the lack of PKCγ immunoreactivity in the dorsal 
funicular of the lumbar spinal cord (Figure 5-7). Therefore, all animals can be 
included in further analysis. 
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Figure 5-7 Absence of PKCγ  in the dorsal funicular of lumbar spinal cord indicates complete lesion of 
CST fibres. 
Pictomicrographs of lumbar spinal cord sections probed for PKCγ. Lack of signal in the dorsal funiculus 
indicates complete lesion of CST fibres. PKCγ . 
To confirm that anterograde BDA tracer labelling of CST in the cortex had been 
achieved, 40µm sections of the brains were probed with Neutr-avidin-TexasRed. 
BDA staining could be found in abundance in the cortex around needle tracts. 
Furthermore, BDA labelled fibres could be seen descending through the 
parenchyma from the BDA infusion site in the cortex (Figure 5-8 [A/B/C/D]). 
To confirm that the HIV-DD-RARβ2 vectors had transduced the cortex and that 
transduced neurons were also labelled with BDA tracer, 40µm brain sections 
were probed with anti-bodies against the GFP reporter, neurons and BDA 
(Figure 5-8 [E]).  
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Figure 5-8 BDA staining in the brain of adult rats colocalises with GFP immunoreactivity 
[A] Sagittal brain section showing BDA labelled fibres descending from the BDA infusion site in cortex. 
[B/C/D] close up images corresponding to boxes indicated in [A]. BDA/NeuN/DAPI. Scale bar=100µm. 
[E] GFP immunoreactivity colocalising with both neurons and BDA tracer labelling in the striatum. 
GFP/NeuN/DAPI/BDA Scale bar=200µm. 
BDA labelled CST fibres were visualized using immunohistochemistry in the 
spinal cord both rostral and caudal to the lesion site. After pictomicrographs 
were taken at 0.5mm intervals, the fibres were counted (Figure 5-9 [A/B]).  
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Figure 5-9 Quantification of BDA labelled CST neurons in the spinal cord of adult rats 8 weeks after 
bilateral dorsal column crush 
[A] Pictomicrograph shows representative spinal cord section, after immunohistochemical staining to 
visualize BDA tracer. Distances in mm. [B] Counts of BDA positive fibres at specified distances rostral and 
caudal to the lesion. +TMP/-TMP. [C] Behavioural analysis of animals crossing ladder apparatus, average 
of total foot slips by both front paws. +TMP/-TMP. 
There was no significant difference in the numbers of fibres found rostral to the 
lesion site in the dorsal CST between the two groups of animals. There was also 
no significant difference between fibres were found in the dorsal CST caudal to 
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numbers of BDA labelled fibres could also be found in the ventral CST (data not 
shown). 
Neurons of the CST are responsible for the fine motor control of limbs. Deficits 
in motor control exhibited by the CST lesioned animals were assessed over an 8-
week period. Pre-lesioned animals were trained to cross a ladder apparatus that 
was suspended above the ground. In the weeks following CST lesion, changes in 
the ability of the rats to cross this apparatus was monitored by recording the 
number of misplaced foot ‘slips’. A baseline test taken before lesion indicated all 
rats could cross the ladder without any slips. In the first week post lesion, all rats 
showed deficits in motor function (Figure 5-9 [C]). In the following weeks, no 
significant differences in motor function appeared between rats eating control or 
TMP diet. 
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5.4 Discussion 
In this study, we began by testing the ability the DHFR DD system to regulate 
levels of the nuclear receptor RARβ2. The DHFR DD technology was supplied 
by the Wandless laboratory. As previously described, (Chapter 3), two different 
domains were supplied: one that had been developed to be used at the N-
terminus of a gene of interest (GOI), and one developed to be used a the C-
terminus of a GOI. In previous work using the DD domains to regulate GFP 
levels, we found that only the ‘3mut’ form imparted desirable regulatory 
characteristics, and that applying that domain to the C-terminus of GFP was 
most favourable. As the 4mut domain had not imparted desirable characteristics 
on GFP (and in the absence of supporting literature available at the time of 
study) only the 3mut domains were tested in this study. With consideration to 
previous observations that the domains’ regulatory properties were dependent on 
the protein they were destabilising, we tested the 3mut DD at both the N- and C-
terminus of RARβ2, expressed from a dual promoter construct. We chose to use 
a dual promoter reporter to provide a robust reporter of cell transduction for cells 
growing in vitro. Furthermore the RARβ2 antibodies that were used in this study 
were not very specific and not suitable for detecting the relatively low levels of 
RARβ2 expression in DRG neurons in immunohistochemistry, therefore a more 
robust reporter of transduction was required. A two-step cloning strategy was 
required due to RE sequences in the DD cassette being non unique in the dual 
promoter vector. 
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When HEK293T cells transduced with lentiviral vectors made from these 
constructs were supplied a range of TMP, only the N-terminally tagged form 
(DD-RARβ2) gave rise to RARβ2 accumulation. The C-terminally tagged form 
failed to express any detectable RARβ2. Cells that were transduced with these 
vectors expressed GFP, (confirming transduction) Furthermore, the experiment 
was repeated several times to confirm the result. The reason for the lack of 
RARβ2 expression from this construct is unclear. It is possible that there could 
be mutations in the CMV promoter that drives RARβ2-DD expression. Although 
the constructs were sequenced prior to lentiviral production, the sequencing 
primers were not designed to cover the promoter, meaning that there could be 
mutations would remain undetected. This might explain why GFP expression 
was still seen, as the SFFV promoter would not necessarily have been affected. 
It may be that this fusion protein is non permissive in the cell, either due to 
interaction between two domains (DD and RARβ2) on one polypeptide chain, or 
interaction with other molecules in the cells. Or perhaps the fusion mRNA forms 
structures that block translation at the ribosome. Although this finding is 
interesting and highlights the importance of testing DD at both termini, we also 
found that DD-RARβ2 accumulates RARβ2 in a dose responsive manner to 
TMP in HEK293T cells and neurons in vitro, indicating that this construct is 
suitable for use in vivo. Therefore, the reason for the lack of expression was not 
investigated further. 
When testing the efficacy of DD-RARβ2 in neural cells, we found more basal 
activation of the system than had been seen in HEK293T cells. The process 
through which the DD tagged proteins are degraded is not fully understood, but 
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it is at least in part mediated by the proteasome, as indicated by the Wandless 
studies that described the accumulation of DD fusions in cells in the absence of 
stabilising ligand when proteasome inhibitors were applied (Banaszynski et al., 
2006; Maynard-Smith et al., 2007) and DD-tagged proteins co-localising with 
subunits of the proteasome (Leong et al., 2012). Proteins destined for 
degradation by the proteasome are usually tagged with multiple ubiquitin 
moieties, and this was recently found to be the case for FKBP12-based DD 
fusion, only minutes after the removal of Shield1. It may be that neurons are 
particularly sensitive to overloading of the ubiquitin-proteasome system (UPS). 
For example, in diseases such as Huntingdon’s disease, Parkinson’s disease and 
ALS (Amyotrophic lateral sclerosis), the proteinaceous inclusions that form are 
comprised of aggregated proteins and among these is ubiquitin. The presence of 
these aggregates reduces the efficiency of the UPS in these cells, so aggregated 
proteins do not get removed and build up. It may be that by overexpressing an 
unstable protein (in the absence of TMP) in neurons, the proteasome becomes 
overloaded and therefore DD-RARβ2 levels increase, giving rise to basal 
expression in the absence of TMP.  
E18 cortical neural cultures have been shown in our lab to contain a high 
percentrage of neurons. Although there are glia present in the culture and they 
will also be transduced with the lentiviral vectors, the low numbers 
(approximately 10%) mean that our result will be  
Overexpressing RARβ2 in adult DRG neurons had been previously shown to 
increase neurite outgrowth (Wong et al., 2006). In our study, while the group of 
Chapter 5 - RARβ2 
 - 170 - 
DRG neurons constitutively expressing RARβ2 do support this finding, a 
similarly convincing result could not be observed in the group of DRG neurons 
that expressed DD-RARβ2 in the presence of TMP. The trend in the extent of 
neurite outgrowth from these neurons mirrors the levels of DD-RARβ2 found in 
DD-RARβ2 transduced DRGs when analysing protein levels by Western Blot 
(Figure 5-4). That is, the levels of DD-RARβ2 in DRG neurons overexpressing 
DD-RARβ2 upon exposure to 50µM TMP did not reach the levels of RARβ2 
observed in DRG neurons overexpressing the constitutive RARβ2 construct. 
Therefore, the lack of extensive neurite outgrowth from the DRG neurons 
expressing the DD-RARβ2 construct may be attributed to the lower levels of 
RARβ2 observed in these neurons, and it may be possible that a certain 
threshold level of RARβ2 is required in order to mediate significant neurite 
outgrowth effects. 
To investigate the ability of the DD system to regulate RARβ2 in the cortex of 
the CNS, an in vivo expression study was performed. This study indicated that 
we could transduce a large area of the cortex and all cortical layers. Furthermore, 
there was a noticeable difference in the levels of DD-RARβ2 between animals 
that were fed TMP and those that were fed a control diet when the sections of 
the respective brains were probed via immunohistochemistry, though this 
technique precludes quantitative analysis. To provide a quantitative assessment 
of transgene levels, a Western blot could be performed. However, Western blot 
analysis of lysates prepared from brain explants had been attempted when 
investigating regulating GFP levels. Even though the anti-GFP antibody had 
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proven highly specific when probing blots of lysates derived from cell lines, we 
could not detect GFP in this way. We concluded that the amount of GPF from 
transduced cells was being diluted beyond the limit of detection. As the anti-
RARβ antibody is less specific and the area of cortex that would need to be 
harvested large, this would not be a robust method to determine DD-RARβ2 
levels. 
Lentiviral vectors constitutively expressing RARβ2 had previously been shown 
to stimulate axon outgrowth and reduce motor function deficits in adult rats in 
the same lesion model of spinal cord injury (Yip et al., 2006). Here we attempted 
to replicate this study using the lentiviral vector overexpressing DD-RARβ2 in 
order to demonstrate that a regulatable lentiviral vector could be utilized in a 
gene therapy for spinal cord injury. Although we found a wide area of BDA-
labelled cell bodies in the cortex and labelled axons could be traced through the 
parenchyma to the brain stem and found in large numbers rostral to the lesion 
site, few were found caudal to the lesion. We did not observe any significant 
differences axonal regeneration between animals that received TMP in their diet 
and those that did not, and this was correlated with the lack of significant 
improvement in the behavioural measurement of motor function (such as the 
ladder crossing test). Yip and Wong et al found much higher numbers of CST 
axons in the caudal spinal cord, correlating with significant reductions in motor 
deficits. This suggests that it is the lack of sufficient outgrowth of CST axons 
from the DD-RARβ2 neurons that led to the poor improvement in motor tasks. 
The small amount of improvement seen could be accounted by the presence of 
BDA labelled fibres in the ventral CST. Ventral CST fibres are not lesioned in a 
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dorsal CST crush and although the ventral CST holds less than 5% of the total 
fibres found in the dorsal CST they can sprout to provide compensation for the 
lost pathway (Niikura et al., 2000; Weidner et al., 2001; Lapenna et al., 2009). 
The main restriction on drawing conclusions from the CST lesioned rats is the 
lack of appropriate numbers of animals and groups in the experiment. Indeed, 
although all rats appear to have the same degree of lesion indicated by PKCγ 
staining, there were very noticeable differences in the motor deficits seen within 
groups. Furthermore, given that the DD-RARβ2 appeared to have higher levels 
of basal RARβ2 expression in the cortical and DRG neuron in vitro in the 
absence of TMP, it would have been advisable to include two further groups of 
animals: one, a negative control group that will receive control GFP lentiviral 
vector; and two, a positive control group that will receive the constitutive 
RARβ2 lentiviral vector. In addition, group numbers of at least 8-10 in each 
group will be required to obtain statistically meaningful immunohistochemical 
and behavioural data. Therefore, to fully determine the efficacy of the DD-
RARβ2 vector, further experiments would have to be performed but this was not 
pursued due to time constraints. 
Our data suggest that DD-RARβ2 may not be able to confer the same degree of 
axonal outgrowth as that observed from a constitutively expressed RARβ2. One 
possibility is that the translocation of RARβ2 to the nucleus in order to act as a 
transcription factor could be affected by the addition of the DD, either due to the 
increased size or changes in protein conformation. While we see DD-RARβ2 
colocalising with DAPI immunostaining in many transduced cells treated with 
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TMP in vitro and in vivo indicating that DD-RARβ2 is able to reach the nucleus, 
this may not be occurring to the same extent as native RARβ2. A further 
possibility is that the DD inhibits, in some part, the biological function of 
RARβ2. The N-terminus of RARβ2 harbours a ligand-independent transcription 
activation function (AF-1) (Bastien and Rochette-Egly, 2004) the function of 
which is not fully understood, although it has been established that it can 
cooperate with similar domains on the same or different isotypes of RARs and 
other coactivators (Bommer et al., 2002), leading to cell type- and promoter 
context dependent activation (Nagpal et al., 1992; 1993; Taneja et al., 1997). As 
the method by which RARβ2 stimulates neurite outgrowth is not completely 
elucidated, it is possible that the activity of this domain is affected by the DD.  
In order to further investigate if this is indeed the case, further experiments will 
have to be carried out using a reporter system, formed by placing RARβ2 
responsive promoter upstream of a luciferase gene (de The et al., 1990; Sucov et 
al., 1990) . The efficacy of the DD-RARβ2 activation function can then be tested 
on this RARβ2 responsive element and compared to that of the endogenous 
RARβ2 protein, allowing one to assess if the DD domain indeed does affect the 
biological activity of RARβ2. These studies will be critical for evaluating the 
utility of these DDs in viral vector systems for use in gene therapy. 
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Chapter 6 CDNF 
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6.1 Introduction 
Parkinson’s disease is a progressive neurodegenerative disorder that affects over 
6 million people worldwide. The severity of the disease is correlated with the 
loss of dopaminergic neurons in the substantia nigra pars compacta (SNPC) of 
the midbrain. This leads to the motor deficits that characterize the disease: 
tremor, bradykinesia, ridigity and postural instability. At this time there is no 
cure for the disease and current treatments serve to alleviate symptoms, for 
example the use of dopamine agonists or L-DOPA to substitute dopamine 
deficits or deep brain stimulation to decrease neuronal activity in the 
subthalamic nucleus. While L-DOPA is the current gold standard treatment, long 
term administration often leads to reduced efficiency and side effects such as 
on/off oscillations and dyskinesias (Obeso et al., 2000; Lees et al., 2009). A 
better treatment that can combat the cause, or halt the progression of the disease 
is required. 
One possible therapeutic intervention to slow or halt the progressive 
degenerative process occurring in Parkinson’s disease to protect the dopamine 
neurons from further degeneration and promote their survival, for example 
through application of neurotrophic factors (NTFs). NTFs are secreted proteins 
that function as growth factors in the developing nervous system, and promote 
survival, formation and maintenance of neuronal connections (Huang and 
Reichardt, 2001; Airaksinen and Saarma, 2002). Thus far, Glial cell line-derived 
neurotrophic factor (GDNF) (Lin et al., 1993) has been found to be the most 
potent NTF to protect and restore the dopaminergic system in rodent and primate 
Chapter 6 - CDNF 
 - 176 -
models (reviewed by Kirik et al., 1998; Evans and Barker, 2008) and has entered 
clinical trials to treat human patients. However, these trials have proven 
controversial. Infusions of GDNF into the putamen of PD patients showed 
clinical benefits in two open-label studies (Gill et al., 2003; Patel et al., 2005; 
Slevin et al., 2005) however another randomized, double-blind study showed no 
clinical benefit (Lang et al., 2006) while another trial suggested that there were 
potential serious side effects after GDNF infusion (Nutt et al., 2003). Therefore, 
the identification of novel neuroprotective (and neurorestorative) factors was 
desired. 
Human conserved dopamine neurotrophic factor (hCDNF) is a secreted 18kD 
glycosylated protein and is the second member of the MANF/CDNF family to 
be discovered. A few years previous to this discovery, the founding member of 
this family - Mesencephalic-astrocyte-derived neurotrophic factor (MANF) – 
was identified from the culture medium of rat mesencephalic type-1 astrocyte 
cell line 1 (VMCL1) and was found to promote survival of dopaminergic 
neurons in vitro (Petrova et al., 2003). CDNF is widely expressed throughout the 
nervous system and is up-regulated in adult mice brain after induction of 
pathological conditions such as status epilepticus and global forebrain ischemia 
(Lindholm et al., 2008), leading to the suggestion that this family could present a 
potential therapy for other neurological disorders.  
CDNF was identified using bioinformatics and found to be 59% homologous to 
its human MANF paralogue (Lindholm et al., 2007). Analysis of the crystal 
structure revealed CDNF and MANF are both composed of two domains: an N-
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terminal domain that is structurally saposin-like and may interact with lipids or 
membranes, and a C-terminal domain that may protect cells against endoplasmic 
reticulum (ER) stress, or be involved with protein folding in the ER (Parkash et 
al., 2009; Lindholm and Saarma, 2010). Both CDNF and MANF have 8 cysteine 
residues, conserved across vertebrate species, and a secondary structure 
dominated by α-helices (Sun et al., 2011).  
CDNF mRNA and protein was detected throughout development in the midbrain 
and also in the adult striatum and substantia nigra (Lindholm et al., 2007), 
suggesting a neurotrophic role for CDNF in dopaminergic neurons. To 
determine if CDNF could promote the survival of dopaminergic neurons in an in 
vivo model of Parkinson’s disease, Lindholm and colleagues administered a 
single pre-lesion treatment of CDNF (10ug) to the striatum of 6OHDA-lesion 
model rats (Lindholm et al., 2007). Indeed, pre-lesion treatment with CDNF was 
protective to dopaminergic neurons in the SNPC in this lesion model; the same 
group went on to show that CDNF treatment 4 weeks after lesion led to partial 
restoration of dopaminergic neurons after lesioning (Lindholm et al., 2007). 
Subsequent to this study, Voutilainen et al. (2011) found that chronic infusion of 
CDNF protein starting two weeks post-lesion inhibited the 6-OHDA induced 
loss of dopaminergic neurons in the SNPC and tyrosine hydroxylase (TH)-
positive fibres in the striatum (Voutilainen et al., 2011), suggesting that CDNF 
can provide a real alternative to GDNF as a neuroprotective, or even 
neurorestorative, therapy for PD. 
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Providing a chronic infusion of CDNF protein to the striatum requires invasive 
surgery to implant the cannulae; furthermore, continuous administration of 
CDNF over an extended period of time may be costly and the implanted 
cannulae may be prone to infection, indicating taht this would not be ideal as a 
therapeutic strategy for PD patients. To provide long-term neurotrophic support, 
a gene therapy approach to deliver CDNF to the brain would be advantageous. 
As neurotrophic factors clearly play important roles in the control of neural cell 
fate, it seems likely that prolonged viral expression may not be desirable in order 
to avoid potential side effects from developing, especially in the peripheral 
nervous system. It will also be important to find the correct dosing and timing of 
delivery of CDNF, in order to maximize the efficacy of neurotrophic support to 
the dopaminergic neurons, whilst minimizing potential side effects. 
Gene therapy approaches to treat PD has been extensively explored and many 
studies have described the use of various viral vectors including adenoviral 
vectors, adeno-associated viral vectors and lentiviral vectors. A number of 
research papers have demonstrated that viral vector mediated delivery of GDNF 
is efficacious in rodent and primate PD models (for example Kordower et al., 
2000; Azzouz et al., 2004a; Dowd et al., 2005; reviewed by Hong et al., 2008). 
Other gene therapy strategies for treating PD include: 1) an AAV vector 
overexpressing neurturin, another neurotrophic factor to protect dopaminergic 
neurons in the SN (Marks et al., 2008); 2) an AAV vector overexpressing 
glutamic acid decarboxylase (GAD) to modulate GABA production in the 
subthalamic nucleus in order to improve basal ganglia function in PD patients 
(LeWitt et al., 2011); 3) AAV vector overexpressing AADC (Aromatic L-amino 
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acid decarboxylase) to increase dopamine synthesizing enzymes in 
dopaminergic neurons (Muramatsu et al., 2010; Mittermeyer et al., 2012) 4) 
EIAV-based lentiviral vector overexpressing AADC, tyrosine hydroxylase (TH) 
and GTP cyclohydrolase I (GCH) in a single transcriptional unit, in order to 
replacing lost dopamine by inducing local production of dopamine with 
dopamine-synthesizing enzymes (Azzouz et al., 2002), or 5) Using three AAV2-
based vectors separately expressing these factors (Shen et al., 2000; Muramatsu 
et al., 2002) . 
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In this chapter we will apply the DFHR regulatory system to the novel 
neurotrophic factor CDNF and test the therapeutic approach of delivering CDNF 
in a regulatable manner in an in vivo model of PD. The system will be initially 
tested in vitro in HEK293T cells and E18 rat cortical neuron cultures, where we 
will determine if TMP can lead to dose dependent secretion of CDNF. We will 
then assess CDNF regulation in vivo, before using the regulatable CDNF vector 
in the 6OHDA lesion model of Parkinson’s disease. 
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6.2 Methods 
6.2.1 Cloning a DD-CDNF construct 
To form a regulatable CDNF construct, the restriction site (RE) optimised 
construct (pRRL-GFP-DD) that had already been designed for investigating the 
DHFR DD system (See Chapter 4) was used. A PCR strategy was used to 
amplify a CDNF fragment flanked by the appropriate RE sites to replace GFP. 
In order to provide a GFP reporter, the expression cassette was then shuttled into 
a dual promoter construct. This gave the final construct pRRL-SFFV-GPP-
CMV-CDNF-DD (hereafter CDNF-DD). 
6.2.2 cDNA clone of CDNF 
cDNA clones of human CDNF were purchased from Gene Service, in the form 
of a bacterial culture transformed with the gene-bearing plasmid, selectable via 
kanamycin resistance. The bacteria were streaked onto LB agar containing 
Kanamycin (100µg/ml, Sigma) and grown at 37
o
C overnight. An individual 
colony was picked into LB-Kanamycin media, grown overnight, and 
miniprepped (Methods 2.1). Plasmids were stored at -20
o
C. 
6.2.3 PCR amplification of human CDNF cDNA from  
PCR was performed (Method 2.1.1) using the primers listed in Table 6-1. PCR 
products for forming pRRL-DD-CDNF were 587bp, while those for forming 
pRRL-CDNF-DD were 594bp. 
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Table 6-1 PCR primers designed to amplify CDNF for insertion into destabilisation domain cassette 
Annotated sequences indicate RE sites. Highlighted bold sequences indicate template complementarity. 
6.2.3.1 Cloning pRRL-CDNF-DD  
PCR products were separated, typically in a 1% agarose gel, the correct band 
was excised and DNA recovered (Methods 2.1.2). Backbone plasmid pRRL-
DD-GFP and CDNF PCR products (to be N-terminally tagged) were digested 
with the REs PspOMI/SalI; pRRL-GFP-DD and CDNF PCR products (to be C-
terminally tagged) with AgeI/NheI. After agarose gel electrophoresis, band 
excision and DNA recovery, products were quantified, and backbone-insert pairs 
ligated, transformed and sequenced as described before (Method 2.1). To insert 
the expression cassette into the dual promoter construct, the parental dual 
reporter plasmid (pRRL-SFFV-GFP-CMV-NCS1 – a gift from Dr Ping Yip, 
Kings College London) was digested with XbaI (NEB), before creating a blunt 
end using Klenow polymerase. After running the digested backbone through a 
PCR clean up column (Qiagen), the backbone was digested with SalI (NEB) and 
subsequently dephosphorylated using the rAPID dephosphorylation kit (Roche), 
before separating the products in an agarose gel. After band excision and DNA 
recovery, products were quantified, and backbone-insert pairs ligated, 
transformed and sequenced (Method 2.1).  
Primer Name             Primer Sequence (5’-3’)
CDNF-DD forward         TAGCATACCGGTGCCACCATGTGGTGCGCGAGCCC   
CDNF-DD reverse          TATAATGCTAGCGAGCTCTGTTTTGGGGTG      
AgeI
NheI
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6.2.4 Preparation and use of HIV-DD-CDNF and HIV-CDNF-DD 
Lentiviral vectors were produced and titred (Method 2.2). In all in vitro 
experiments in this chapter, vectors were used at MOI1. HEK293T cells and E18 
rat cortical neurons seeded and transduced (methods 2.5.3 and 2.6.4 
respectively). TMP was supplied at a range of doses – 0, 0.5, 5, 50µM – to both 
cell types. To harvest the culture supernatant to analyse secreted CDNF-DD, the 
media was aspirated and centrifuged at 17,900 RCF for 5 minutes, before 
removing supernatant to a fresh tube and storing at -20
o
C. To prepare for loading 
into an 8% SDS-PAGE gel, 20µl supernatant was mixed with 20µl 2x loading 
dye (Method 2.4.1) before boiling. Cells were prepared as described in Method 
2.4.1. 
6.2.5 Preparation of trimethoprim stock solutions 
For use in vitro, TMP (Sigma) was dissolved in neat DMSO (Sigma) to make a 
200mM solution, and typically used at dilutions below 50µM. For use in vivo, 
TMP was used as a powder and disseminated in powdered normal rat chow 
before mixing with water and flavouring agents to make a mash - final 
concentration either 0.2% TMP, or 0.05% TMP. 
6.2.6 Stereotactic injection of HIV-CDNF-DD to the CNS of adult rats 
In all in vivo experiments in this chapter, adult male Wistar rats (250-300g) 
received infusions of lentiviral vector via stereotactic injection (0.2nl/min 
infusion rate). Additional post-operative analgesia was not used, however, it 
must be noted that there is trauma to tissues when forming in vivo models of PD 
and that in the future we would seek to administer additional post-operative 
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analgesia, continuing for several days after surgical intervention. This would be 
unlikely to confound behavioural findings if all animals received the same dose. 
It must also be noted that patients receiving surgery for PD are treated with 
analgesia, so this may help to improve the efficacy of potential therapies when 
using the rat PD model. At the end of experiments, the animals were terminated 
using 150mg/Kg
 
pentobarbital (Euthatal) and the brain harvested (Method 2.7).  
6.2.6.1 Titres of lentiviral vectors used in vivo 
Lentiviral preparations above 1x10
8
tfu/ml were considered sufficient to provide 








Rabise pseudotyped SFFV-GFP-CMV, 2.73x10
8
tfu/ml (This virus was prepared 
in collaboration with Dr Oscar Cordero Llana, Plasmid containing rabies coat is 
described by Mazarakis et al, 2001) Titres were not matched for in vivo 
experiments. 
6.2.6.2 Expression study 
5 rats received a 2µl infusion of HIV-CDNF-DD vector into the striatum of the 
right hemisphere at the co-ordinate (AP/ML/DV relative to bregma) 0/3.5/4.75. 
Three weeks later, 3 rats had normal chow replaced with a mashed diet 
containing 0.2% TMP, 3 rats received mashed chow that did not contain TMP. 
Once feeding began, this diet was continued for 3 days, recording the amounts 
consumed daily. The animals euthanized using 150mg/Kg
 
pentobarbital 
(Euthatal) on day 4, and following perfusion fixation (Method 2.7.3) the brain 
was harvested, and prepared for section via cryostat (Method 2.8.1). 
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6.2.6.3 Intranigral infusion of VSV-G pseudotyped vectors 
To directly transduce cells in the SNPC, 2µl VSV-G pseudotyped HIV-GFP 
vector was infused at the coordinate (AP/ML/DV relative to bregma): -5.3/-
2.2/7.2. 
6.2.6.4 Intrastriatal infusion of Rabies-G pseudotyped vectors 
Rabies-G pseudotyped HIV-GFP was infused at two coordinates in the striatum 
(AP/ML/DV relative to bregma): 0/3.5/4.8 and 1/3.5/4.8. 
6.2.7 6-hydroxy dopamine lesion model of Parkinson’s disease 
6.2.7.1 Nigro-Striatal lesions 
6-Hydroxydopamine (6OHDA, Sigma) was made up to 5g/L in deoxygenated 
water (bubbled with N2 for 5 minutes) and aliquoted under sterile conditions and 
stored at -80
o
C. To prevent the rapid oxidation of 6OHDA, a new aliquot was 
used for every animal. Adult male Wistar rats received two unilateral stereotactic 
injections of 6OHDA (2µl each site, 20µg total 6OHDA at a rate of 
400nl/minute) to induce a pre-terminal lesion in the striatum, as described by 
Kirik and colleagues (Kirik et al., 1998). Coordinates (AP/ML/DV relative to 
bregma): 0/-2.6/5.0 and -1.2/-3.9/5.0. Infusion of 6OHDA into these sites in 
striatum should lead to approximately 70% loss of TH positive neurons in the 
SNPC in the lesion hemisphere three weeks after lesion (Kirik et al., 1998). A 
total of 34 rats were used in this study. In all surgeries, viral group injections 
were randomised by distributing animals in each group between surgeons (Ben 
Houghton and Oscar Cordero Llana) and over the course of the day. 
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6.2.7.2 Behavioural measurements 
In order to assess the functional integrity of the nigro-striatal dopaminergic 
system, rotation behaviour is triggered by the injection of either apomorphine (a 
dopamine receptor agonist) or amphetamine (a dopamine releasing compound). 
The number of rotations, due to the imbalance of striatal dopamine signalling 
between lesioned and non-lesioned hemispheres, correlates with the magnitude 
of the SNPC lesion and DA neuron loss. Apomorphine typically induces 
contralateral rotations, while amphetamine typically induces ipsilateral rotations. 
Animals were injected IP with 2.5mg/kg D-amphetamine sulphate (Sigma) or 
subcutaneously with 0.25mg/kg R-apomorphine hydrochloride hemihydrate 
(Sigma). Amphetamine solutions were made up fresh on the day of turning 
whereas for apomorphine, a 10X stock (apomorphine 2.5g/L 0.1% [w/v] 
ascorbic acid) was made up in deoxygenated-sterile ddH2O and kept at -80ºC. 
Immediately after injection of the drugs, animals were placed inside 30-cm 
rotometer bowls (loaned from Oxford Biomedica) and attached to the revolution 
counter using an elastic harness. Ipsilateral and contralateral rotations were 
recorded every 5min using the rotarod software (purposely-designed in Oxford-
Biomedica). Animals were monitored for up to 60 minutes in apomorphine-
induced rotations or up to 90 minutes in amphetamine-induced rotations and 
returned to their cages. 
6.2.8 Tissue preparation and immunohistochemistry 
Brains were cryoprotected in sucrose and frozen in preparation for sectioning to 
40µm slices via cryostat (Method 2.8.1). Typically the brain was sequentially 
dived into 5 and one fifth of the brain used for immunohistochememistry 
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(Methods 2.9, see Table 2-5 for detail of antibodies). Anti-CDNF and Anti-TH 
antibodies were a kindly supplied by the Caldwell laboratory. 
6.3 Results 
6.3.1 Cloning a CDNF-DD construct 
CDNF is a secreted protein, and we anticipated that a DD cloned to the N-
terminus would be removed with the secretion signal (Lindholm et al., 2007). 
We chose the ‘3mut’ form of the DHFR DD (Chapter 4) and applied it to the C-
terminus of CDNF using a PCR based strategy. We then shuttled the expression 
cassette in to a dual promoter vector (Yip et al., 2010) that constitutively 
expressed GFP under a spleen focus forming virus (SFFV) promoter. The 
resulting CDNF-DD plasmid could then be used to make lentiviral vectors. 
 
 
Figure 6-1 Schematic diagram of the viral insert of CDNF-DD 
6.3.2 HEK293T cells and E18 rat cortical neurons dose dependently secrete 
CDNF when treated with TMP 
A HIV lentiviral preparation of CDNF-DD was made and used to transduce 
HEK293T cells, alongside a HIV-GFP control (Chapter 5). TMP was supplied 
over a range of doses - 0 - 50µM - 48h prior to harvesting the culture supernatant 
and cell pellets in preparation for Western blot analysis. Blots revealed that there 
was a dose-dependent increase in the levels of CDNF in the culture supernatant 
from both HEK293T and E18 cortical neurons cells expressing the CDNF-DD 
construct (Figure 6-2 [A/B]). There was a small accumulation of CDNF within 
CDNF-DD WPRECMVSFFV GFP CDNF DD dLTRdLTR RRE cPPT/CTS
Chapter 6 - CDNF 
 - 188 -
the cells expressing CDNF-DD, some of which remained when cells were 
treated with TMP. This effect appears slightly enhanced in E18 cortical neurons. 
6.3.3 CDNF accumulates in the striatum of adult rats transduced with HIV-
CDNF-DD when TMP is supplied in the diet 
Six adult male Wistar rats received stereotactic infusions of HIV-CDNF-DD to 
the striatum of the right hemisphere (Method 5.2.4.2) Three weeks later, the diet 
of three of the rats was exchanged for chow containing 0.2% TMP (On average 
260mg/kg TMP eaten per day), while the remaining three rats received a control 
diet. Three days later, the brains were harvested, sectioned and 
immunohistologically probed before visualizing the CDNF either by DAB 
staining, or using fluorophore conjugated antibodies (Figure 6-2 [C]). Both 
DAB and fluorescent staining revealed the presence of more CDNF in the 
striatum of rats that had received TMP in their diet. This suggests that the DD 
system can be used to regulate the levels of CDNF in the brain and can therefore 
be tested in the 6OHDA lesion model for Parkinson’s disease. 
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Figure 6-2 Validation of HIV-CDNF-DD in HEK293T cells, E18 rat cortical neurons and adult male 
rats 
[A] HEK293T cells transduced with HIV-CDNF-DD were treated to a range of TMP concentrations (left to 
right: 0, 0.5, 5 and 50µM) 48h prior to harvesting the media supernatant (sCDNF-D) and cell pellets 
(cCDNF-DD). Supernatants were centrifuged to remove cell debris, before mixing 1:1 with sample loading 
buffer in preparation for Western blot analysis. Approximate molecular weight of CDNF-DD is 37kDa. [B] 
Similarly, E18 rat cortical neurons were transduced and received the same range of TMP doses 96h prior to 
harvesting, before preparing in the same way. [C] Adult male Wistar rats received stereotactic injections of 
HIV-CDNF-DD into the striatum of the right hemisphere. After three weeks, some rats received mashed 
chow containing 0.2% TMP for three days prior to perfusion fixation and harvesting of the brain. After 
cryoprotection, brains were sectioned into 40µm sections in a cryostat. [C] Some sections were DAB 
stained for CDNF (light microscope images) Scale bar=50µm. [D] Other sections were stained using 
ALEXA-conjugated secondary antibodies. CDNF/GFP/DAPI. Scale bar=50µm. 
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6.3.4 Optimising the viral delivery method of CDNF expressing vectors to the 
SNPC of adult rats 
In order to transduce as much of the SNPC as possible, while not physically 
damaging the area, two different methods of viral delivery were considered. As 
implemented in our previous studies, VSV-G-pseudotyped vectors can be used 
to transduce cell bodies at the site of injection. These vectors require precise 
targeting of the SNPC in stereotactic surgery. Rabies-G-pseudotyped vectors 
have the ability to retrogradely transport along the processes projecting into the 
striatum from cells in the SNPC. By avoiding direct infusion to the SNPC, this 
may avoid damaging the SNPC with infusion needles, and be more reliable in 
targeting this small area. Preparations of Rabies-G-pseudotyped HIV-CDNF 
were made and infused into striatum of adult male Wistar rats at two sites 
(Method 6.2.6.4). To assess our ability to accurately target the SNPC, 
preparations of VSV-G-pseudotyped HIV-CDNF were infused directly to the 
SNPC (Method 6.2.6.3). Three week post-infusion, the animals were 
transcardially perfused and the brains collected. After cryoprotection and section 
via cryostat, the brains were probed for CDNF and visualized using fluorescent 
antibodies. Tyrosine hydroxylase (TH) was also probed to reveal the SNPC. 
Animals that had received Rabies-G-pseudotyped vector had very few 
transduced neurons in the SNPC (located by staining for tyrosine hydroxylase 
positive cells) (Figure 6-3 [A/B/E]. In contrast, animals that had received 
infusions of VSV-G-pseudotyped vectors directly to the SNPC had many 
transduced neurons in the SNPC (Figure 6-3 [C/F]. This suggests that while 
there is slight danger of damaging the SNPC by infusing viral vectors directly to 
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Figure 6-3 HIV-CDNF pseudotyped with Rabies-G or VSV-G delivered to the striatum or SNPC 
[A/B] Rabies-G-pseudotyped HIV-GFP delivered to the striatum. Labelled boxes indicate close-up photos 
below showing [D] GFP in the striatum and [E] presence of one transduced TH+ neuron in the SNPC. [C] 
VSV-G-pseudotyped HIV-GFP delivered to the SNPC. [F] Close-up of SNPC indicated in [C] shows many 
TH+ neurons. GFP/TH/DAPI. Scale bar=200µm. 
6.3.5 Testing HIV-CDNF-DD in the 6OHDA lesion rat model of Parkinson’s 
disease 
Adult male Wistar rats received infusions of VSV-G-pseudotyped HIV-CDNF-
DD, HIV-CDNF (constitutive expression of CDNF) or HIV-GFP directly into 
the SNPC (for coordinates, see 6.2.6.3). In the same surgery, they received two 
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further infusions of 6OHDA in the striatum. This meant that the rats were 
lesioned at the same time as CDNF viral vector delivery. One day after surgery, 
some CDNF-DD rats were supplied chow that contained 0.2% TMP, while the 
remaining received a control diet. Two weeks later, apomorphine induced 
rotation behaviour was stimulated in the rats restrained in rotometer bowls 
(Method 6.2.7.2). Rotation data was also collected on weeks 3, 4, 6 and 8 post-
lesion (Figure 6-4 [A]).  
CDNF rats showed significantly lower number of turns over time compared to 
the control GFP rats. CDNF-DD rats not eating TMP also showed considerably 
reduced turning behaviour. These data suggested that the animals that received 
CDNF had a reduced dopaminergic deficit in the striatum that was induced by 
the 6-OHDA lesion, that is, CDNF protected dopamine neurons from 
degeneration. Unexpectedly, CDNF-DD rats maintained on a diet containing 
TMP immediately after surgery rotated substantially more than those that did not 
eat TMP. Rats that had been lesioned without viral vector infusion and 
maintained on a TMP diet also showed a similar increase in turning behaviour. 
CDNF-DD rats that had started eating TMP two weeks after surgery did not 
show an increase in turning behaviour (Figure 6-4 [A]).  
To investigate the difference between CDNF-DD rats maintained on a TMP or a 
control diet, amphetamine was used to induce rotation behaviour. Rats that had 
been maintained on a TMP diet exhibited 8 fold more turning behaviour than 
rats eating a control diet (Figure 6-4 [B]). 
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These data indicate that TMP was affecting the drug-induced behaviour of the 
6OHDA lesioned animals. Because animals that were not injected with vectors 
but were eating a TMP diet also increased in turns, we hypothesised that the 
effect was not due to problems caused by the overexpression of CDNF-DD, but 
rather that TMP was directly affecting the dopamine signalling pathway in these 
lesioned animals. 
6.3.6 Testing the effects of TMP on rats with 6OHDA lesion 
We considered that feeding the rats TMP immediately after surgery could be 
exacerbating the formation of the 6OHDA lesion. To investigate if delaying 
feeding abrogated this behaviour, rats lesioned as before were fed a normal diet 
for three weeks, before commencing on a TMP diet. During the three weeks, the 
apomorphine-induced turning behaviour was monitored to establish baseline 
readings. This data enabled distribution of the animals into groups, such that 
there was no difference in cumulative rotations between the groups. The 
lesioned rats were divided into 3 groups maintained on a diet of 0.2% TMP 
chow, a reduced 0.05% TMP chow or a control chow that did not contain TMP. 
Apomorphine-induced rotation behaviour was to be monitored over the 
following 8 weeks. However, during this experiment, rats developed self-
mutilation behaviour and in order to prevent this the dose of apomorphine used 
to induce rotations was lowered. Furthermore, the harnesses for restraining the 
rats in the rotometer bowls were changed. These changes during the experiment 
made it difficult to draw firm conclusions from this part of the experiment. 
However, at 8 weeks post-lesion, amphetamine was used to induce rotation 
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behaviour. Rats that had been eating 0.2% and 0.05% TMP diet showed a 2.5 
and 2.7 fold increase in rotation behaviour respectively (Figure 6-4 [C]). 
 
 
Figure 6-4 Rotation data of 6OHDA lesion rats 
[A] Adult male Wistar rats lesioned with 6OHDA and expressing either CDNF, CDNF-DD, GFP or no 
virus and eating mashed chow containing 0.2% TMP as indicated in the graph key. Turning behaviour was 
induced by apomorphine and data collected over 90 minutes (n=3-6). [B] Cumulative amphetamine-induced 
rotations of CDNF-DD rats eating TMP or control diet (n=3). [C] Cumulative amphetamine-induced 
rotation of adult male Wistar rats lesioned with 6OHDA, commencing either a diet containing 0.05% TMP, 
0.2%TMP or a control diet, three weeks post lesion (n=4). 
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Figure 6-5 Counts of TH
+
 cells in the SNPC 
[A] Brains of 6OHDA lesion rats eating either 0.05% TMP, 0.2% TMP or a control diet were sectioned 
coronally. One fifth of the brain was immunohistochemically stained for tyrosine hydroxylase (TH) to 
reveal the neurons in the SNPC, substantia nigra pars reticulata, and VTA (ventral tegmental area). Neurons 
of the SNPC were counted over at least 7 sections per animal, an average was taken, before taking another 
average for each group [B]. [C] TMP feeding data for rats on a diet of 0.2% TMP or 0.05% TMP over an 8 
week period, commencing 3 three weeks after 6OHDA lesion. Rats receiving a 0.2% TMP diet ate an 
average 270mg/kg per day. Rats receiving a 0.05% TMP diet ate an average 70mg/kg per day. 
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6.4 Discussion 
In this chapter, we aimed to fuse the DHFR destabilization domain to the CDNF 
protein in order to obtain regulatable secretion of CDNF in dopaminergic 
neurons in an in vivo model of Parkinson’s disease. Fusion of the DHFR 
destabilization domain to the C-terminus of the CDNF protein resulted in TMP-
responsive secretion of CDNF from neurons in vitro and in vivo. When we tested 
the efficacy of this regulatable CDNF in the 6-OHDA lesion rat model, we 
unexpectedly found that rats that received the CDNF-DD viral vector and 
maintained on a TMP diet showed an increase in dopaminergic deficit as 
assessed by drug-induced rotational behaviour.  
CDNF is a secreted protein and the protein sequence of CDNF indicates that 
there is a 26 amino acid secretory signal at the N-terminus of the peptide 
(Lindholm et al., 2007). This means that any moiety placed at the N-terminus 
should be removed as the secretion signal is cleaved off upon entry into the 
endoplasmic reticulum. Therefore, we only developed a C-terminally tagged 
form of CDNF, using the DD domain that had given the best regulatory 
characteristics in earlier work (Chapter 4). When HEK293T cells expressing 
CDNF-DD were treated with TMP, there was a dose dependent increase in the 
levels of CDNF in the supernatant. While the transduced cells did not secret a 
detectable amount of CDNF in the absence of TMP, a small amount 
accumulated within the transduced cells which was partially removed in the 
presence of TMP. A similar trend was observed in E18 cortical neurons. It is 
currently unclear why accumulation of CDNF in the transduced cells in the 
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absence of TMP was observed. It is possible that the degradation of the fusion 
CDNF protein in the proteasome occurs at low efficiencies leading to 
accumulation of the protein in the cell, or that TMP on its own can affect the 
secretion of the CDNF protein. 
As hCDNF is only 161 residues long after the removal of the 26-residue pro-
sequence, it is encouraging that the 159-residue DHFR DD can regulate the 
levels of secreted CDNF. Not only is the DD nearly doubling the size of the 
small protein, but the C-terminus has an important role in CDNF secretion. The 
recent study by Sun et al explained that CDNF secondary structure is dominated 
by 8 α-helices. Using mutagenesis they inserted proline (α-helix blocker) 
between each one. When the proline was between the penultimate and final α-
helices, CDNF was not efficiently sorted to secretory granules destined for the 
regulatory secretory pathway (Sun et al., 2011). While the DD may potentially 
be interfering with the folding of the C-terminus of the CDNF, we still saw dose 
dependent secretion when TMP was applied, suggesting constitutive secretion at 
least was still occurring. 
To investigate the efficacy of using the CDNF-DD construct in an in vivo model 
of Parkinson’s disease, we performed an expression study. We found that when 
TMP was added to the diet of rats that had received an infusion of HIV-CDNF-
DD, there was markedly more CDNF present when we probed brain sections 
using immunohistochemistry. There was also very little CDNF present in 
animals receiving a control diet. Using a DAB staining protocol, we hoped that 
secreted CDNF could be visualized in a similar way to how the Björklund lab 
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recently visualised GDNF secretion (Decressac et al., 2011). We cannot be sure 
if the lack of the ‘dark halo’ of staining is due the CDNF-DD not being secreted 
as we see in vitro, or due to the antibody used in staining or methodologies used 
when harvesting or staining the brain. It is unlikely that this is due to insufficient 
viral transduction in the striatum, as viruses of similar titre have produced robust 
transduction in the striatum, as previously shown in this thesis (See chapters 3 
and 4). 
In unilaterally 6OHDA-lesioned rats, we had hoped that when HIV-CDNF-DD 
was used to transduce the SNPC of rats that also received a diet containing TMP, 
we would see a reduction in induced turning behaviour thus demonstrating that 
regulated CDNF expression is neuroprotective in this lesion model. However, in 
our experiments, we found that these animals exhibited increased turning 
behaviour compared to CDNF-DD rats on a TMP-absent diet, or animals that 
had received a control GFP vector.  
High doses of TMP can lead to inhibition of protein and purine synthesis by 
inhibiting endogenous DHFR in mammalian cells. This could lead to the 
exacerbation of the effects of the 6OHDA, as cells fail to cope with the added 
burden. However, our data suggest that it was not TMP exacerbating the 
6OHDA lesion that led to the increase in turning behaviour. When TMP diet was 
withheld until three weeks after lesion, the same effect was also seen. Cell 
degeneration and death induced by 6-OHDA in the lesion model occurs between 
one to four weeks and is usually complete within 4 weeks of administration of 
6OHDA. The fact that the same effects were observed when TMP was 
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administered after the 6-OHDA lesion had stabilized suggested that TMP was 
not affecting the lesion size or characteristics per se. Furthermore, TH
+
 cell 
counts in the SNPC reveal that there were no significant differences in TH+ cell 
counts between groups eating TMP eating a control diet (Figure 6-5), suggesting 
that the effect of TMP on turning behaviour is not due increased death of DA 
neurons. This indicated that the behavioural read-out from these animals 
reflected differences in the levels of DA in rats eating TMP or a control diet. 
There are several documented cases of humans receiving high dose 
Trimethoprim-Sulphamexazole (TMP-SMX) medication developing tremors and 
movement disorders as side effects. Many of these are adult patients with AIDS 
(Borucki et al., 1988; Van Gerpen, 1988; Aboulafia, 1996; Salkind, 2000) while 
some were immunocompetent (Patterson and Couchenour, 1999; Dakin, 2009), 
including a child (Bua et al., 2005). Indeed, horses receiving high dose TMP 
medication also developed abnormal gait and erratic behaviour (Stack and 
Schott, 2011), suggesting this effect is not specific to humans. The one juvenile 
human reporting an adverse reaction had a deficiency in dihydropteridine 
reductase – an essential enzyme in the regeneration of tetra-hydrobiopterin 
(Woody and Brewster, 2008). This suggests a mechanism by which TMP fed to 
unilaterally 6OHDA lesioned rats can lead to increased turning behaviour. 
Although mammalian DHFR (mDHFR) binds TMP 3000-fold less tightly than 
the E. coli DHFR (Matthews et al., 1985), off target effects will be seen when 
animals are consuming a particularly high TMP diet over long periods. mDHFR 
reduces 7,8-dihydropterin to tetrahydrobioperin, a cofactor required for the 
production of dopamine (Figure 6-6). Inhibition of mDHFR through TMP 
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binding could lead to a reduction in tetrahydrobiopterin synthesis, thereby 
leading to lowered DA levels. In unilaterally lesioned rats, TMP will also lead to 
an overall reduction in DA. However, the lesioned hemisphere will already have 
a dopamine deficit due to the loss of dopaminergic neurons, leading to an even 
greater differential between intact and lesioned hemispheres. We suggest that 
this increased fold difference between the hemisphere leads to the greater 
turning behaviour seen in rats eating a TMP diet. Further experiments will be 




Figure 6-6  Dopamine synthesis schematic diagram 
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TMP diet group in our experiment. Rats eating 0.2% TMP diet ate an average of 
280mg/kg per day over the experiment, while those eating 0.05% TMP ate 70 
mg/kg per day on average (Figure 6-5 [C]). However, we did not see a 
difference in the rotation behaviour of these animals. Further work must be 
carried out in order to find a dose of TMP that can be used in vivo to both 
activate a DHFR DD tagged GOI, yet not induce rotation behaviour. Since the 
start of these experiments, the Wandless lab have published their data on the 
DHFR DD system (Iwamoto et al., 2010). To activate the system in rat CNS, 
they used TMP supplied in the drinking water. The rats consumed approximately 
20mg/kg per day and they saw activation of the system after three weeks. This 
suggests that a much lower dose of TMP could be used when investigating DD-
tagged therapeutic genes, potentially abrogating the TMP-dependent turning 
behaviour we observed. However, in some cases it may be desirable to activate 
the system in a shorter time scale. Further studies are needed to fully elucidate 
the kinetics of the system in vivo when different feeding or dosing regimes are 
employed. 
We observed that rats that received an infusion of CDNF-DD that ate a control 
diet actually exhibited the least amount of turning behaviour out of all the 
experimental groups. In vitro we saw low levels of CDNF-DD accumulating in 
cell bodies in the absence of TMP and although this basal activity was not 
detectable in immunostaining on brain sections from rats that had been 
maintained on a TMP-free diet, we suggest that low levels below the detection 
limit are present. Voutilainen et al noticed a dose dependent effect of CDNF 
when chronically infusing CDNF into lesioned rats, such that the highest dose 
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was not the best for protecting the DA neurons in the SNPC (Voutilainen et al., 
2011). While further experiments would be needed to confirm this finding, it is 
possible that low levels of CDNF-DD can have a greater therapeutic effect than 
high levels. 
CDNF-DD rats that commenced on a TMP diet two weeks later than other rats 
did not show an increase in rotation behaviour when TMP feeding began, 
suggesting that they had been made resistant to the effects of TMP by protection 
of DA neurons. Furthermore, animals infused with CDNF-DD (eating TMP or 
control diet) exhibited reduced amphetamine induced turning behaviour at 8 
weeks post-lesion overall compared to control lesioned animals (eating TMP or 
control, respectively). Overall, this suggests that CDNF-DD can cause some 
degree of protection in the SNPC irrespective of TMP administration. Again, we 
would need to carry out more experiments with bigger group numbers to 
confirm these ideas.  
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Chapter 7 Discussion 
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7.1 Investigating the FKBP12-derived destabilisation (DD) 
regulatory system 
In this study we set out to investigate a novel method of regulating the 
expression of therapeutic agents delivered via lentiviral vectors for the treatment 
of neurological disorders. We chose to assess the destabilisation domain 
technology developed by Thomas Wandless and colleagues (Banaszynski et al., 
2006). This system consists of a mutated protein (FKBP12) domain that is 
unstable when expressed and immediately degraded, unless rescued by a 
stabilising ligand called Shield1. Fusion of this domain to a gene of interest 
(GOI) confers conditional instability onto the fusion partner. We designed two 
restriction enzyme-optimised cassettes: one with the destabilisation domain 
fused N-terminally to GFP, the other C-terminally to GFP. When Shield1 was 
supplied to HEK293T or E18 rat cortical neurons that had been transduced with 
lentiviral vectors expressing these cassettes, the N-terminally fused DD-GFP 
construct exhibited the lowest basal expression. Assessment of the kinetics of 
activation of the system indicated that maximal levels of induction are reached 
within 24 hours, although increases in GOI levels were seen almost immediately 
after addition of Shield1. This concurs with other studies using the FKBP12 DD 
system (Dolan et al., 2011; Skafte-Pedersen et al., 2012). Due to our 
experimental techniques, we were unable to determine the inactivation kinetics 
of the system, as this may be dependent on the GOI, which may influence the 
rate of degradation of the fusion protein in the absence of Shield1. However, 
reports have suggested that the half life of degradation is between 2.5 hours 
(Schoeber et al., 2009) and 4 hours (Banaszynski et al., 2006). 
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The means by which the DD leads to protein degradation was not completely 
resolved, although it has been observed that applying proteasome blockers in the 
absence of Shield1 lead to DD-fusions accumulating and these fusions co-
localise with subunits of the proteasome (Banaszynski et al., 2006; Maynard-
Smith et al., 2007). Recently, the Wandless laboratory discovered that FKBP-
derived DD domains become ubiquitinated within minutes after removal of 
Shield1 (Egeler et al., 2011), indicating not only the involvement of the 
ubiquitin-proteasome system (UPS), but also the rapidity of the induction of 
degradation. Doxycycline or ecdysone regulated systems will not consistently 
match this speed for gene silencing, as they are dependent on the endogenous 
stability of the GOI. However, substrate recognition by the UPS is not well 
defined and therefore DD fusion proteins, especially DD fusion reporter 
proteins, could be useful as model substrates to help elucidate molecular 
mechanisms responsible for recognising and degrading misfolded cellular 
proteins. 
We used the lentiviral vectors to transduce cells in the striatum of living rats. In 
animals that received a vector constitutively expressing GFP we observed 
abundant GFP expression in neurons. As Shield1 is not expected to cross the 
blood-brain-barrier (BBB), animals that had received a vector expressing DD-
GFP received a second stereotactic intracranial injection to deliver Shield1. 
When the brains from these animals were analysed, only very weak GFP signal 
could be detected in the area surrounding the injection site. Investigation of the 
effects of increasing the multiplicity of infection (MOI) of the vectors in 
HEK293T cells indicated that the low level of expression seen at the injection 
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site in the animals was due to high MOI at the site of injection, not weak 
activation of the system. Investigation into the ability of Shield1 to cross the 
BBB is hindered by the significant cost of the ligand. Alternative regulatory 
systems, such as TetOn, and indeed the DFHR-based DD system, utilize a 
cheap, widely available activating ligand (Doxycycline and Trimethoprim 
respectively) that also crosses the BBB. This may explain why the FKBP12 DD 
system has been extensively utilised for in vitro studies, yet none of these are 
looking to regulate protein levels in either neurons or the CNS. 
There have been three studies that utilize the FKBP12 DD system in living mice, 
all reporting the ability to regulate GOI satisfactorily and in two cases, tunably 
so. Maximal expression levels were reached in 12 hours after intravenous 
treatment with Shield1, and returned to baseline within 48 hours (Banaszynski et 
al., 2008; Rodriguez and Wolfgang, 2012). This is fast induction, most likely 
due to there being plentiful mRNA and protein already being produced at the 
time of Shield1 addition. Transcriptionally regulated systems take longer to 
reach maximal induction, as mRNA must be built up from very low levels. The 
inactivation kinetics are most likely related to the rate of clearance of Shield1 
from the body. There are already several ligands in the Shield1 family and it is 
possible that looking for further derivatives may yield a ligand with more 
desirable pharmacokinetic properties. 
While the reversibility of the DD system does allow for pulsatile expression of 
GOI (Kwan et al., 2011), this is restricted to pulses with a time course of 
approximately three days. For experiments investigating pulsatile expression of 
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GOI, defining the dose of Shield1 to give predictable levels of transgene over 
time is necessary; yet obtaining data such as this may be difficult for a 
therapeutic GOI. Wandless and colleagues used a DD-luciferase reporter 
expressed in tumourgenic xenografts in mice, providing them with quantifiable 
expression levels in vivo after delivery of Shield1. This approach could be 
adopted to allow quantifiable GOI expression by fusing luciferase to the DD-
GOI fusion using a 2a self-cleaving peptide (Szymczak et al., 2004). As the both 
the DD-GOI and Luciferase are co-transcribed, the levels of luciferase could be 
used to approximate of the GOI. However, the presumed inability of Shield1 to 
cross the BBB makes it an unattractive candidate for further development of 
in vivo methodologies using the FKBP12 DD system. In addition, delivery of the 
ligand in this system in vivo, especially via an oral route, may be hampered by 
the significant cost of Shield1. 
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7.2 Investigating the DHFR-derived DD regulatory system 
During the course of our study using the FKBP12 DD system, a second DD 
system was developed, comprising a mutated E. coli dihydrofolate reductase 
(DHFR) protein that is stabilized by trimethoprim (TMP) (Iwamoto et al., 2010). 
The Wandless laboratory selected two Ds, designed to be optimal for applying to 
either the N- or C-terminus of GOIs. The DD for applying to the N-terminus had 
three mutations (“3mut”) while the C-terminal form had four (“4mut”). In the 
absence of published data at this time, we produced four DD/GOI constructs: 
both the “3mut” and “4mut” forms of DD were applied to both the N- and C- 
terminals of GFP. Lentiviral vectors of these constructs were used to transduce 
HEK293T cells and E18 cortical neurons. The “3mut” domain cloned to the C-
terminus of GFP (GFP-3mutDD) was found to be the most destabilizing to GFP 
in the absence of TMP, yet exhibited a dose-dependent increase GPF levels in 
the presence of TMP.  
In vivo, adult rats that had received a stereotactic injection of GFP-3mutDD into 
the striatum accumulated GFP after a stereotactic infusion of TMP into the same 
location three weeks later. However, TMP is highly absorbed from the gut and 
can cross the BBB, presenting a non-invasive method of activating the system. 
When the experiment was repeated and rats were fed a diet containing TMP, 
GFP accumulated in rats eating TMP, but not in animals eating a control diet.  
Only three other studies have been reported since the system was first described. 
Interestingly, one of these was looking at regulating levels of GOI in neurons 
(Cohen et al., 2012). Cohen and colleagues used the DHFR DD system to 
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conditionally and spatially regulate the levels of both a small GTPase (RhoA) 
and the Wallerian degeneration slow protein (Wld
s
) within neurons using a 
microfluidic culture platform. In the microfluidic devices, neuronal processes 
extend through narrow channels to a separate compartment that fluidically 
isolates them from the cell bodies of the neurons. This means TMP can be 
applied to the cell bodies alone, or to both cell bodies and axons, thereby 
potentially revealing the subcellular site of action of protein in neurons. Using 
this approach, they found that both RhoA and Wld
s
 exert their function 
(reducing NGF mediate neuron outgrowth, and protection of degenerating axons, 
respectively) primarily through their axonal pool.  
A poster communication at the ESGCT conference (2011) reported regulation of 
glial-derived neurotrophic factor in the rat CNS, but this has not yet been 
published. The final study was based in P. falciparum and reported the ability of 
the system to dose dependently regulate the levels of the proteasome lid subunit 
Rpn6 in living parasites (Muralidharan et al., 2011). Prior to the development of 
the DFHR system, the FKBP12-DD system was one of the few methodologies 
available to conditionally proteins in this species and has received a lot of 
interest, despite Shield1 being toxic to the parasite (Russo et al., 2009). 
In comparison to the FKBP12-based DD system, where Shield1 must be injected 
to animals, the DFHR-based system is advantageous, as TMP is rapidly 
absorbed from the gut and can therefore be supplied in the drinking water 
(Iwamoto et al., 2010) or in the diet. While this provides a non-invasive means 
to provide TMP, there will be fluctuations in dosage as animals do not eat 
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consistently throughout the day and night. It is also unclear at the present time, 
what proportion of the circulating TMP enters the central nervous system in 
rodents and more importantly in humans. While some pharmacokinetic data on 
TMP administration to rats has been reported and suggests TMP in the brain is 
about 10% that of the lung, kidneys and spleen, these focus of intravenous 
delivery of TMP (Tu et al., 1989). Information on the circulating levels of orally 
delivered TMP and its clearance rates by the liver in humans will probably be 
more readily available, as TMP is a commonly prescribed antibiotic for urinary 
tract infections, or used in combination with other drugs to treat pneumonia. 
Further studies would be needed to determine the impact of fluctuations in 
consumption of TMP have on the levels of TMP in circulation in the body and 
therefore on levels of DD GOI fusion proteins. Fluctuations in the levels of 
proteins in the CNS can be highly important in the context of gene therapy. For 
example, in the clinical trial of AADC therapy for Parkinson’s disease, 
fluctuations in the oral dosing regime of L-DOPA can lead to L-DOPA-induced 
dyskinesia (Cress, 2008). If this form of regulatable gene therapy is applied to 
humans, it is quite likely that we will be able to control for fluctuations in TMP 
dosage by ensuring that regular doses of TMP are administered to patients.  
In our experiments using the DFHR-based DD, we noticed some cells exhibited 
basal expression in the absence of TMP. One way to combat the ‘leakiness’ of 
the system would be to place the DD/GOI fusion cassette under the control of 
another form of regulatory system, such as a tetON system. In the off state (Dox 
and TMP absent), very little mRNA would be transcribed, and therefore very 
low amounts of destabilized proteins will be produced, which should be easily 
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degraded by the proteasome. While this may provide the tight regulation 
required for use in a clinical setting, compound systems are more complex, 
require more optimization to achieve correct dosage and present more safety 
risks. Also, the inclusion of another layer of regulation may affect the rate at 
which the system can be turned on, thereby negating the advantage of the quick 
tunability of the DHFR DD system.  
It is clear that the site of the fusion of the DDs to the GOI should be optimized 
and rigorously tested for individual genes before selecting a configuration for 
use in vivo. We and others have found that the DDs should be tested at both the 
N- and C-terminals of the proteins, as the GOI may have effects of the efficiency 
of the DD system and vive versa (Ma et al., 2012). Interestingly, Sellmyer and 
colleagues (Sellmyer et al., 2012) showed that DD fusion proteins that were 
localised in the cytoplasm or nucleus can be efficiently degraded in mammalian 
cells; however, if the fusion proteins were targeted to the mitochondrial matrix 
or ER lumen, accumulation of the protein occurs even in the absence of ligand 
due to limited activation of the ubiquitin-proteasome system (UPS) and 
subsequent degradation of the DD. This suggests that specific cellular 
compartments such as the ER are tolerant of high DD levels in the absence of the 
ligand and that the DD is quite sensitive to local, compartment-specific protein 
quality control. This aspect of the DD technology should be considered when 
applied to different genes or proteins, for example tunability of mitochondrial or 
ER proteins may not be as readily achieved compared to nuclear or cytoplasmic 
proteins. 
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When looking at using the DD systems as potential tools for a clinical gene 
therapy, it is clear that more studies are required to determine the effects of high 
levels of DD fusion proteins in the targeted cells. As evidenced by diseases such 
as Parkinson’s disease and Huntington’s disease, neurons are particularly 
sensitive to accumulations of misfolded proteins. Therefore, safety concerns 
relating to the long-term overexpression of misfolding proteins must be raised. 
Furthermore, although TMP has been used for many years as a drug for human 
use and has very suitable pharmacokinetic properties, the interaction with the 
dopaminergic system is another serious concern, particularly after long periods 
of high trimethoprim consumption. There are, as yet, no other studies using the 
DFHR system in vivo (beyond proof of concept investigations). 
As a tool to perturb the timing and levels of proteins of interest, DDs are 
powerful, offering a means to allow rapid, reversible and tunable of a wide range 
of different GOI. The DFHR-based DD is still very much in it infancy, yet it has 
advantages over the FKBP12-based system, particularly for use in the CNS, due 
to the desirable pharmacokinetic properties of the TMP ligand. As mentioned 
above, one potential application is to use the DD system to regulate protein 
levels in different subcompartments of an individual cell. The microfluidic 
devices that facilitate these studies will be described in more detail in the next 
section. Development of technologies not directly related to gene regulation may 
also prove useful. The Cornish lab at the University of Columbia were interested 
in developing a means to fluorescently label genes of interest, other than creating 
a GFP fusion protein. They initially demonstrated the feasibility of conjugating 
fluorophores to antifolates such as methotrexate and TMP and using these 
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molecules to visualise DHFR-GOI fusion proteins in cells (Miller et al., 2004) 
(Miller et al., 2005). Therefore, the chemistry has already been developed to 
visualize and stabilize DFHR-DD fusion proteins simultaneously, potentially 
allowing observation of the subcellular distribution of newly stabilized fusion 
proteins. Fluorophore-TMP binding to DHFR-DD is reversible, potentially 
allowing the DD system to be activated and inactivated (Calloway et al., 2007) 
in a dose dependent manner.  
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7.3 Developing a regulatable RARβ2 vector for use in nerve 
injury models 
Yip and Wong et al. (Yip et al., 2006) had previously shown that a lentiviral 
vector overexpressing RARβ2 in the sensorimotor complex led to increased 
sprouting of corticospinal tract (CST) neurons and improvement in behavioural 
deficits in a rodent model of spinal cord injury. In this study, we aimed to 
capitulate this finding using a RARβ2 regulated the DFHR-based DD domain. 
In vitro, we found that accumulation of RARβ2 could be dose dependently 
induced by TMP and reach high maximal levels. In neuronal cells, we found a 
higher degree of basal activity than observed in HEK293T cells but inducibility 
was maintained. Levels of DD-RARβ2 were increased in response to TMP in 
DRG cells, and this resulted in increased neurite outgrowth from DRGs This 
indicated the ability of DD-RARβ2 to induce TMP-dependent neurite outgrowth. 
When we assessed the efficacy of the DD-RARβ2 vector in vivo, we failed to 
see significant differences in behavioural tasks or numbers of newly sprouted 
axons between animals eating TMP or rats eating a control diet. The most likely 
reason for the lack of functional improvement observed in this study is the low 
group numbers in the experiments and the study will have to be repeated to 
confirm this finding. However, we cannot discount the possibility that fusing the 
DD to RARβ2 may have led to a partial loss of biological activity of RARβ2. To 
investigate this further, we proposed to develop a direct RARβ2 functional assay 
by cloning a luciferase reporter downstream of an RARβ2 responsive promoter. 
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The efficacy of the DD-RARβ2 to drive luciferase expression could then be 
compared to that of endogenous or constituently expressed RARβ2. Due to time 
constraints we were unable to complete these latter experiments. 
Developing a regulatable form of RARβ2 therapy would have enabled us to 
investigate the effects of inducing or silencing RARβ2 overexpression at 
different time points after spinal cord injury, allowing us to determine if there is 
a therapeutic window for RARβ2 expression. Existing methodologies exploring 
the efficacy of RARβ2 expression has thus far required delivering the RARβ2 
vector in advance of creating a spinal cord lesion. This does not allow us to 
determine if RARβ2 is a potential therapeutic agent for human spinal cord injury 
that will work after the injury has occurred. We had hoped to be able to inject 
the vector prior to lesion, yet induce RARβ2 levels at different time points after 
lesion. However, due to the outcome of the in vivo experiments and time 
constraints, we have not been able to perform such studies and therefore unable 
to determine if RARβ2 overexpression would be suitable as therapeutic 
intervention for spinal cord injury.  
The mechanisms by which RARβ2 induces outgrowth of neurites from DRG or 
CST neurons is as yet unknown, but it is thought that RARβ2 can 
transcriptionally activate target genes and/or activate cAMP/Akt signalling 
pathways to stimulate growth from injured neurons. In cultured DRG neurons, 
RARβ2 overexpression leads to an increase in cytosolic cAMP (Wong et al., 
2006), while in cerebellar granule neurons, RARβ induced phosphorylation of 
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Akt (Agudo et al., 2010). More recently it has been shown that RARβ2 can 
transcriptionally repress the expression of Lingo-1, a component of the Nogo 
receptor complex through which the myelin-derived inhibitory molecules signal 
to induce growth cone collapse (Puttagunta et al., 2011). Further studies such as 
microarray profiling to identify direct transcriptional targets of RARβ signalling 
following spinal cord injury and exploration of the interaction of RA- RARβ 
pathways with other pro-regenerative signals will yield insight into the complex 
molecular pathways that are involved during axonal regeneration. 
Many of the interventions currently being explored are combination therapies, 
where two factors shown to have an effect on recovery after injury synergize to 
create a more efficacious treatment. As discussed in the introduction to this 
thesis, chondroitinase ABC (ChABC) is receiving a lot of interest as a potential 
therapy for spinal cord outgrowth after injury. Recently, lentiviral vectors have 
been used to deliver ChABC in a rat model of spinal cord injury (Zhao et al., 
2011a). The extensive secretion of ChABC, both locally (spinal cord 
transduction) and from long-distance axon projections (striatal CST cell body 
transduction), reduced axonal recession and promoted sprouting and short-range 
regeneration of CST axons. Chondroitinase and RARβ2 therapies may work 
synergistically in a combination approach. This may be particularly useful, as 
ChABC will alleviate inhibition by chondroitin sulphate proteoglycans while 
RARβ2 can suppress myelin signalling through transcriptional repression of 
LINGO-1. A bicistronic vector could be used to deliver ChABC and RARβ2 
together into the sensorimotor cortex. Alternatively the bicistronic lentiviral 
vector could be pseudotyped with a Rabies-G envelope glycoprotein which will 
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facilitate retrograde transport of the vector to the cell bodies of corticospinal 
neurons following injection into the lesion site (Wong et al., 2004). The 
advantages of using a Rabies-G pseudotyped lentiviral vector are two-fold: first, 
local expression of chondroitinase and RARβ2 will modify the inhibitory 
environment at the site of injury and second, retrograde transport of the vector in 
the injured corticospinal neurons and subsequent expression of RARβ2 and 
chondroitinase in these neurons can stimulate growth pathways and/or prevent 
atrophy. The combinatorial effects of RARβ2 and chondroitinase may have 
significant synergistic effects on axonal growth and plasticity, thereby 
facilitating repair and restoring spinal cord function. 
When investigating DD-RARβ2 in DRG neurons we used methodology as 
described by Wong et al (Wong et al., 2006). However, recently developed 
microfluidic devices (Taylor et al., 2005) may provide an alternative 
methodology that is of particular interest when combined with the DHFR 
system. The devices consist of two media reservoirs separated by channels 
(“microgrooves”) 10µm wide x 3µm high. Cells such as DRGs, plated into one 
reservoir will extend process through the microgrooves into the other reservoir, 
allowing separation of cell bodies from axon/dendrite material. By using slightly 
more media in one reservoir, a hydrostatic gradient can be produced, meaning 
that the compartments are fluidically isolated. Cohen and colleagues used this in 
combination with the DFHR system (Cohen et al., 2012). They found that they 
could stabilize DD-fusion proteins in the cell body compartment with TMP, yet 
the fluidic isolation prevents TMP penetrating the axonal compartment, thus 
preventing DD-fusion protein stabilization. Axonal stabilisation could be 
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rescued by addition of TMP to that compartment. Many proteins are translated 
locally at the synapse, therefore addition of TMP in the axonal fraction would 
stabilize molecules produced in the processes but not near the cell body. This 
tool could be of potential interest for studying factors that induce neurite 
outgrowth, by determining the location of both translation and biological action. 
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7.4 Developing a regulatable CDNF vector to test in models of 
Parkinson’s disease 
During the course of the study, the DHFR-based DD domain was also applied to 
regulate CDNF (conserved dopamine neurotrophic factor), a recently discovered 
neurotrophic factor that has been shown to mediate neuroprotection of 
dopaminergic neurons in rodent models of Parkinson’s disease. 
The DHFR-based DD was fused to the C-terminus of CDNF and by varying 
TMP concentrations we were able to regulate the levels of secreted CDNF 
produced by both cell lines and primary E18 rat cortical neurons transduced with 
HIV-CDNF-DD vector. When we injected this vector into rat striatum, we found 
that more CDNF accumulated in rats that had received a diet containing TMP 
compared to control rats. This suggested that CDNF levels in the brain can be 
regulated by TMP administration and therefore we proceeded to test this vector 
in the 6OHDA rat model of PD.  
Infusion of the CDNF protein has previously been shown to protect neurons in 
the substantia nigra pars compacta (SNPC) from 6OHDA induced 
neurodegeneration (Lindholm et al., 2007). Here we used a lentiviral vector to 
overexpress CDNF or the CDNF-DD fusion protein in 6OHDA lesioned rats and 
assessed apomorphine/amphetamine-induced rotation behaviour. Animals that 
received the constitutively expressed CDNF showed a reduction in turning 
behaviour, however, we found that CDNF-DD rats that were maintained on a 
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TMP diet showed the opposite effect, that is, apomorphine/amphetamine rotation 
behaviour was increased. 
This result was unexpected and upon closer examination of literature describing 
the use of TMP, we found reports that suggest that TMP treatment has also been 
responsible for Parkinsonian symptoms in human patients (Bua et al., 2005). 
Although the parental E. coli DHFR binds TMP at a much higher affinity 
compared to mammalian DHFR (approximately 3000-fold (Dauber-Osguthorpe 
et al., 1988)), it is possible that the high doses of TMP that were administered to 
the rats led to inhibition of endogenous DHFR which is required for the 
synthesis of the essential cofactor tetrahydrobiopterin (BH4). BH4 is an essential 
cofactor for tyrosine hydroxylase, the main enzyme responsible for catalysing 
the conversion of L-tyrosine into L-DOPA, and low levels of BH4 may have a 
significant impact on dopamine synthesis leading to lowered dopamine levels in 
the rats. The persistently low levels of dopamine in rats that were maintained on 
TMP diet may have led to heightened dopamine receptor sensitivity and upon 
injection of apomorphine/amphetamine, these receptors were hyper-activated 
resulting in an increased number of rotations during the behavioural assessment. 
The implications that this has on using the DHFR DD system in the CNS must 
be considered. In the paper published by Iwamoto et al. (2010) TMP was 
supplied to rats at a much lower dose and it is possible that using a lowered dose 
of TMP may not inhibit endogenous DFHR. At the moment, this is our working 
hypothesis and a number of future experiments may help clarify this unexpected 
result. 
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Dopamine is produced by both SHSY5Y cells and rodent ventral mesencephalon 
(VM) cultures. By exposing these cells or cultures to TMP, we can investigate if 
the concentrations of TMP that we used in our studies affect dopamine 
production by analysing dopamine levels in the culture supernatant using high-
performance liquid chromatography (HPLC). Additionally, Western blotting 
could be used to investigate the levels of dopamine synthesis enzymes in the 
presence of TMP. In vivo, we could analyse cerebro-spinal-fluid (CSF) 
harvested from the striatum by microdialysis, to confirm that TMP causes 
changes in the levels of striatal dopamine.  
The unexpected finding that long-term administration of TMP may lead to 
decreased dopamine levels in this study suggests that the use of this regulatable 
gene therapy system in PD should be approached with caution. A continuous 
supply of growth factors over a long period of time may lead to adverse effects 
and whilst it is desirable to be able to regulate levels of CDNF in a gene therapy 
approach for PD, more studies will have to be conducted to assess the off-target 
effects of TMP on endogenous dopamine production in the CNS. 
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7.5 Summary 
Gene therapy approaches for neurodegenerative diseases would clearly benefit 
from novel vectors that allow for transient transgene delivery, for example by 
using gene promoters that automatically shut off after several weeks to months, 
or promoters that can respond to a changing environment by turning gene 
expression off once the transgene is no longer required. The ability to regulate 
the levels of the proteins that are produced from gene therapy vectors will 
greatly enhance their efficacy and safety thus increasing the appeal of genetic 
medicines in the clinic.  
Here we have shown for the first time the use of the DFHR-based system in 
lentiviral vectors to regulate levels of two proteins – RARβ2 and CDNF – and 
have explored the use of these regulatable systems in a nerve injury model and 
PD model respectively. This system has now been used to regulate cytosolic 
proteins (GFP, YFP, Luciferase, RhoA, Rpn6 (Iwamoto et al., 2010; 
Muralidharan et al., 2011; Cohen et al., 2012)) predominantly nuclear proteins 
(Wld
s
 (Cohen et al., 2012)), nuclear receptors (RARβ2), transmembrane proteins 
(CD8α, β2AR (Iwamoto et al., 2010)) and secreted proteins (CDNF), indicating 
the versatility of the system. While the use of DHFR-based regulatable gene 
therapy vectors is still in its infancy and more refinement will be required before 
further applications, it will be interesting to see how other studies develop this 
technology in the future. The ultimate goal of gene therapy will be to deliver 
genetic medicines in a regulatable, safe and efficacious manner.  
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List of Abbreviations 
6OHDA    6-hydroxy dopamine 
AACD    Aromatic L-amino Acid Decarboxylase 
AAV     Adeno associated virus 
AD     Alzheimer’s disease 
AdV     Adenovirus 
AIDS    Acquired immunodeficiency disease 
ALS     Amyotrophic lateral sclerosis 
AP/ML/DV   Anterior-Posterior/Medial-Lateral/Dorsal-Ventricular 
ATF3    Activating transcription factor 3 
ATP     Adenosine triphosphate 
BBB     Blood-brain-barrier 
BDNF    Brain derived neurotrophic factor 
BH4     Tetrahydrobiopterin 
BMP    Bone morphogenetic proteins 
BMSC    Bone marrow stromal cells 
bp     Base pair 
BS    Bottenstein and Sato’s medium 
BSA     Bovine serum albumin 
cAMP    Cyclic adenosine monophosphate 
CAR     Coxsackie adenovirus 
CDNF   Conserved dopamine neurotrophic factor 
ChABC   Chondroitinase ABC 
CNS     Central nervous system 
CNTF    Ciliary derived neurotrophic factor 
cPPT/CTS    Central polypurine tract 
CsCl     Caesium chloride 
CSF     Cerebro-spinal fluid 
CSPGS    Chondroitinase sulphate proteoglycan 
CST     Corticospinal tract 
DA     Dopaminergic 
DD     Destabilisation domain 
DHFR    Dihydrofolate reductase 
DMEM   Dulbecco’s Modified Eagle Medium 
DMSO    Dimethyl sulphoxide 
DNA     Deoxyribosenucleic acid 
Dox     Doxcycline 
DRG    Dorsal root ganglion 
E. coli    Escherichia coli  
EcR     Ecdysone receptor 
EDTA    Ethylenediaminetetraacetic acid  
EIAV    Equine infectious anaemia virus 
ERE     Ecdysone responsive element 
ESGCT    European society of gene and cell therapy  
EtBr     Ethidium bromide 
FACS    Fluorescence-activated cell sorting 
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FGF    Fibroblast growth factor 
FKBP12   FK506-binding protein, 12kDa 
FRAB   Krupple-associated box 
FRB*    FKBP-rapamycin binding domain 
GABA   Gamma-aminobutyric acid 
GAD    Glutamic decarboxylase 
GCH-1    GTP cyclohydrolase 
GDNF    Glial derived neurotrophic factor 
GFP     Green fluorescent protein 
GOI     Gene of interest 
HBS     HEPES-buffered saline 
HBSS    Hanks Balanced Salt Solution 
HD     Huntington’s disease 
HEK     Human embryonic kidney 
HIV-1    Human immunodeficiency virus 
HSPG    Heparin sulphate proteoglycan 
HSV     Herpes simplex virus 
IGF1    Insulin-like growth factor 
IP    Intraperitoneal 
iPSC    Induced pluripotent stem cells 
IRES    Internal ribosome entry site 
ITR     Inverted terminal repeat 
L-DOPA    L-3,4-dihydroxyphenylalanine 
LB    Luria Broth 
LHS     Left-hand side 
LRRK2    Leucine rich repeat kinase 2 
LTR    Long terminal repeat 
LV     Lentivirus 
MAG    Myelin associated glycoprotein 
MANF    Mesenchymal-astrocyte neurotrophic factor 
MFBB    Medial forebrain bundle 
MOI     Multiplicity of infection 
MoMLV    Moloney-murine leukaemia virus 
MPTP    1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
mRNA   Messenger ribonucleic acid 
NaBu    Sodium butyrate 
NGF     Nerve growth factor 
NGS     Normal goat serum 
NPC     Neural progenitor cell 
NTF     Neurotrophic factor 
OEC     Olfactory ensheathing cells 
PCR     Polymerase chain reaction 
PD     Parkinson's disease 
PFA     Paraformaldehyde 
PI3K    Phosphoinositide 3-kinase 
PINK1    PTEN-induced novel kinase 1 
PKA    Protein kinase A 
PKCγ   Protein Kinase C gamma 
PROTACs    Proteolysis targeting chimeric protein 
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PTEN    Phosphatase and tensin homolog 
RA     Retinoic acid 
RAG     Regeneration-associated genes 
RALDH2    Retinaldehyde dehydrogenase 2 
RAR     Retinoic acid receptor  
RARE    Retinoic acid response element 
RBP4   Retinol binding protein 4 
RE     Restriction enzyme 
RHS     Right-hand side 
RRE     Rev-responsive element 
RXR    Retinoid X receptor 
SCI     Spinal cord injury 
SCID    Severe combined immunodeficiency disease 
SFFV   Spleen focus forming virus 
SLF     Synthetic ligand for FKBP  
SMA     Spinal muscular atrophy 
SMN1    Survival of motor neuron gene 
SN     Subthalamic nucleus 
SNPC    Substantia nigra pars compacta 
SURF    Split ubiquitin for the rescue of function 
SVZ     Subventricular zone 
Tet     Tetracycline 
TH    Tyrosine hydroxylase 
THF     Tetrahydrofolate 
TMP     Trimethoprim 
TRE     Tet responsive element 
TS     Temperature sensitive 
tTA     Tet-controlled transcription activator 
UPS     Ubiquitin-proteasome system 
USP     Ultraspiracle Protein 
VEGF    Vascular endothelial growth factor 
VSV-G    Vesicular Stromal Virus G-protein 
VTA     Ventral tegmental area 
Wld
s
     Wallerian slow degradation protein 
WPRE    Woodchuck post transcription regulatory element 
YFP     Yellow fluorescent protein 
 
 
